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Abstract 
 
An often explored hypothesis is that in at risk patients the chances of experiencing a 
thrombotic event is associated with the level of P2Y12 platelet blockade. However, 
studies have failed to show any benefits of ex vivo platelet function tests (PFT) and 
subsequent tailoring of treatment in patients receiving dual anti-platelet therapy 
(DAPT). This failure is possibly because these tests do not consider the environment in 
which platelets reside in vivo. Namely, that the strong synergies between P2Y12 
inhibitors, prostacyclin (PGI2) and nitric oxide (NO) mean that in vivo platelet reactivity 
will be a function of the level of P2Y12 receptor blockade and levels of endothelial-
derived NO and PGI2. 
 
This thesis investigates the relationship between P2Y12 blockade and endothelial 
mediators, emphasising the role of the endothelium in pathways of platelet activation.  
Initial in vitro platelet aggregation, release and flow cytometry experiments 
demonstrated the powerful, synergistic interactions between P2Y12 blockade, NO and 
PGI2. Immunoassays highlighted that cAMP rather than cGMP is the major driver of this 
synergy.  
 
By giving healthy individuals standard P2Y12 blockers it was determined that these in 
vitro observations hold true in man, with platelet responses powerfully influenced by 
the presence of NO and PGI2. Furthermore, in patients with peripheral arterial disease 
(PAD) NO and PGI2 strongly interacted with P2Y12 blockade to inhibit platelet activation, 
adding further evidence that the in vivo environment is vital in determining platelet 
reactivity during DAPT. 
7 
Overall, this thesis highlights the importance of endothelial mediators in determining 
the therapeutic efficacy of P2Y12 blockers, highlighting that endothelial function testing 
alongside ex vivo PFT could enhance risk prediction. It also provides a future basis to 
redefine optimal DAPT regimens in clinical populations, suggesting that alongside potent 
P2Y12 receptor blockade, enhancement of inhibitory cyclic nucleotide pathways in 
platelets, rather than the co-administration of aspirin, could represent an effective 
therapeutic approach. 
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1.1 The cardiovascular system and haemostasis 
 
The purpose of the cardiovascular system is to service the needs of the tissues. It serves 
to transport nutrients, including proteins, oxygen and hormones to and waste products 
from tissues, in order to maintain a homeostatic environment to allow optimal cell 
survival. This complex system consisting of the heart, fluid blood and the vasculature is 
regulated by complex mechanisms controlling cardiac output and arterial pressure to 
ensure blood flow corresponds to the tissues needs. It is divided into the systemic 
circulation which supplies all of the tissues of the body apart from the lungs and the 
pulmonary circulation and can be divided into functional parts. The left side of the heart 
acts as a pressure pump that pumps blood into the systemic arteries at a pressure 
sufficient enough to drive blood into the tissues. The right side of the heart pumps blood 
into the pulmonary arteries at a relatively lower pressure to supply the lungs. Arteries 
transport blood under high pressure to tissues with arterioles making up the last small 
branches of the arterial system acting as control valves that release blood into the 
capillaries to alter blood flow according to the needs of the tissue. Capillaries are thin 
walled and function to exchange fluid and substances between blood and the interstitial 
fluid. Blood is collected from the capillaries into venules which progressively increase in 
size to become veins that act not only as conduits for transport of blood to the heart but 
also as a controllable reservoir of blood depending on the organisms needs.  
 
Of note, the greatest cross-sectional area of the cardiovascular system are the capillary 
beds and whilst the same volume of blood flows through each part of the circulation at 
any one time, the actual velocity of blood flow will be inversely proportional to the cross-
sectional area of the vessel. For example, at rest blood will travel in the aorta at 
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approximately 33cm/sec however, in the capillary beds this velocity is reduced a 1000 
fold to 0.3mm/sec. The cross-sectional areas and also the velocities of blood flow within 
the system are highlighted in table 1.1 and represent an important physical 
characteristic of the circulation.  
 
Vessel Cm2 
Aorta 2.5 
Small arteries 20 
Arterioles 40 
Capillaries 2500 
Venules 250 
Small veins 80 
Venae cavae 8 
 
Table 1.1: Cross-sectional areas of the cardiovascular system [1] 
 
Another fundamental principle of circulatory homeostasis is the existence of blood in a 
fluid state flowing in a pattern of laminar flow. I will now consider haemostasis, a major 
homeostatic mechanism of the cardiovascular system and a focus of this thesis. 
 
The term haemostasis means the arrest of bleeding. The circulatory system has 
developed a range of haemostatic processes to maintain its integrity.  Following vessel 
rupture, haemostasis is achieved by several mechanisms including vascular spasm, 
development of a platelet plug, blood clot formation as a result of blood coagulation 
and finally growth of fibrous tissue into the clot to allow wound healing to occur. A 
fundamental property of the cardiovascular system is how systemic imbalance will affect 
haemostasis differently between sites to allow for local clot formation yet keeping blood 
in other areas of the vasculature in a fluid state [2].  
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Three principal players in the processes of haemostasis in arterial vessels are the 
circulating blood platelets, the coagulation cascade and the endothelial cells that line 
the interior surface of blood vessels.  Platelets respond to breakages in the arterial wall 
by sensing the underlying exposed proteins, adhering, activating and attracting in more 
platelets to rapidly build a platelet plug. This process also activates the clotting cascade 
to add insoluble fibrin strands to strengthen and bind together the growing thrombus.  
In parallel the cascade of factors leading to clot formation is limited by generation of 
anti-clotting processes that limit clot growth to ensure it remains focused on the local 
bleeding event.   
 
Given the pivotal role of platelets in all aspects of haemostasis, in vascular spasm, 
coagulation and thrombosis it is not surprising that they are central to cardiovascular 
health and lie at the crux of many pathologies of the cardiovascular system. Platelets are 
therefore the targets of many therapeutic strategies in the fight against cardiovascular 
disease. Platelets will be the next focus of this thesis which will then go on to describe 
the process of haemostasis and underline the importance of the endothelium in 
cardiovascular homeostasis and in the control of platelet behaviour and how this is 
affected by anti-platelet therapies. 
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1.2 Platelets 
 
Platelets are anucleate, discoid cells which were first described in the late 18th and early 
19th centuries by scientists such as Osler, Bizzozero, Wright and Duke who recognised 
their anatomy and role in haemostasis and thrombosis. Since then our understanding of 
platelet biology and function has greatly expanded. We appreciate that the principal 
function of blood platelets is to ensure primary haemostasis and the cessation of 
bleeding following vascular injury but that unfortunately, these mechanisms overlap 
with the pathophysiological role of platelets in arterial thrombosis. It is also increasingly 
recognised that platelets are involved in other processes such as inflammation, 
angiogenesis and atherosclerosis.   
 
1.2.1 Platelet formation and clearance 
Platelets or thrombocytes are derived from megakaryocytes, highly specialised 
precursor cells descended from pluripotent stem cells that reside primarily within the 
bone marrow. Thousands of platelets are released from a single megakaryocyte during 
the process of thrombopoiesis, a process which is regulated by the cytokine 
thrombopoietin [3]. During maturation megakaryocytes undergo a cytoplasmic 
expansion phase and accumulate cytoplasmic proteins, organelles and granules that are 
essential for platelet function. The current model of platelet formation recognizes that 
mature megakaryocytes then extend long, branching processes, designated proplatelets 
via microtubule tracks into the vascular sinusoids of the bone marrow from where the 
platelets are then released into the bloodstream [4]. This process, in health is 
responsible for producing approximately 100 billion platelets a day to maintain a normal 
platelet count of 150-400×109/ml. A process which is intricately regulated to avoid 
spontaneous bleeding or arterial occlusion. The platelet lifetime, if it is not activated, is 
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approximately 10 days with older platelets changing in morphology by for example, 
losing volume and RNA and shedding receptors glycoprotein (GP) VI and GPIb. The exact 
mechanisms of platelet clearance are not fully understood but the majority are cleared 
by the reticuloendothelial system in the liver and spleen.  
 
1.2.2 Platelet morphology 
Mature platelets are discoid cell fragments measuring approximately 2 µm making up 
the smallest cellular blood component. They do not contain a nucleus so cannot 
transcribe DNA. However, they contain pre-mRNA and spliceosome machinery so are 
able to translate mRNA in to proteins. They comprise a phospholipid bilayer membrane 
on which the glycolyx rests and contain an extensive cytoskeleton, cannicular system, 
mitochondria and secretory granules comprising biologically active molecules [5]. 
Platelets contain three major types of secretory granules, alpha granules, dense 
granules and lysosomes. Platelet alpha granules are the most abundant platelet granule 
with 40-80 granules present in a single platelet containing many proteins including von-
Willebrand factor (vWF), coagulation factor V, thrombospondin, P-selectin and 
fibrinogen [6]. Dense granules are less numerous and smaller than alpha granules and 
contain the adenine nucleotides adenosine triphosphate (ATP) and adenosine 
diphosphate (ADP), serotonin, pyrophosphate, calcium, and magnesium [7]. Lysosomes 
are the third type of platelet granule which contain acid hydrolases. Platelets contain 
few lysosomes and their function is not entirely understood.  
 
Upon activation platelets undergo dramatic changes in morphology. In the shape change 
process following platelet activation, the cytoskeleton is rearranged with the projection 
of pseudopodia from the discoid membrane consisting of actin filaments and 
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tropomyosin [8]. Platelets lose their discoid shape, taking on an irregular spiky 
morphology with a much larger surface area driven by myosin phosphorylation [5]. 
Microtubules and granules are centralised during the shape change process in 
preparation for secretion.  
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1.3 Haemostasis 
 
Haemostasis is the process which causes bleeding to stop and is the body’s instinctive 
response to limit blood loss following injury. Haemostasis is maintained in the body by 
three intertwined mechanisms. 
 
1.3.1 Vasoconstriction 
This is the first response of blood vessels to local injury. Smooth muscle cells under 
control of the vascular endothelium contract. Vessel damage is sensed by local 
sympathetic nociceptors which promote vasoconstriction limiting blood loss. The 
increase in vascular resistance will increase the local shear forces on platelets and this, 
alongside their exposure to the subendothelial matrix will lead them to become 
activated. Activated platelets and the endothelium will release mediators such as 
serotonin, ADP and thromboxane (TX) A2, all of which, increase the effect of 
vasoconstriction.  
 
1.3.2 Primary haemostasis (Platelet aggregation) 
Vitally, when the integrity of the vascular endothelium is breached platelets are exposed 
to pro-thrombotic proteins within the sub-endothelial matrix such as vWF or the primary 
platelet agonists collagen and thrombin. These triggers initiate a cascade of complex 
intracellular signalling pathways leading to the production of secondary platelet 
agonists, notably TXA2 and ADP. These mediators constitute powerful positive feedback 
loops that greatly potentiate activation signals to drive formation of platelet-rich 
thrombi [9]. Primary haemostasis can be further divided into three stages, adhesion, 
activation and aggregation which are reviewed in detail below.  
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1.3.2.1   Adhesion 
A key factor influencing platelet adhesion and aggregation is blood flow with distinct 
mechanisms operating in different shear conditions [10]. Notably, platelets are exposed 
to a broad range of haemodynamic conditions in vivo with low shear flow rates in 
venules and veins (<500 s-1) to small arterioles (5000 s-1) and shear rates over 40,000 s-1 
in stenosed arteries [11]. 
 
Under normal conditions and laminar flow in the cardiovascular system, platelets due to 
their small size are marginalized to the periphery of the blood vessel by red blood cells. 
They travel or ‘roll along’ in close proximity to the endothelium allowing for close 
interactions between integrins and glycoproteins. This process is dependent upon the 
weak interaction between the A1 domain of immobilized vWF and the N-terminus of 
GP1bα, a portion of the GPIb-V-IX receptor on the platelet surface which promotes initial 
platelet tethering to the vessel wall. Though usually kept in a quiescent state within the 
circulation, platelets tethered at sites of vessel injury can become activated following 
exposure to sub-endothelial matrix components or other thrombogenic substrates.  
Notably, damage to the endothelium leads to the binding of vWF to exposed collagen 
which induces conformational changes allowing firm binding to GP1b facilitating stable 
adhesion and shape change.  
 
1.3.2.2   Activation 
The second stage of thrombus formation is described as platelet activation which can 
occur through a variety of platelet agonists and G-protein receptors described below. 
Platelets adhered to the site of vascular injury and exposed to the platelet agonists 
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reviewed below will become activated and through production of paracrine mediators 
activate and recruit freely circulating platelets in close proximity to the injury site.  
 
1.3.2.2.1 Collagen 
Sub-endothelial collagen fibrils that become exposed at areas of endothelial disruption 
play a major role in firm adhesion and promoting platelet arrest. There are two 
constitutively expressed receptors for collagen on platelets, GPVI and integrin α2β1. GPVI 
is a low affinity collagen immunoglobulin receptor exclusively expressed on platelets and 
megakaryocytes. It exists in a complex with the Fc receptor (FcR) γ-chain which is 
essential for collagen induced platelet aggregation [12]. GPVI activates platelets through 
the phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) on 
the FcR γ-chain by the GPVI associated Src tyrosine kinases Lyn and Fyn [13]. This results 
in the activation of Syk which eventually causes phosphorylation and activation of 
phospholipase (PL) Cγ2 and the second messengers inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). This will lead to an increase in intracellular calcium and activate 
protein kinase (PK) C causing shape change, degranulation and the release and 
generation of the secondary mediators ADP and TXA2, respectively [14]. The second 
collagen receptor integrin α2β1 exists in a low affinity state requiring a conformational 
change to a high affinity state in order to bind collagen. Initial PKC activation by GPVI 
causes inside-out signalling and the switch of α2β1 to a high affinity conformation binds 
collagen strongly and stabilizes platelet adhesion, reinforcing GPVI signalling [15].  
 
1.3.2.2.2 Thrombin 
Thrombin is the most potent platelet agonist, as well as being key in the coagulation 
cascade. Tissue factor (TF) and activation of factor XIIa are the initiators of thrombin 
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generation following injury vascular injury and trauma through activation of the 
coagulation cascade. Following factor Xa activation, thrombin is proteolytically cleaved 
from prothrombinin the blood stream. The interaction of factor Xa with factor Va greatly 
enhances the cleavage of thrombin from prothrombin and therefore, thrombin 
generation on the surface of platelets [16].  
 
Activation of platelets by thrombin is mediated by the protease-activated receptors 
(PARs) PAR1 and PAR4 which are present on human platelets and have different 
affinities to thrombin. Activated PAR1 and PAR4 are both coupled to G12/13 and Gq [17]. 
PAR1 is the major thrombin receptor with PAR4 existing as a lower-affinity thrombin 
receptor that can form a heterodimer with the high affinity PAR1 receptor [18]. PAR-1 
has a high affinity for thrombin and leads to strong platelet activation at low 
concentrations of thrombin, whereas PAR-4 signals only at high concentrations of 
thrombin but for a prolonged duration [19]. The PAR receptors share a common 
proteolytic mechanism of activation with thrombin cleaving the N-terminal extracellular 
domain of the receptor at a specific site to create a new N-terminus that activates the 
receptor as a tethered ligand [20]. It is this tethered ligand mechanism that TRAP-amide, 
commonly used in the study of platelets, takes advantage of to induce platelet activation 
in vitro [21]. Gq activation then leads to the generation of the second messengers IP3 
and DAG leading to increases in extracellular calcium and PKC activation resulting in 
shape change and granule secretion and also in integrin αIIbβ3 activation [22]. G12/13 
activation also induces shape change through the Rho/Rho-kinase pathway by causing 
myosin light chain phosphorylation [16].  
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1.3.2.2.3 ADP 
ADP is stored and released from platelet dense granules upon activation with other 
agonists such as thrombin, collagen or TXA2 [23]. It acts as a strong autocrine and 
paracrine platelet activator and has an important role as a positive-feedback mediator 
for platelet activation. ADP acts upon two platelet receptors each coupled to a distinct 
G-protein with different effects. The P2Y1 receptor which is linked to a Gq subunit and 
the P2Y12 receptor which is linked to a Gi subunit. P2Y1 mediates ADP-induced shape 
change and initiates weak, reversible aggregation through PLC which releases IP3 from 
the membrane phospholipids and activates DAG, resulting in PKC activation and 
increased levels of intracellular calcium [24]. The P2Y12 receptor amplifies and sustains 
platelet aggregation by inhibiting the activation of adenylyl cyclase (AC) which reduces 
intracellular cyclic adenosine monophosphate (cAMP) levels and by activating 
phosphoinositide 3-kinase [16]. Co-activation of both G protein-coupled receptors is 
essential for normal ADP-induced platelet aggregation [25]. 
 
1.3.2.2.4 TXA2 
TXA2, like ADP is an important positive-feedback mediator during platelet activation and 
aggregation. TXA2 is a prostanoid formed from arachidonic acid (AA) following its 
liberation from glycerophospholipids by PLA2. Cyclooxygenase (COX) -1 and COX-2 
catalyse the oxidation of AA to prostaglandin (PG) G2 and then this is reduced by 
peroxidation to PGH2. Thromboxane synthase then regulates the formation of TXA2. 
TXA2 acts on the G-protein coupled TP receptor, which exists in two forms: TPα and TPβ 
[26]. Through this receptor linked to Gq, TXA2 activates PLC which causes IP3 and DAG 
signalling and mobilisation of intracellular calcium. This prostanoid is a mediator of 
platelet aggregation and thrombus formation, as well as a potent vasoconstrictor and it 
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also induces smooth muscle proliferation [27]. The actions of this pro-aggregatory 
prostanoid are considered to oppose those of the inhibitory endothelial prostanoid, 
prostacyclin (PGI2), whose actions are reviewed in a further section of this thesis. The 
balance of these two mediators is considered a fundamental factor in the health of the 
cardiovascular system [28]. Chronic increase in TXA2 is linked with the development of 
inflammatory diseases such as atherosclerosis and hypertension. 
 
1.3.2.3   Aggregation 
The ability of platelets to form a thrombus depends on their innate ability to aggregate. 
Platelet aggregation describes the process whereby activated platelets clump together 
forming a growing thrombus. This process occurs concomitantly to the platelet 
activation processes described above. Activation of the platelet receptor integrin 
αIIb/β3 is key to aggregation and particularly important in mediating the platelet-
platelet interactions which must occur to facilitate thrombus formation. This integrin or 
GPIIb/IIIa as it also known, is the most abundant receptor on the surface of platelets 
with approximately 80,000-100,000 copies present per individual platelet [29]. This 
receptor is also present in alpha granules which become accessible following platelet 
stimulation [30].  
 
Stimulation of this receptor can occur through a wide range of agonists acting through 
their separate receptors. Collagen, thrombin, ADP and TXA2 detailed above are all 
examples. Central to GPIIb/IIIa’s ability to mediate thrombus formation is its transition 
from a resting, low-affinity state to an active, high-affinity state revealing a RGD-binding 
sequence to bind its ligands. Activation then occurs by ‘inside-out’ signalling mediated 
by the GTPase Rap1b in response to both Gi and Gq signalling [31]. The active form of 
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αIIb/β3 can then bind divalent fibrinogen, multivalent vWF, prothrombin, fibronectin 
and other adhesion molecules which serve to bridge platelets together forming 
aggregates in the developing thrombus [32]. The key role of this receptor is highlighted 
as blockade of its functions inhibits the process of aggregation [33].  
 
1.3.3 Secondary haemostasis (Coagulation) 
Coagulation is the third and final step in haemostasis leading to the transformation of 
blood from a liquid to a gel like substance through activation of clotting factors and pro-
coagulants. It describes the complex network of processes which result in the conversion 
of soluble fibrinogen into a fibrin mesh which reinforces the platelet plug. 
 
The coagulation cascade of secondary haemostasis has two initial pathways which both 
lead to fibrin formation. These are the contact activation or intrinsic pathway and the 
TF or extrinsic pathway which converge leading to activation of factor X to factor Xa and 
activation of the final common pathway to produce fibrin [34]. The pathways are a series 
of reactions, in which inactive enzyme precursors and co-factors interact to become 
activated components that then catalyze the next reaction in the cascade. The intrinsic 
pathway is initiated with the activation of factor XII whereas the extrinsic pathway is 
started by the exposure and interaction of TF following vessel wall damage with factor 
VII [35]. Activation of the final common pathway will facilitate the formation of thrombin 
from prothrombin and the subsequent formation of fibrin from fibrinogen.  
 
Platelets are central to several key coagulation processes. Activated platelets release a 
number of pro-coagulant molecules such as factor V and fibrinogen that are stored in 
alpha granules [36]. They also expose phosphatidylserine (PS) to support the function of 
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the prothrombinase complex greatly enhancing coagulation [37], interact with many 
coagulation factors [38] [39] and associate with TF [40]. Platelets are instrumental in 
providing a surface for large scale thrombin production [41] and are involved in fibrin 
formation and organisation with activated GPIIb/IIIa receptors regulating clot retraction 
[42]. 
Thus, from this we can recognise the importance of the physiological processes that take 
place in platelets to achieve haemostasis following compromise in the integrity of the 
vascular endothelium. We can also start to appreciate how these protective processes 
can turn pathological in atherothrombosis where atherosclerotic plaque rupture 
induces inappropriate rapid platelet activation leading to potential deadly thrombus 
formation. The next section of this thesis will go on to describe the physiology of the 
powerful endothelium and the fundamental role it plays in regulating cardiovascular 
homeostasis by maintaining platelets in a quiescent state within the vasculature. 
Following this I will then discuss how this critical balance can become disturbed in the 
process of atherothrombosis.   
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1.4 The Endothelium 
 
The endothelium consists of a single layer of endothelial cells which line the lumen of 
every blood vessel providing a non-thrombogenic lining for the cardiovascular system. 
In adults, approximately ten trillion cells form an almost 1kg organ [43]. It is strategically 
located to separate the thrombogenic vascular wall from the circulation and from blood 
cells. Although once considered inert it is now recognised as being highly metabolically 
active. Endothelial cells are crucial in maintaining cardiovascular health and are involved 
in many physiological processes. Their vital roles in barrier function, vasomotor tone and 
haemostatic control in health and disease are further detailed below. The fundemental 
role of the endothelium in the regulation of platelet aggregation will be visited in more 
detail in the following section of this thesis. 
 
In 1980 the seminal report from Furchgott and Zawadski described the obligatory nature 
of the endothelium in producing blood vessel relaxation and regulating vasomotor tone 
[44], work that earnt Furchgott the Nobel Prize in Medicine or Physiology in 1998. Since 
then, there has been a vast quantity of literature published in the area of blood vessel 
regulation by endothelial cells, building also on studies from the 1960s and 1970s by 
researchers such as Florey, Jaffe, Gimbrone and Vane [45].  Together these studies have 
characterised endothelial cells as a remarkably diverse cell population in both structure 
and function with differing properties in different vascular beds, in arterial, venous and 
microcirculations, and even within the same blood vessel with each cell displaying an 
inherent quality of being able to adapt to the needs of the underlying tissue [46, 47]. For 
example, endothelial cells lining post-capillary venules are primarily responsible for 
mediating leucocyte trafficking, whereas those found in the arterial system primarily 
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regulate vascular tone. Endothelial cells exert autocrine, paracrine and endocrine 
actions influencing smooth muscle cells, platelets and leucocytes [43]. A fundamental 
property of the endothelium is its phenotypic heterogeneity which is explained by its 
broad distribution receiving input signals from the extracellular environment varying 
throughout the vascular tree from astrocytes in the blood brain barrier to hepatocytes 
in the hepatic sinusoids [48]. In fact, different endothelial cells can generate different 
responses to the same stimulus. Endothelial cell phenotype also varies widely in health 
and disease and these cells are involved in many disease processes including 
atherosclerosis, hypertension and sepsis. The metabolic and synthetic function of 
endothelial cells is highlighted in figure 1.1. 
Figure 1.1: The metabolic and synthetic function of endothelial cells 
 
The endothelium in most vascular beds is continuous and non-fenestrated (arteries and 
veins) but it can be continuous fenestrated and discontinuous/sinusoidal (capillaries) 
reflecting different functions in the body. It is mesodermal in origin and characterised 
by tight junctions at the lateral borders of each cell that restrict the passage of 
macromolecules. Its simple squamous cells are long flat cells, on average 20-40 µm long, 
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10-15 µm wide and only 0.1-0.5 µm thick [49]. It has a slow turnover rate of 
approximately 3 years but damage occurring from atherosclerosis for example, can lead 
to replacement by cells that do not possess the same properties as normal endothelial 
cells [50]. It acts as a selectively permeable barrier between intravascular and 
extravascular compartments and controls several physiological processes; allowing for 
interactions between circulating blood cells and the vessel wall, it regulates leukocyte 
trafficking by upregulation of adhesion molecules and chemokines (P-Selectin/E-
Selectin/ vascular cell adhesion molecule 1 (VCAM-1)/ intercellular adhesion molecule 1 
(ICAM-1)). It is also involved in cell survival and proliferation, vascular remodelling, 
metabolism, innate and acquired immunity, inflammation and angiogenesis. “You are 
only as old as your endothelium”, the wise words of Dr. Rudolph Altschul in 1954 reflect 
the important contributions of the endothelium to cardiovascular physiology and 
pathology. 
 
1.4.1 Barrier function 
Macro molecules can cross the endothelial barrier by passing through endothelial cells 
themselves, through endothelial gaps, through intracellular junctions or via vesicular 
and caveolae transport. It is therefore, not surprising that caveolae are much more 
numerous in capillaries than they are in veins or arteries. Basal and inducible 
permeability are differently regulated across the vascular tree [51]. Increases in 
endothelial permeability to water and solutes are mediated by reorganisation of inter-
cellular junctions by actin and myosin, which can be induced by inflammatory mediators 
such as thrombin and histamine, vascular endothelial growth factors (VEGF’s) and ‘low’ 
shear stress [52]. A wide variety of injurious stimuli such as cigarettes or high fat diets 
contribute to endothelial dysfunction by increasing endothelial permeability leading to 
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lipid accumulation and the development of atherosclerotic plaques. Opposing this, 
protective stimuli for example, exercise by increasing blood flow and sheer stress 
leading to the release of vasoprotective molecules such as PGI2 and nitric oxide (NO) 
preserve the endothelial barrier [49]. The endothelial glycocalyx, consisting of negatively 
charged proteins and proteoglycans also contributes to the protection of the vessel wall. 
Its destruction is linked to the loss of vascular responses, increased endothelial 
permeability and platelet aggregation and leads to the initiation and progression of 
atherosclerosis [53].  
 
1.4.2 Vasomotor tone 
The endothelium produces a number of vasodilator and vasoconstrictor substances 
which play a major role in the regulation of vasomotor tone. NO, PGI2, endothelin (ET) 
and endothelial-derived hyperpolarizing factor (EDHF) are all powerful vasoactive 
substances released by endothelial cells in response to mechanical and humoral stimuli.  
The net balance of local endogenous healthy endothelium-derived relaxing factors 
(EDRFs) and endothelium-derived vasoconstrictor factors (EDCFs) maintains normal 
vascular tone. Examples of EDRFs are bradykinin, EDHF, NO and PGI2. NO is a potent 
vasodilator important in maintaining the vasculature in a state of vasodilatation. Both 
endothelial constitutive and cytokine inducible nitric oxide synthase (eNOS and iNOS) 
which catalyse the production of NO are found in endothelial cells [54]. In smooth 
muscle cells, NO acting through secondary messengers inhibits calcium entry into the 
cells, as well as decreases myosin light chain phosphorylation to cause vasodilatation 
[55]. PGI2 is also synthesized by endothelial cells in response to similar stimuli as for NO, 
as well as other stimuli such as platelet derived and epidermal growth factors and 
inflammatory mediators such as IL-1. It is also a powerful vasodilator. These two 
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powerful inhibitors will be revisited in more detail in the following section. ET, 
angiotensin and prostanoids such as TXA2 are examples of EDCFs. ET is a vasoconstrictor 
produced by endothelial cells that has a marked effect on vasculature tone. It also 
stimulates cell proliferation. There are three types of ET but it is ET-1 which is 
synthesised by endothelial cells. There is a wide distribution of ET receptors in the body 
and in the vasculature. Stimulation of ETA receptors in the vasculature causes 
vasoconstriction and stimulation of ETB causes both vasoconstriction and vasodilatation, 
depending on the vascular bed [56]. There is considerable cross-talk between NO, PGI2 
and ET-1 in the control of vascular tone [57]. In pathological conditions such as 
hypertension (HTN) and diabetes mellitus (DM), an increase in EDCFs, as well as a 
decrease in EDRFs will favour vascular contraction and potentially, pathophysiological 
changes. In these conditions ET-1, as well as acting as a vasoconstrictor is implicated in 
proliferative responses and is also a chemoattractant for monocytes. Figure 1.2 
represents the net balance of EDRFs and EDCFs in healthy and dysfunctional 
endothelium. 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Healthy versus unhealthy endothelium - the net balance of EDRFs and 
EDCFs 
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1.4.3 Haemostatic balance 
The endothelium is integrally involved in mediating haemostasis. Whilst the liver 
synthesizes a constant amount of pro-coagulant (fibrinogen, clotting cascade proteases) 
and anti-coagulant (protein C/antithrombin III) molecules, the endothelium produces a 
‘regulatable’ supply. Endothelial cells produce a repertoire of endothelial-derived 
anticoagulant and procoagulant molecules which they display within the vasculature.  
Thrombomodulin, endothelial protein C (EPCR), heparin, CD39, eNOS and tissue factor 
pathways inhibitor (TFPI) are examples of the anticoagulants expressed by endothelial 
cells. Thrombomodulin is the major physiological buffer for the pro-coagulant effects of 
thrombin as it binds to the same site as fibrinogen, platelets and factor V so blocks all of 
these functions and instead activates anticoagulant protein C [43]. TF, factor VIII, 
plasminogen activator inhibitor (PAI) and vWF are procoagulant molecules produced by 
endothelial cells. The majority of vWF is synthesised in endothelial cells in one of two 
forms: vWF dimers, which are secreted into the plasma and sub-endothelial matrix and 
vWF multimers, which are stored in Weibel-Palade bodies in endothelial cells. The 
heterogeneity of the vascular tree is key, with each mediator differentially expressed 
both in a temporal and spatial manner explaining how systemic changes in the 
procoagulant and anticoagulant molecules listed above can lead to site specific 
thrombosis [2]. Specifically, for example, TFPI is mostly expressed in the capillaries, 
eNOS in the arterial circulation, vWF in the venous side of the circulation, 
thrombomodulin is widely expressed in all vessels apart from the cerebral circulation, 
tissue plasminogen activator (t-PA) is expression is more restricted to the pulmonary 
and cerebral arteries and EPCR is found in large veins and arteries. Therefore, 
endothelial cells at different sites within the vasculature will employ site specific 
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‘formulas’ of haemostatic proteins to maintain blood fluidity and promote limited blood 
clot formation following a breech in the integrity of the endothelium [48].  
 
1.4.4 Endothelial cells in disease 
In response to systemic inflammation the expression of these various factors changes in 
ways that differ between vascular beds [46]. Quiescent endothelial cells express an 
anticoagulant, anti-adhesive and vasodilatory phenotype, whereas activated or 
dysfunctional cells associated with disease states express pro-coagulant, pro-adhesive 
and vasoconstricting properties [58].  
 
In the 1980s Gimbrone demonstrated that specific stimuli could induce expression of 
endothelial markers [59]. Since then it has become understood that endothelial cells can 
become activated to express inflammatory mediators such as IL-1 and tumour necrosis 
factor alpha (TNF-α) which correlate with this procoagulant activity. Therefore, 
endothelial cells are able to sense and respond to their extracellular environment. They 
can become adaptive whereby activation is a phenotypic response to an inflammatory 
stimulus, whereas endothelial dysfunction is thought of as a maladaptive response from 
otherwise adaptive responses that become excessive, sustained or misplaced 
representing a net liability to the host [58]. These cytokines, growth factors, lipids and 
enzymes modulate cell function and lead to lipid accumulation, vasoconstriction and 
promotion of thrombosis [43].  
 
Haemodynamic forces are fundamental to endothelial cell biology,function and 
interactions with smooth muscle cells. It is well recognised that disturbed flow is 
atherogenic whereas steady laminar flow is atheroprotective. This is because flow 
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stimulates vasoactive genes and products, cytokines, adhesion molecules and growth 
factors from endothelial cells. Pathological flow will activate endothelial cells with a shift 
in the haemostatic balance to increased permeability and procoagulation increasing 
reactive oxygen species (ROS) and vasoconstrictors, whereas physiological flow will 
increase anticoagulants, vasodilators and antithrombotic molecules and decrease 
permeability [60]. It is suggested that endothelial cells in areas of disturbed flow are 
primed for activation with increased levels of nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κβ) in their cytoplasm, with systemic imbalances leading to the 
translocation of NF-κβ into the nucleus resulting in increased expression of adhesion 
molecules and procoagulants [47]. Production of thrombomodulin and the vasodilators 
PGI2 and ET-1, as well as NO through increased eNOS activity are all altered by shear 
stress [61-63]. Oxidative stress and ROS affect endothelial health and contribute to 
endothelial dysfunction and atherosclerosis. Oxidative stress results as a consequence 
of imbalances of anti-oxidative and pro-oxidative enzymes, for example heme 
oxygenase and nicotinamide adenine dinucleotide phosphate (NADPH), respectively 
leading to ROS production. ROS include the oxygen radicals (superoxide and hydroxyl 
radical) and non-radical oxygen derivatives (ozone and hydrogen peroxidase). Flow 
again contributes significantly to this balance with physiological flow inducing conditions 
with lower ROS and higher NO bioavailability and pathological flow tipping the balance 
towards higher ROS levels and reduced NO bioavailablity.  
 
From this we can start to build a picture of the fundamental role of the endothelium in 
cardiovascular health and how this is altered in disease. In the following section I will 
consider specifically the role of the endothelium in regulating platelet function and how 
this becomes dysregulated in endothelial dysfunction and atherothrombosis.  
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1.5 The regulation of platelet function 
 
Within the circulation platelets are subject to precise regulation to maintain them in a 
quiescent state to prevent their rapid and inappropriate activation [64]. The 
endothelium limits platelet activation by separating blood from the pro-thrombotic sub-
endothelial matrix, as reviewed in a previous section. Crucially, as mentioned above 
endothelial cells are also responsible for the production of the two soluble inhibitory 
mediators that constantly bathe circulating platelets and limit their reactivity [45], the 
free radical NO and the inhibitory prostaglandin, PGI2. Indeed, it is important to 
recognise that within the circulation each platelet is balanced by and under the influence 
of approximately 50 endothelial cells (e.g. 1.25 trillion platelets vs. 60 trillion endothelial 
cells in a 70 kg man).  
 
1.5.1 PGI2 
PGI2 is a prostanoid formed via the cyclooxygenase pathway, as described previously. It 
is synthesised by the enzyme PGI2 synthase which is concentrated in the endothelium 
[65] and its production and release is highly dependent on the pulsatile and steady flow 
shear stress of blood within the vasculature [66] The actions of PGI2 on platelets are 
mediated through the G-protein coupled prostacyclin (IP) receptor, which couples to Gs 
and when activated leads to activation of AC activity to produce an increase in 
intracellular cAMP [67]. PGI2 acts upon neighbouring smooth muscle cells and platelets 
in a paracrine fashion causing its primary effects of vasodilatation and the inhibition of 
both platelets and smooth muscle cell proliferation, as previously highlighted [68]. 
Considered the physiological antagonist of TXA2, PGI2 produces protective anti-
inflammatory, anti-thrombotic and anti-angiogenic effects within the cardiovascular 
system [69] and plays an important role in the prevention of cardiovascular diseases 
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such as atherosclerosis [68]. It has a short half-life of less than 3 minutes within the 
circulation but forms the stable metabolite 6-keto-PGF1α, which can be measured as a 
surrogate of PGI2 activity. Importantly, this means that in in vitro tests of platelet 
function PGI2 is no longer present or active.   
 
1.5.2 NO 
NO is produced from L-arginine by a family of enzymes named NOS of which there are 
three members; eNOS, iNOS and neuronal NOS (nNOS). As previously highlighted, NO is 
a potent inhibitor of platelet aggregation and vasoconstriction, released from 
endothelial cells following their activation by shear forces or via receptor mediated 
process (e.g. bradykinin/acetylcholine (ACh)/insulin/substance P) [64]. It is also 
recognised to exert important antioxidant, antiadhesive, and anti-proliferative effects 
[70]. NO diffuses freely through the vessel wall into platelets activating soluble GC to 
increase intracellular cGMP levels [71]. This in turn activates PKG leading to reduced 
intracellular calcium and inhibition of IP3 which reduce cell activation leading to reduced 
platelet activity and vasodilatation. cGMP also inhibits the actions of phosphodiesterase 
(PDE) 3A who’s role it is to breakdown cAMP [70].   
 
1.5.3 Adenosine 
Endothelial cells produce ectonucleotidases which are enzymes that dephosphorylate 
ADP to AMP and then to adenosine [72]. Adenosine acts through the platelet A2b 
receptor to activate AC, leading to an increase in cAMP which reduces platelet 
aggregation [16]. Adenosine has also been shown to be an important regulator of blood 
vessel tone under hypoxic conditions [73].  
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1.5.4 The inhibitory effect of endothelial NO and PGI2 on platelet reactivity 
As outlined above, NO causes the production of cGMP while PGI2 produces cAMP.  
Elevation of either cGMP or cAMP in platelets causes a reduction in platelet reactivity 
and the two together are strongly synergistic, as established more than 25 years ago 
[74], with platelets with elevated levels of cAMP and cGMP rendered rather 
unresponsive [75]. Because of the key roles of these critical secondary messengers in 
regulating cellular signalling and function, platelets are also equipped with a range of 
enzymes that rapidly remove both cAMP and cGMP, the PDE’s which are also 
fundamental for platelet function [76]. A very dynamic balance exists in platelets with 
endothelial cell inhibitory mediators constantly stimulating the formation of cAMP and 
cGMP and intraplatelet systems constantly removing them, with the reactive state of 
platelets determined as a product of these two systems.  
 
With this we can construct a view of how the endothelium promotes platelet inhibition 
and so assists in maintaining blood fluidity; platelets are central to blood clotting and 
their innate reactivity is balanced by a 50-fold excess of endothelial cells.  These 
endothelial cells make intimate contact with the platelets principally in the 
microvasculature exposing them to NO and PGI2 and so elevating platelet levels of cGMP 
and cAMP, which are strongly inhibitory and ‘tame’ platelets during their journey 
through the vasculature through multiple effects [77-79], including the regulation of 
platelet binding to fibrinogen [80] and collagen [81], stimulating calcium extrusion [82] 
and calcium uptake into the dense tubular system [83], inhibiting phospholipases [84], 
reducing platelet pro-thrombinase activity [85], decreasing thrombin binding [86], 
inhibiting P-selectin expression [87], inhibiting GPVI dimerization [88], phosphorylating 
GPIb inhibiting collagen-induced polymerization of platelet actin [89], reducing PS 
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exposure and blunting platelet pro-coagulant activity [90]. Therefore, fundamentally 
cyclic nucleotides are global inhibitors of platelet function and their production is 
dependent on NO and PGI2 produced by the endothelium, once described as the 
maestro of the circulation by Sir John Vane. Importantly, but not often emphasized anti-
platelet drugs interact with cyclic nucleotide systems in platelets and these are the same 
systems that mediate key endogenous pathways of platelet regulation. After 
considering the roles of the endothelium and platelets in atherothrombosis these anti-
platelet drugs will be reviewed in detail and then these important pathways and 
interactions considered. 
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1.6 Atherothrombosis 
 
Thrombosis describes the process of formation of a blood clot inside a blood vessel 
obstructing the flow of blood through the circulatory system. It is the same protective 
mechanisms involved in haemostasis that lead to the development of a pathological 
thrombus at inappropriate sites under certain conditions, which can be potentially 
detrimental to the host. Obstruction to blood flow can result in anoxia and oxygen 
deprivation leading to infarction and tissue death.  
 
Thrombosis can occur in both the venous and arterial sides of the circulatory system. 
Thrombosis in the venous circulation is mainly dependent on coagulation factors. In the 
arterial side however, platelets are the main drivers with the physiological response 
potentially becoming a major cause of pathology. The processes involved in 
atherothrombosis are covered in the next section of this thesis.   
 
Cardiovascular disease, involving the heart and vasculature is the leading cause of 
mortality and morbidity worldwide with one third of the population dying of 
complications attributable to atherothrombosis. 17.3 million deaths occur each year, 
mainly from ischaemic heart disease (IHD) and cerebrovascular disease, a number which 
is expected to grow to 23.6 million by 2030 [91]. Future cardiovascular burden is likely 
to be aggravated by the obesity epidemic, an aging population, the increasing 
prevalence of cardiovascular risk factors and insufficient implementation of prevention 
strategies [92].   
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1.6.1 Atherosclerosis 
Atherothrombosis is a potentially devastating complication of atherosclerosis which is a 
chronic, inflammatory systemic disease leading to vascular events such as myocardial 
infarction (MI), cerebrovascular accident (CVA) or peripheral arterial disease (PAD). 
Mechanisms as to which specific sites are affected whilst others at distinct locations are 
spared are not fully understood but genetic predisposition, smoking, HTN, 
hypercholesterolaemia, DM and obesity are all recognised risk factors for the 
development of the disease.  
 
The endothelium and the vascular wall constantly undergo repair processes following 
mechanical and chemical injury however, prolonged exposure to the above risk factors 
can impair these repair processes leading to inflammation and endothelial dysfunction 
[93]. Adherent platelets at sites of inflammation play a crucial role in the development 
of atherosclerosis by releasing cytokines, chemokines and growth factors promoting 
endothelial dysfunction and leukocyte recruitment [94]. There are two major initiators 
involved in the development of atherosclerosis, the production of ROS and lipid 
oxidation. Firstly, ROS is associated with a reduction in the anti-inflammatory and anti-
atherogenic activities of NO which leads to endothelial dysfunction. ROS activate matrix 
metalloproteinases (MMP’s) which can cause plaque destabilisation and rupture and 
also activate the transcription factor NF-κβ which initiates the expression of pro-
inflammatory and pro-thrombotic genes. The second important factor is the oxidation 
of low-density lipoproteins (LDL) in blood vessels which leads to an inflammatory 
response and the development of atherosclerosis with foam cell formation. Foam cells 
will accumulate to lead to the apparition of fatty streaks which are the earliest 
atherosclerotic lesion to appear. With time, atherosclerotic plaques develop with their 
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pro-inflammatory milieu supporting accumulation of lipids, smooth muscle cells, 
monocytes, T cells and platelets leading to the apparition of mature plaques 
characterised by a complex necrotic lipid and cellular core covered by a fibrous cap [93]. 
These lesions can remain asymptomatic however, as plaque progression continues the 
fibrous cap can become eroded, thin and weak precipitating plaque disintegration and 
rupture exposing its highly thrombogenic core to circulating platelets [95]. This can lead 
to platelet activation, aggregation and thrombus formation, potentially presenting as a 
clinically relevant cardiovascular event. This is recognised as an acute coronary 
syndrome (ACS) should thrombus formation take place in a coronary artery. 
 
1.6.2 ACS 
Three types of ACS have been distinguished and described as occlusive, non-occlusive 
and disperse coronary thrombosis. Occlusive coronary thrombosis results in ST-segment 
elevation and Q-wave formation on the electrocardiogram (ECG) and is otherwise 
known as a STEMI (ST segment elevation myocardial infarction). Non-occlusive 
thrombosis is seen in NSTEMI (Non-ST segment elevation myocardial infarction) which 
can be associated with ST-segment depression, T wave inversion or a normal ECG. 
Dispersive coronary thrombosis represents unstable angina which can result in 
ischaemic changes on the ECG or present with a normal ECG but can also result in death 
due to arrhythmia. Interestingly, there is a circadian rhythm associated with thrombotic 
events which are known to occur with increased frequency in the morning. Reasons put 
for forward for this are increased platelet reactivity and hypercoagulable blood or higher 
levels of beta-adrenergic hormones.   
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These acute cardiovascular events are associated with high morbidity and mortality. 
Therefore, aggressive strategies such as lifestyle changes and therapeutic intervention 
with statins, angiotensin-converting-enzyme (ACE) -inhibitors and beta-blockers are 
prescribed as an effective preventative approach in reducing further events. Given the 
central role of platelets at each stage of atherothrombosis, anti-platelet agents that 
serve to inhibit specific steps in the platelet activation process are the mainstay of 
treatment for patients with established cardiovascular disease. A thorough overview of 
these different therapeutic agents is given in the next section. The mechanisms of action 
of two of the most commonly prescribed agents, aspirin and P2Y12 receptor antagonists 
will then be related to the endogenous pathways in both endothelial cells and platelets 
that I have alluded to so far in this thesis. 
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1.7 Anti-platelet therapies 
 
Several classes of agent are indicated in the treatment of cardiovascular disease, with 
substantial therapeutic developments having been made over the last decade. The 
principal therapeutic agents are reviewed below. 
 
1.7.1 Aspirin 
Acetylsalicyclic acid, first marketed in tablet form in 1899 by Bayer, is established in 
clinical practice as the default anti-platelet therapy in cardiovascular disease. 
Acetylsalicyclic acid is derived from the naturally occurring substance salicyclic acid, 
from Latin ‘salix’ for willow tree, the source from which it used to be obtained. 
Salicylates’s anti-inflammatory, anti-pyretic and analgesic properties have been 
recognised for over 2000 years and were known to physicians such as Hippocrates and 
Galen. Aspirin was first synthesised in the late 19th century when Hoffman acetylated 
the benzene ring of salicylic acid [96]. Aspirin exerts its therapeutic effects by preventing 
the formation and release of prostaglandins. The elucidation of the mechanism of action 
of aspirin came from the seminal work of Sir John Vane who in London in 1971 identified 
the shared mechanism of action of aspirin like drugs [97], work for which he shared the 
Nobel Prize in Physiology and Medicine in 1982 with Sune Bergström and Bengt 
Samuelsson.  
As already mentioned, AA through the cyclooxygenase activity of PGHS (COX) is 
converted to PGG2 which is further metabolised into PGH2 though PGHS’s peroxidase 
activity. From this PGE2, PGD2, PGF2α, PGI2 and TXA2 are produced [98]. Aspirin acts by 
permanently inhibiting the COX enzymes which catalyse this first committed step to 
prostanoid synthesis. It causes irreversible inhibition of COX-1 through acetylation of 
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serine 529 residue and serine 516 residue in COX-2 causing a conformational change to 
the active site leading to inhibition of AA binding [99]. NSAIDS on the contrary cause 
reversible inhibition of COX by temporarily binding to the channel and obstructing the 
active site during the active period of the drug before it is metabolised [100]. Due to this 
shared mechanism of action and COX target it is thought that NSAIDs interact with 
aspirin reducing its overall anti-thrombotic properties [101]. Aspirin is also reported to 
have effects on haemostasis which are unrelated to its ability to inactivate COX-1, 
namely suppression of plasma coagulation and enhancement of fibrinolysis [102].  
 
Aspirin is rapidly absorbed from the stomach and small intestine with peak plasma levels 
occurring 30-40 minutes post ingestion and evidence of platelet TXA2 inhibition by 1 
hour [103]. The oral bioavailablity of aspirin is 40-50%, although COX-1 is acetylated in 
the presystemic circulation so platelet inhibition is largely independent of this. Aspirin 
has a short half-life in plasma of 15-20 minutes so it is only detected for a short time 
before it is metabolised in the liver, gut and blood [104].  
 
In platelets, by irreversibly blocking COX aspirin inhibits the production of TXA2 [97, 98, 
105]. TXA2, when unchecked, drives further aggregation through stimulation of TP 
receptors on neighbouring platelets.  While aspirin is short-lived in the circulation, it 
permanently inhibits the COX-1 enzyme through acetylation, and as platelets lack the 
apparatus to produce replacement COX-1 protein individual platelets remain inhibited 
for their lifetime [106].  Platelets circulate for around 7-10 days and so the concept has 
arisen of once a day dosing with aspirin to produce blockade of the entire platelet 
population in most individuals [107]. The human body turns over approximately 10% of 
platelets a day although this can be increased in certain diseases associated with high 
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platelet turnover such as DM. Since only a small proportion of uninhibited platelets have 
been shown to be required to trigger a thrombotic response a twice daily dosing regime 
has been suggested in these patient groups [108]. In contrast, inhibition of COX-2 
requires much higher doses and more regular dosing intervals because high peroxidase 
tone at sites of inflammation inhibits COX-2 acetylation by aspirin and because 
nucleated cells rapidly resynthesize the enzyme [109]. 
 
Aspirin is currently the first line anti-platelet agent for the secondary prevention of CAD. 
This is based upon robust, widely accepted data that in patients with occlusive vascular 
disease low dose aspirin reduces thrombotic events by around 30% [110-112].  Aspirin 
is effective in doing this at what is generally referred to today as low dose, 75-
100mg/day. Interestingly, this dose has evolved from 900-1500mg previously used in 
cardiovascular trials [113-115]. The second international study of infarct survival (ISIS-2) 
randomised controlled trial (RCT) published in 1988 actually analysed the safety and 
efficacy of low dose aspirin (162.5mg) at one-tenth of the aspirin dose employed in 
earlier trials and demonstrated a 23% reduction in mortality, a 46% reduction in non-
fatal stroke and a 49% reduction in non-fatal reinfarction [113]. Several influential 
Antiplatelet Trialists’ Collaboration meta-analyses have been conducted over the last 
three decades with the first in 1994 recommending an aspirin dose of 75-325mg as the 
most effective regime, which was later refined to 75-150mg in the 2002 Antithrombotic 
Trialists’ Collaboration [114, 115].   
 
The efficacy and safety of aspirin has been evaluated in a spectrum of clinical 
phenotypes from patients presenting with STEMI to healthy low-risk individuals.  Many 
studies conducted consistently demonstrate the benefits of aspirin in the prevention of 
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thrombotic events in high risk patients where the benefits clearly outweigh the risks 
with a 4-8% annual thrombosis risk, whereby aspirin prevents 10-20 fatal and non-fatal 
vascular events per 1000 patients (NNT 50-100) at the cost of 1-2 major bleeding 
complications for 1000 per year (NNH 500-1000) [115]. Aspirin however, is not 
recommended for primary prevention in low risk individuals without pre-existing 
vascular disease. Although trials in primary prevention show a reduction in ischaemic 
events this is associated with an increase in bleeding, both in the GI tract and 
haemorrhagic stroke [116, 117]. It was estimated that aspirin in primary prevention 
reduced fatal MI 1-3 per 1000 however, was associated with 1-2 per 1000 major GI 
bleeds and 0.1-0.2 per 1000 intracranial bleeds [116]. Therefore, in these patients, 
decisions regarding anti-thrombotic therapy need to be made on an individual patient 
basis. This is because aspirin therapy is associated with an increased risk of 
haemorrhagic complications and it is generally accepted that aspirin-induced 
impairment of primary haemostasis cannot be separated from its antithrombotic effect 
[100]. This critical balance will depend on the assessment of absolute thrombotic risk 
versus the bleeding risk in an individual patient and it is important to evaluate the net 
benefit of aspirin therapy versus the harm in order to avoid potentially devastating 
complications such as intra or extracranial bleeds which, are thankfully rare 
complications. Aspirin can also cause serious GI bleeding as a result of direct inhibition 
of COX-1 in the gastric mucosa, as well as COX-1 inhibition in platelets. The incidence of 
GI complications however, appears to be related to the aspirin dose employed [100].  
Although currently only recommended in guidelines for the prevention of cardiovascular 
disease aspirin therapy has been associated with a reduction in the incidence of cancer 
[118], especially colon cancers [119]. This chemopreventative action of aspirin and other 
NSAIDs has been linked to inhibition of both COX-1 and COX-2 [118].    
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1.7.2 P2Y12 receptor antagonists 
The secondary mediator ADP which is released from dense platelet granules following 
platelet activation plays a crucial role in thrombus formation and therefore, its receptors 
are valuable targets for anti-thrombotic therapies. As discussed, ADP mediates its 
effects through activation of two purinergic receptors on platelets: P2Y1 and P2Y12. The 
P2Y1 receptor is expressed in virtually all tissues in the human body. Antagonists of the 
P2Y1 receptor have the potential to be effective anti-platelet agents and are under 
development. The P2Y12 receptor has a much more selective tissue distribution and as 
such has been an important target for anti-thrombotic agents for a number of years. 
P2Y12 antagonists are currently prescribed alongside aspirin as dual anti-platelet therapy 
(DAPT) which is recommended for the secondary prevention of atherothrombotic 
events in patients with ACS or following percutaneous coronary intervention (PCI). 
 
1.7.2.1   Thienopyridines  
This class of drug irreversibly blocks the P2Y12 receptor to inhibit the pro-aggregatory 
effects of ADP on platelets. Until recently, these agents included ticlopidine and 
clopidogrel but over the last decade prasugrel has also been developed. The reversible 
nonthienopyridine platelet ADP P2Y12 inhibitors ticagrelor and cangrelor are also now in 
clinical use. 
 
1.7.2.1.1 Ticlopidine 
Ticlopidine, a pro-drug requiring a two-step metabolism by cytochrome P450 (CYP P450) 
enzymes became the first P2Y12 receptor antagonist for clinical use in 1978 [120]. 
Despite reducing cardiovascular events by 30% its utility was hindered by GI side effects 
and toxicity which included neutropenia and rarely thrombotic thrombocytopenic 
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purpura (TTP) [121]. Following the results of a large meta-analysis which found 
compared to ticlopidine, its structural analogue clopidogrel significantly reduced major 
adverse cardiovascular events (MACE) (2.1% versus 4.0%, p<0.002) [120] and was not 
associated with adverse haematological side effects, ticlopidine was replaced by 
clopidogrel. 
 
1.7.2.1.2 Clopidogrel 
Clopidogrel is structurally related to ticlopidine but better tolerated with fewer adverse 
side effects. Like ticlopidine, it is inactive in vitro and requires a two-step metabolic 
conversion into its active compound to exert its anti-platelet effects. Following 
ingestion, 85% is inactivated by the CYP P450 enzyme, CYP2C19. The remaining 15% 
undergoes hydrolysis by the CYP3A4 enzyme into its active form which binds irreversibly 
to the platelet P2Y12 receptor for the lifespan of the platelet. This prolonged metabolism 
accounts for the slow onset pharmacological profile of clopidogrel which takes 4-5 days 
to reach maximum effect of platelet ADP inhibition at a daily dose of 75mg, although 
this can be reduced to 2-5 hours following a loading dose of 300-600mg [122]. 
Clopidogrel has several other limitations despite being the workhorse of this class of 
drug for over a decade. Clopidogrel is associated with a wide individual variability in 
pharmacodynamic response, relating to factors affecting its generation into an active 
metabolite, such as loss-of-function polymorphisms of the CYP2C19 gene, meaning that 
a third of patients do not achieve a satisfactory level of platelet inhibition [123]. 
Hyporesponsiveness can also be attributed to other factors such as nonadherence, poor 
absorption or comorbidities [124]. Many drugs have been shown to interfere with the 
metabolism of clopidogrel with well-known drug interactions at the CYP level to statins, 
proton-pump inhibitors (PPIs) and calcium channel antagonists [125].  
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Several clinical trials have demonstrated the benefits of clopidogrel prescribed in 
combination with aspirin. Since then DAPT has been adopted as standard treatment 
following ACS or PCI [126, 127] and although the optimum duration of this therapy is 
disputed (6, 12 or 18 months, for example) it has indeed translated into improved 
patient outcomes [128]. Addition of clopidogrel to aspirin in patients with NSTEMI or 
unstable angina reduced MACE by 20% in the landmark CURE trial [129]. In the CURE-
PCI substudy death rates, MI and target vessel revascularization (TVR) were improved 
with a 30% relative risk reduction (RRR) at 30 days [130]. The advantages of clopidogrel 
have also been demonstrated in STEMI patients in the COMMIT/CCS-2 study which, in 
2005 found the composite endpoint of death, re-infarction or stroke was significantly 
reduced from 10.1% to 9.2% (p=0.002) without a significant increase in bleeding with 
clopidogrel [131]. The use of clopidogrel has not been found to be beneficial in primary 
prevention. High-risk patients without recent events in the CHARISMA trial in 2006 
showed no significant reduction in MI, stroke or death (6.8% versus 7.3%, p=0.22) but a 
significant increase in global use of strategies to open occluded arteries (GUSTO) 
moderate bleeding (2.1% versus 1.3%, p=0.046) compared to those patients treated 
with aspirin alone [132].  
 
The dosing regime of clopidogrel has been assessed and optimised in several clinical 
trials. Of note, the CREDO trial found a significant decrease of 26.9% RRR in MACE at one 
year in patients undergoing PCI who received a loading dose of clopidogrel 300mg 
compared to placebo [133]. The CURRENT/OASIS trial reported that a 7-day double-dose 
clopidogrel regimen led to a decrease in cardiovascular events and stent thrombosis (ST) 
in patients undergoing PCI for ACS compared to standard dose. This reduction however, 
came at the cost of a significant increase in bleeding [134].  
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An Interesting point is that because of the manner in which this therapeutic approach 
has evolved most large-scale RCT carried out over more than a decade to assess the 
efficacy of P2Y12 inhibitors have nearly always been conducted in the presence of aspirin. 
A sparse exception was the CAPRIE trial, which was the first major clinical trial to test 
the safety and efficacy of clopidogrel compared to aspirin published in the Lancet in 
1996 [135]. This study of 19,185 patients with symptomatic coronary, cerebral or PAD 
found clopidogrel to be superior to aspirin in risk reduction of cardiovascular events 
(5.32% versus 5.83%; 8.7% RRR with clopidogrel; p<0.05). At that point, clopidogrel was 
considerably more expensive than aspirin and therefore, did not replace aspirin therapy 
in the treatment of cardiovascular disease. In the MATCH trial of patients with recent 
transient ischaemic attack (TIA) or ischaemic stroke the addition of aspirin to clopidogrel 
led to a non-significant reduction in major vascular events (RRR 6.4%) but a significant 
increase in bleeding (1.3% to 2.6%) [136]. Therefore, importantly and unbelievably, RCT 
assessing the efficacy of clopidogrel without aspirin are lacking.  
 
1.7.2.1.3 Prasugrel 
More recently, prasugrel and ticagrelor have been marketed as third generation P2Y12 
receptor antagonists. Prasugrel is a pro-drug which irreversibly inhibits the platelet ADP 
P2Y12 receptor. Compared to clopidogrel it has a faster onset of action, produces 
stronger and more consistent levels of P2Y12 blockade and is associated with less 
interpatient variability. Prasugrel is metabolised in a two-step process, initially rapidly 
hydrolysed by esterases in the intestine, liver and plasma into thiolactone which then 
undergoes CYP 450 oxidation to form the active metabolite R-138727 [137]. 
Importantly, prasugrel does not substantially inhibit the CYP1A2-, CYP2C9-, CYP2C19-, 
CYP2D6-, or CYP3A-mediated metabolism of co-administered drugs [138]. Its active 
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metabolite appears in plasma within 15 minutes of dosing and peaks at around 30 
minutes [139]. The median plasma half-life of the active metabolite is approximately 4 
hours, and excretion is mainly urinary [140]. The landmark TRITON-TIMI 38 trial 
compared prasugrel to clopidogrel in 13,500 patients undergoing PCI. Prasugrel 
significantly reduced the primary endpoint of cardiovascular death, MI or stroke (9.9% 
versus 12.1%, p<0.001) however, this occurred at the expense of significantly increased 
rates of thrombolysis in myocardial infarction (TIMI) major and minor bleeding 5% 
versus 3.8%, p=0.004) [141]. The net clinical benefit favoured prasugrel (12.2% versus 
13.9%) however, identified two groups of patients who did not benefit; those patients 
weighing less than 60kg and those aged over 75 and therefore the dose prescribed to 
these patients is reduced from 10mg to 5mg. One group, those with a prior history of 
CVA or TIA actually showed net harm from prasugrel (HR=1.54, p=0.04) and this therapy 
is therefore, contra-indicated in these patients.  
 
1.7.2.2   Nonthienopyridines 
These represent a new class of drug which target the P2Y12 ADP receptor. 
 
1.7.2.2.1 Ticagrelor 
The first cyclopentyltriazolo-pyridine (CPTP) is oral ticagrelor which received U.S Food 
and Drug Administration (FDA) approval in 2011 for use in patients following ACS. 
Ticagrelor is direct acting, not requiring conversion to an active metabolite and 
therefore, results in a more predictable pharmacological profile. It does however, 
undergo principally hepatic metabolism via the CYP P450 pathway with generation of 
active metabolites which bind reversibly to the P2Y12 receptor at an independent ligand 
site, non-competitively blocking ADP induced platelet aggregation [142]. Ticagrelor has 
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a rapid absorption with a peak concentration reached at 90-180 minutes and a half-life 
of 7 to 12 hours so needs to be administered twice daily [143]. In the ONSET/OFFSET 
study, Gurbel et al compared the effects of ticagrelor (180 mg LD, 90 mg bd MD) to 
clopidogrel (600 mg LD, 75 mg od MD) on inhibition of platelet aggregation (IPA) in 123 
patients with stable CAD on aspirin [144]. The primary end point for onset, IPA at 2 hours 
after loading (20 µM ADP) was significantly greater for ticagrelor than for clopidogrel 
(88% versus 38%) and was significantly greater at 0.5, 1, 4, 8, and 24 hours after loading 
and also at 6 weeks (p<0.0001 for all). Ticagrelor was significantly faster in offset after 
drug discontinuation and on day 3 after the last dose IPA in the ticagrelor group was 
comparable to the IPA in the clopidogrel group at day 5. The pivotal multicentre, double 
blind phase III PLATO trial comparing ticagrelor to clopidogrel in 18,624 patients with an 
ACS clearly demonstrated improved cardiovascular outcomes, including a reduction in 
ischaemic events and all-cause mortality with ticagrelor as compared to clopidogrel with 
comparable rates of major bleeds [145], in contrast to prasugrel in the TRITON-TIMI 38 
trial [141]. This trial ultimately led to FDA approval for the drug in 2011. Interestingly, in 
keeping with other studies, for example the DISPERSE-2 trial [146], PLATO found 
significantly higher rates of dyspnoea and ventricular pauses associated with ticagrelor 
therapy. There was also an intriguing incongruity referred to as the ‘North American 
paradox’ in the study, with the outcome of the trial indicating reduced efficacy of 
ticagrelor versus clopidogrel in North American patients. The reason for this 
geographical difference remains unproven and could just be a consequence of the 
vagaries of substudy analysis. However, Mahaffey et al analysed patient characteristics 
based on geographical regions and raised the possibility that the higher doses of aspirin 
used in the United States could play a role in the differential response to ticagrelor [147]. 
Whilst this could be simply attributable to statistical chance, it highlights the possibility 
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of the existence of a class effect of P2Y12 blockers interacting with aspirin, as has been 
previously suggested by Leadbeater et al [148] and Warner et al [149]. This hypothesis 
is being explored in ongoing largescale RCT, namely the GLOBAL-LEADERS, 
https://clinicaltrials.gov/ct2/show/NCT01813435; and TWILIGHT trials, which will 
provide important new information. For now, the FDA currently recommend the use of 
aspirin at doses of less than 100mg, with doses exceeding this possibly reducing the 
effectiveness of ticagrelor.  
 
1.7.2.2.2 Cangrelor 
Cangrelor is another potent, short-acting novel inhibitor of ADP induced platelet 
aggregation belonging to the CPTP class of drugs, which received approval from the FDA 
in June 2015. Like ticagrelor, it is reversible as it does not lead to a structural change in 
the ADP receptor. However, unlike ticagrelor it is an ATP analogue which binds 
competitively to the P2Y12 receptor and is only available for use through the intravenous 
(IV) route. It does not require conversion to an active metabolite and is metabolised 
through dephosphorylation pathways in plasma [150]. Once administered, it leads to 
almost immediate P2Y12 blockade and due to its half-life of 3-6 minutes results in rapid 
reversal of anti-platelet effects after cessation of the infusion [151].  Initially, two large 
phase III trials, CHAMPION-PCI and CHAMPION-PLATFORM were abandoned due to 
poor interim results in mid-2009. The CHAMPION-PCI trial compared cangrelor to 
clopidogrel 600mg loading dose finding no significant difference in either the primary or 
secondary end points studied between the two groups [152]. The CHAMPION-
PLATFORM study randomized patients with an ACS to receive either cangrelor or 
placebo during PCI. Again, the trial was terminated early as it was unlikely that it would 
show superiority of cangrelor. The primary end-point of composite death, MI or 
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ischaemia-driven revascularization at 48 hours post-PCI was non-significantly decreased 
by cangrelor (7.0% versus 8.0%, p=0.17). A reduction in the secondary end point of a 
reduction in ST rates was observed however, significantly higher bleeding rates were 
also observed in the cangrelor group [153]. The CHAMPION PHOENIX trial was a later 
phase III randomized study comparing cangrelor to clopidogrel in 11,145 patients 
undergoing PCI. Cangrelor reduced the likelihood of patients experiencing death, MI, 
ischemia-driven revascularization, or ST (5.9% to 4.7%), with the occurrence of ST 
reduced (1.4% to 0.8%)[154]. The BRIDGE trial evaluated the use of cangrelor as a bridge 
to coronary artery bypass graft (CABG) surgery in patients receiving DAPT. Results 
confirmed the efficacy and safety of cangrelor in this population demonstrating that 
cangrelor could represent an effective bridging therapy for patients taking 
thienopyridine antiplatelet agents, such as clopidogrel who are scheduled for surgery. 
Patients randomised to the cangrelor arm had significantly lower levels of platelet 
reactivity throughout the treatment period compared with placebo (98.8% versus 
19.0%, p=0.01) but did not experience increased bleeding rates (11.8% versus 10.4%, 
p=0.76) [155].  
 
1.7.2.2.3 Elinogrel 
Elinogrel is a novel reversible ADP P2Y12 receptor antagonist which can be given both 
orally and IV. It does not require activation and has a rapid onset and offset of action. 
Elinogrel was assessed in the phase II trial INNOVATE-PCI, which showed platelet 
inhibition was significantly higher with elinogrel compared with clopidogrel [156] but no 
differences in major or minor bleeding were observed [157]. There are currently 
however, no Phase III trials of elinogrel planned. 
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1.7.3 PDE inhibitors 
Whilst aspirin and P2Y12 receptor antagonists block specific receptors, PDE inhibitors 
reduce the breakdown of cyclic nucleotides. As discussed, cAMP and cGMP regulate 
platelets by activating PKA and PKG respectively, which phosphorylate intracellular 
protein substrates. Hence, the intensity of the signal transduction in platelets is 
determined by the concentration of these cyclic nucleotides with elevation of either 
causing a reduction in platelet reactivity [158]. Because of the key roles of these 
secondary messengers in regulating cellular signalling and function, platelets also 
contain a range of enzymes that rapidly degrade both cAMP and cGMP, the PDEs. These 
are fundamental for platelet function and are the targets of this class of drug. There are 
11 isoforms of PDEs in the human body with different tissue distributions, specificities, 
targets and sensitivities to inhibitors [159]. There are over 100 PDE proteins and 
platelets are known to express PDE-2, PDE-3A and PDE-5 [160]. PDE-2 and PDE-3A 
hydrolyze cAMP and PDE5 hydrolyzes cGMP and therefore, both PDE-3A and PDE-5 
inhibitors are marketed. It is important to note that PDEs are not specific to platelets 
but are widely expressed in various tissues and cells and PDE inhibitors therefore, 
produce a wide range of pharmacological effects and are associated with a broad range 
of side effects such as headache, palpitations, and diarrhoea. 
 
1.7.3.1   Cilostazol 
Cilostazol is a potent inhibitor of cAMP specific PDE-3A in platelets and smooth muscle 
cells where it increases levels of cAMP to produce smooth muscle relaxation and platelet 
inhibition [161]. Cilostazol inhibits platelet aggregation induced by various agonists. It is 
metabolised by CYP3A5 and CYP2C19 and is associated with substantial interindividual 
response [162]. Cilostazol was first introduced in 1988 and has been used for the 
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treatment of PAD and stroke. It was tested against placebo in the cilostazol stroke 
prevention study and found to be effective in the prevention of reoccurrence of stroke 
[163]. In a study evaluating the effects of cilostazol on walking distances in patients with 
intermittent claudication caused by PAD, cilostazol significantly increased absolute 
claudication distance at all measured time points [164]. The addition of cilostazol to 
DAPT has been shown to achieve greater platelet inhibition in patients with MI [165]. 
Cilostazol has been shown to prevent restenosis following PCI through inhibiting 
vascular smooth muscle cell proliferation. In the CREST and DECLARE-DIABETES trials, a 
reduction in stent restenosis was observed with the addition, of cilostazol to DAPT 
following BMS and DES implantation [166] [167].   
   
1.7.3.2   Dipyridamole 
Dipyridamole primarily blocks PDE-5 which hydrolyzes cGMP. In the European stroke 
prevention study 2 (ESPS-2), dipyridamole was tested in the treatment of TIA and stroke. 
It was found to be as effective as low-dose aspirin in the reduction of stroke and the 
combination of the two was twice as effective; aspirin 18%, dipyridamole 16% and the 
combination 37% compared to placebo [168]. The PRoFESS trial compared the efficacy 
and safety of two anti-platelet regimens, aspirin plus dipyridamole versus clopidogrel. 
The primary endpoint of recurrent stroke was 9% in the combination treated group and 
8.8% in the clopidogrel treated group. The secondary outcome of stroke, MI, or death 
from vascular causes was 13.1% in both groups but there were more haemorrhagic 
events in the aspirin and dipyridamole group (4.1% versus 3.6%). This large non-
inferiority trial concluded that there was no evidence that either of the two treatments 
was superior to the other in the prevention of recurrent stroke [169]. Today, 
dipyridamole has limited clinical indications and is only recommended in combination 
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with aspirin for people who have had an ischaemic stroke only if clopidogrel is 
contraindicated or not tolerated. 
 
1.7.4 Glycoprotein IIb/IIIa inhibitors 
The GPIIb/IIIa receptor is another target of anti-platelet therapy and the GPIIb/IIIa 
inhibitors represent the most potent platelet inhibitors in the treatment of acute 
thrombosis. As previously reviewed, although several different platelet agonists can 
stimulate platelet activation GPIIb/IIIa activation marks the final common step of 
platelet aggregation [170]. The importance of this receptor is highlighted in the rare 
autosomal recessive disorder Glanzmann thrombasthenia. These patients lack 
functional GPIIb/IIIa receptors and display impaired platelet aggregation to all platelet 
agonists but normal ristocetin aggregation and suffer mucocutaneous bleeding and 
increased bleeding following surgery or trauma [171].  
 
There are three parental GPIIb/IIIa inhibitors currently approved for clinical use; the first 
to be developed was the monoclonal antibody abciximab, followed by eptifibatide and 
tirofiban which have shorter half-lives. These molecules bind to GPIIb/IIIa receptors in 
resting and active forms with different affinities in stimulated and unstimulated 
platelets. The binding site for abxicimab is on the β-chain of the GPIIb/IIIa receptor, 
which is different to the site of low molecular weight inhibitors eptifibatide and tirofiban 
which target the RGD ligand binding sequence. Abxicimab has a short plasma half-life of 
10-30 minutes however, it has long pharmacodynamics due to high affinity and a slow 
dissociation rate from the GPIIb/IIIa receptor and thus, can remain bound to platelets 
for 15 days [172]. Tirofiban and eptifibatide bind reversibly to the GPIIb/IIIa receptor 
and have a plasma half-life of approximately 2 hours. Tirofiban is associated with a rapid 
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recovery of platelet reactivity within 4-8 hours of therapy cessation [173]. Cessation of 
eptifibitide therapy also results in early restoration of platelet activity [174]. 
 
GPIIb/IIIa inhibitors are indicated for use as adjuvant therapy in high risk patients 
undergoing PCI or in the treatment of unstable angina with planned PCI with an 
increased risk of thrombosis [175]. All three agents have been tested both upstream 
(administered after diagnosis) and downstream (given immediately before) of PCI.  
 
1.7.4.1   Abciximab 
Abciximab administered as a bolus before PCI followed by a 12 hour infusion in addition 
to unfractionated heparin and aspirin has been shown to reduce the risk of acute 
complications compared to placebo in three landmark trials; the EPIC, EPILOG and 
EPISTENT trials. Of note, theinopyridines were not administered to participants as they 
were not indicated at the time of the EPIC and EPISTENT trials. Abciximab in the EPIC 
trial significantly reduced the composite end point of death, MI or urgent intervention 
by 35% in high-risk patients undergoing PCI, although it did also lead to a doubling of 
bleeding complications [176]. The EPILOG trial also found a reduction in the composite 
endpoint of death, MI or urgent revascularization in more stable patients treated with 
abciximab and low dose-heparin (5.2%) and abciximab and standard-dose heparin 
(5.4%), as compared to placebo treatment (11.7%). Interestingly, in this study there 
were no significant differences in major bleeding among the treatment groups [177]. A 
similar reduction was observed in the EPISTENT study in the presence of 
theinopyridines, whereby abciximab treatment in combination with aspirin, ticlopidine 
and heparin was associated with a lower combined end point of death or MI compared 
to placebo in elective and urgent patients receiving a coronary stent (5.3% versus 10.8%) 
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or following balloon angioplasty (6.9%) [178]. More recently the ISAR-REACT study 
found the same rate of primary ischaemic outcome of 4% in elective patients receiving 
600mg clopidogrel with or without the addition of abciximab [179]. However, the ISAR-
REACT 2 trial which recruited patients with NSTE-ACS treated with aspirin and 
clopidogrel found that the addition of abciximab therapy reduced the composite 
outcome of death, MI or urgent revascularization (8.9%) versus placebo (11.9%) 
suggesting that this agent may be more effective used in the treatment of higher risk 
patients [180].    Results of studies in the context of STEMI however, have been mixed 
with some reporting the benefits of abciximab but others publishing negative results 
from the addition of this agent. Following the publication of the GUSTO IV-ACS trial, 
which showed not only no significant benefit from abciximab in medically treated 
patients but also a trend towards higher mortality associated with the administration of 
abciximab for 48 hours over placebo, this agent is not recommended for the treatment 
of patients in whom PCI is not planned and is also contraindicated in the upstream 
setting [181].  
 
1.7.4.2   Eptifibatide 
The effect of eptifibatide on platelet inhibition is dose dependent and the optimal dose 
was difficult to establish in initial trials such as the IMPACT [182] and PURSUIT [183] 
trials. This was thought to be due to the use of citrate as the choice of anticoagulant 
which led to an overestimation of the effect of eptifibatide following calcium chelation 
and the anticoagulant was changed to D-phenylalanyl-L-prolyl-L-arginine chloromethyl 
ketone (PPACK). This, in conjunction with a dose increase to two 180 µg/kg boluses 
followed by a 2.0 µg/kg infusion led to levels of platelet inhibition of 90% in 90% of 
patients tested during PCI [184]. There were two large studies conducted with 
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eptifibatide in the downstream setting, namely the IMPACT-II and ESPRIT trials. In the 
IMPACT-II trial a comparatively lower dose of 135 µg/kg followed by an infusion of 0.5 
µg/kg/minute led to a nonsignificant reduction in primary endpoint (9.2% vs 11.4%) 
[185]. The ESPIRIT trial employed a larger dose of two 180 µg/kg boluses and 2 
µg/kg/minute in patients undergoing elective PCI. This trial observed a 37% reduction in 
primary endpoint of death, MI, urgent TVR and thrombotic bailout at 48 hours (6.6% vs 
10.5%, p=0.0015) but also a significant increase in severe bleeding rates (1.3% vs 0.4%, 
p=0.027). The benefits of eptifibatide persisted at 30 days and 6 months [186]. However, 
eptifibatide, is not recommended in the upstream setting prior to visualisation of the 
coronary anatomy or decision to undergo PCI. Although results of the earlier PURSUIT 
trial indicated a reduction in death or MI at 30 days in the treatment group of NSTEMI 
patients managed medically or with PCI compared to placebo, these results were not 
mirrored in the later EARLY-ACS trial which investigated the early upstream use of 
eptifibatide compared to delayed in ACS patients treated either conservatively, by PCI 
or CABG. This strategy led to a significant increase in severe bleeding (2.6% vs 1.8%, 
p=0.02) but had no impact on the primary endpoint of all-cause mortality, MI, TVR or 
thrombotic bailout (9.3% vs 10.0%, p=0.23) [187]. 
 
1.7.4.3   Tirofiban 
The RESTORE trial tested the use of downstream tirofiban compared to placebo in 
addition to aspirin and heparin in ACS patients undergoing PCI. A significant RRR of 27% 
in the primary endpoint of death, MI, repeat PCI or CABG due to PCI failure was observed 
at day 7 (p=0.02). However, this risk reduction became nonsignificant at day 30 (16%) 
and was lost at 6 months [188]. The PRISM and PRISM-PLUS studies investigated the use 
of upstream tirofiban in high risk ACS patients. The original PRISM study demonstrated 
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a 32% reduction of the composite endpoint of death, MI or refractory ischaemia at 48 
hours in the group receiving tirofiban compared to the unfractionated heparin group 
[189]. However, the follow up PRISM-PLUS trial in which patients received either 
tirofiban and heparin or heparin or tirofiban alone was stopped prematurely due to 
excess mortality in the tirofiban treatment only group as compared to the heparin group 
only at 7 days (4.6% vs 1.1%) [190].  
 
Importantly, many of the trials testing GPIIb/IIIa antagonists were conducted prior to 
the establishment of thienopyridines in the treatment of PCI patients and limited data 
have assessed the benefits of adding a GPIIb/IIIa inhibitor to the combination of aspirin 
and a P2Y12 inhibitor. Although there is evidence that this class of agent can be of benefit 
in high risk patients treated with aspirin and clopidogrel undergoing PCI [191] the net 
beneficial effects are reduced and therefore, their use has become slightly marginalised 
partly due to the safer and cheaper treatment options of clopidogrel, prasugrel and 
ticagrelor. In those patients undergoing PCI receiving prasugrel or ticagrelor, GPIIb/IIIa 
inhibitors are restricted to bailout of thrombotic complications as no study has 
investigated the role of GPIIb/IIIa inhibitors in patients treated with these agents [126].  
 
Drawbacks of this class of agent is their inability to inhibit platelet activation, associated 
thrombocytopenia and also their narrow therapeutic range because the same 
mechanisms are involved in haemostasis and thrombosis. Interestingly, oral GPIIb/IIIa 
antagonists are not clinically available. Orbofiban, sibrafiban, and xemilofiban have not 
been shown to be effective in reducing ischemic events following ACS [192]. In fact, they 
were found to increase mortality by approximately one-third [193].  
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1.7.5 PAR-1 antagonists 
As previously discussed, thrombin exerts its effects on platelets through stimulation of 
PAR-1 and PAR-4 receptors. PAR receptors are abundant throughout the body and are 
found on many cell types and are involved in a number of processes including healing, 
neoplastic growth, vascular tone and inflammation, as well as of course, haemostasis 
and thrombosis [194]. Of the two PAR receptors found on platelets, PAR-1 is the target 
of this class of anti-thrombotic drug.  
 
1.7.5.1   Vorapaxar 
Vorapaxar is a novel, reversible oral anti-platelet agent which has been developed to 
competitively target the PAR-1 receptor. It is the first PAR-1 antagonist approved by the 
FDA for reduction of thrombotic events in patients with MI or PAD but is contraindicated 
in those with a previous stroke or TIA. Several phase II studies have taken place with 
vorapaxar with some finding that this agent was safe and helpful in reducing ischemic 
risk in patients. The TRA-PCI study investigated its use in patients undergoing non-urgent 
PCI already taking DAPT. This study found no increase in the primary endpoint of TIMI 
major or minor bleeding associated with vorapaxar therapy. They also found that the 60 
day MACE rate was non-significantly reduced in those prescribed vorapaxar [195]. 
However, there have been studies which do not show any efficacy benefits but an 
increased risk of bleeding. The phase III trial TRACER randomized 12,944 ACS patients 
on DAPT to receive either vorapaxar or placebo. A finding of increased bleeding rates 
actually led to the recommendation that the trial terminate early however, the following 
endpoints had already been met. Vorapaxar therapy reduced the primary endpoint of a 
composite of death from cardiovascular causes, MI, CVA, recurrent ischaemia with 
hospitalization or urgent coronary revascularization (18.5% versus 19.9%, p=0.07) 
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however, statistical significance was not reached. The secondary endpoint of a 
composite of death from cardiovascular causes, MI or CVA was significantly reduced 
(14.7% versus 16.4%, p=0.02) however, this came at a cost of significantly increased 
GUSTO bleeding (7.2% versus 5.2%, p<0.001) [196]. The addition of vorapaxar to 
standard therapy was also assessed in 26,499 stable patients in the TRA 2 degrees P-
TIMI 50 trial. Vorapaxar reduced the composite endpoint of cardiovascular death, MI or 
stroke as compared to placebo (9.3% versus 10.5%, p<0.001) however, vorapaxar 
similarly to the TRACER trial, was associated with an increase in GUSTO moderate or 
severe bleeding (4.2% versus 2.5%, p=0.001). Of concern, there was an increase in ICH 
in the vorapaxar arm (1% versus 0.5%, p<0.001) [197]. As a result, study investigators 
recommended premature cessation of vorapaxar in patients with prior stroke and it 
indeed remains contra-indicated in these patients. Scirica et al, on performing a pre-
specified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial suggested that 
vorapaxar could be helpful in those patients experiencing MI but without prior history 
of CVA [198]. A recent meta-analysis of 4 trials of vorapaxar concluded that adding 
vorapaxar to standard DAPT may be efficient in reducing the incidence of MACE but at 
the cost of increasing the risk of bleeding events [199]. Therefore, there are safety 
concerns, primarily bleeding associated with vorapaxar when prescribed in addition to 
standard DAPT. The role of vorapaxar may lie in patient populations in whom the 
benefits might outweigh the risks, such as those with PAD, a disease which is associated 
with a poorer prognosis following ACS.    
 
1.7.6 Anti-coagulants   
Early reperfusion therapy is standard in the treatment of STEMI. Fibrinolytic therapy 
with adjunctive unfractionated heparin to act against thrombin was easy to administer 
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and was shown to have marked benefits. This therapy has been largely superseded by 
primary PCI and adjuvant anti-platelet therapy and intravenous low molecular weight 
heparins (LMWH) such as fondaparinux which is superior to fibrinolysis [200].  
 
1.7.6.1    Vitamin K antagonists 
Several trials evaluating the role of oral anti-coagulants in AMI have taken place 
spanning over three decades [201]. Until recently the only available oral anticoagulants 
were the coumarin derivatives such as warfarin, which was first approved for use as a 
medication in 1954, having been initially introduced as a pesticide in 1948. The discovery 
of warfarin came as a result of the unexplained haemorrhagic deaths of cattle who had 
consumed mouldy silage made from a sweet clover plant, 'sweet clover disease' as it 
was known at the time. Chemist Dr Paul Link isolated the anticoagulant dicoumarol in 
1939 as the cause of the disease. Named warfarin, after the Wisconsin Alumni Research 
Foundation (WARF) which funded his research, this agent went on to become the most 
commonly prescribed anti-coagulant for the next 60 years saving millions of lives. This 
class of agent, the so called vitamin K antagonists work by blocking the vitamin K-
dependant production of coagulation factors II, VII, IX and X in the liver. Following the 
introduction of the International Normalised Ratio (INR) and lower doses of aspirin, 
warfarin therapy alone and in combination with the latter has been shown to reduce 
ischaemic events in several secondary prevention trials but at the cost of increased risk 
of major bleeding [202, 203]. Warfarin therapy however, has an established role in the 
treatment of venous thromboembolism (VTE) and also markedly reduces the risk of 
thromboembolism and stroke in atrial fibrillation (AF). However, more recently the rates 
of major and minor bleeding associated with triple therapy warfarin, aspirin and a 
thienopyridine have been highlighted as clinically important and significantly greater 
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than those reported with DAPT, leading to changes in the routine prescription of this 
therapeutic strategy and often the removal of aspirin from this regime [204]. 
 
One major drawback of warfarin is its narrow therapeutic window which requires 
monitoring to avoid life threatening bleeding although, adoption of the INR by the World 
Health Organization (WHO) in 1983 resulted in greater safety and effectiveness of the 
oral anticoagulant [201]. However, treatment with warfarin remains problematic 
despite monitoring, with less than two-thirds of patients found to be within the 
recommended INR range of 2-3 at testing, its many interactions with drugs and food 
types, and its most variable dose-response curve [205]. These limitations led to the 
development of the novel oral anti-coagulants (NOACs) in recent years.  
 
1.7.6.2   Novel oral anticoagulants 
The three currently licensed NOACs, rivaroxaban, dabigatran and apixaban are 
alternatives to vitamin K antagonists for use in the prevention of VTE in non-valvular AF, 
as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism 
(PE). They are promising in that they have a predictable effect without the need for 
monitoring, fewer food and drug interactions, a shorter plasma half-life and an 
improved efficacy/safety ratio to warfarin [206]. Dabigatran is an oral direct thrombin 
inhibitor (DTI) and rivaroxaban and apixaban are oral factor Xa inhibitors.  
 
1.7.6.2.1 Dabigatran 
The FDA granted dabigatran exilate, the second clinically tested DTI approval in 2010 
and issued a further statement in 2014 that compared to warfarin it reduced the overall 
risk of mortality and stroke but increased the risk of GI bleeding. It is a low molecular 
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weight peptidomimetic that binds directly and reversibly to the catalytic site of 
thrombin. It has low bioavailability, is a prodrug which is converted to the active drug 
dabigatran by serum and liver esterase hydrolysis with peak levels appearing at 2-3 
hours. It has a half-life of 12 hours and excretion is predominantly via the renal route as 
unchanged drug [207]. In two large trials published in the New England Journal of 
Medicine (NEJM) the RE-LY trial and the RE-COVER trials, dabigatran was shown to be 
non-inferior to warfarin in patients with AF and VTE, respectively [208, 209]. It was also 
tested in a phase II study in secondary prevention following ACS in the RE-DEEM study 
in combination with aspirin and clopidogrel. Dabigatran patients showed higher 
bleeding event rates with limited reductions in ischaemic complications and dabigatran 
is therefore, not indicated in the ACS setting [210]. An antidote to dabigatran, 
idarucizumab, a monoclonal antibody, which completely reverses the anticoagulant 
effect of dabigatran within minutes has been developed by Boehringer Ingelheim and 
received approval by the FDA in October 2015 [211]. 
 
1.7.6.2.2 Oral factor Xa inhibitors 
Factor X is synthesized by the liver. It is the first member of the final common 
coagulation pathway as it is positioned at the convergence point of the intrinsic and 
extrinsic pathways of coagulation. Factor X is activated by hydrolysis into factor Xa by 
both factor IX, with its cofactor factor VIII and factor VII, with its cofactor TF and goes 
on to catalyze the conversion of prothrombin to thrombin.  
 
1.7.6.2.2.1   Rivaroxaban 
Rivaroxaban is the first orally available factor Xa inhibitor, manufactured by Bayer. It is 
a highly selective reversible factor Xa inhibitor which inhibits prothrombinase and clot-
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bound factor Xa. The compound is well absorbed from the gut with plasma levels 
peaking at around 4 hours. Its effects last 8–12 hours but factor Xa activity does not 
return to normal within 24 hours so rivaroxaban is prescribed once-daily. Two thirds is 
excreted unchanged in urine and the rest is metabolized in the liver by CYP P450 
dependent and P450 independent mechanisms [212]. Importantly, is has no known 
drug-drug interactions. Rivaroxaban was shown to be more effective than enoxaparin in 
the prevention of VTE in the RECORD trials and as effective as warfarin in the treatment 
of VTE, PE and AF associated prevention of stroke in the EINSTEIN trials and ROCKET 
trials, respectively [213-215]. Its use was also evaluated in the secondary prevention of 
ACS in addition to aspirin with or without clopidogrel in the ATLAS and ATLAS-II studies. 
Although rivaroxaban reduced ischemic events it caused significant increases in major 
bleeding, clinically relevant bleeding, non-CABG bleeding and ICH in a dose-dependent 
manner and rivaroxaban is yet to receive FDA approval for use in the ACS setting [216, 
217].  
 
1.7.6.2.2.2   Apixaban 
Apixaban, like rivaroxaban, is a highly effective reversible factor Xa inhibitor that inhibits 
prothrombinase activity and factor Xa within the prothrombinase complex. It has good 
bioavailability, reaches peak levels at 1-4 hours in plasma, has a half-life of 8-15 hours 
and is metabolized in the liver via CYP3A-4 dependent mechanisms. It was tested in the 
treatment and prophylaxis of DVT and PE in the ADVANCE and AMPLIFY trials and was 
approved for use in Europe in 2012 and in the US in 2014 [218, 219]. The ARISTOTLE trial 
in AF patients with a risk factor for stroke, found apixaban compared to warfarin therapy 
not only significantly reduced the occurrence of stroke and systemic embolism but also 
reduced the risk of major bleeding [220]. Apixaban however, is not indicated in the 
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secondary prevention of ACS after both APPRAISE trials showed increased dose-related 
rates of bleeding with little positive impact on ischemic events leading to their 
premature closure [221, 222]. 
 
From this overview, one can appreciate that all of these anti-platelet agents that act to 
reduce thrombotic risk are all associated with increased bleeding risk given the 
overlapping nature of the mechanisms of haemostasis and thrombosis. Given this, a 
wealth of cardiovascular research is ongoing with the ultimate goal of establishing 
therapies that will optimize thrombotic risk but not at the cost of bleeding. Agents in 
development at present include GPVI, GP1b, vWF and integrin α2β1 inhibitors that are 
out of the scope of this review but hold future promise as potential anti-thrombotic 
agents.         
 
Despite this broad range of therapeutic approaches recurrent coronary thrombosis still 
occurs. Given the central role of platelets in thrombosis there have been great efforts 
made to find ex vivo tests of platelet function that could assess and optimise on 
treatment platelet reactivity to improve patient outcomes. Some of the principle 
methods of platelet testing are reviewed in the next section after first highlighting the 
important interactions taking place between one of the most commonly prescribed anti-
platelet therapies, DAPT and endogenous pathways in both platelets and endothelial 
cells. Key interactions that will become the principal focus of this thesis. 
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1.8 DAPT, NO and PGI2  
 
The aim of this next section is to highlight the key interactions taking place between the 
anti-platelet drugs, aspirin and P2Y12 receptor blockers, prescribed as DAPT and 
endogenous platelet pathways whilst underlining the importance of the endothelium. 
For some time it has been appreciated that an important interplay exists between the 
endothelium, platelets and the mediators that they produce which, is fundamental to 
cardiovascular homeostasis. However, in more recent years exciting interplays between 
anti-platelet drugs and endogenous pathways in both platelets and endothelial cells are 
emerging. 
 
1.8.1 Aspirin 
As previously described platelets and endothelial cells use COX to produce TXA and PGI2, 
respectively. Low dose aspirin prescribed today (<100 mg) is sufficient to completely 
inhibit platelets [107]. It has been demonstrated that lack of blockade of platelet COX-1 
in people taking regular low dose aspirin is remarkably rare [223] and that in fact, in 
patients administration of 30mg daily is sufficient to suppress TXA2 production by 95% 
[224]. Importantly, in addition to its effects upon platelets, aspirin will also inhibit COX 
at other sites in the body, including the blood vessel wall [225-227].  Higher doses of 
aspirin have anti-inflammatory, anti-analgesic and anti-pyretic effects which are 
mediated through inhibiting COX at sites other than the platelet. This can lead to 
changes in the balance of the formation of pro-aggregatory TXA2 by platelets and anti-
aggregatory PGI2 by the blood vessel wall, a mechanism which is thought to account for 
the increased risk of thrombosis associated with strong, whole body blockade of COX 
enzymes [228]. These changes can be followed by the measurement of urinary 
metabolites [225, 226, 229-232].  For example, Fitzgerald et al established that 80mg 
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aspirin reduced urinary TXA2 metabolites by around 80% and PGI2 metabolites by 
around 50%; 325mg aspirin reduced the metabolites, respectively, by around 95% and 
70% [225]. Interestingly, the investigators concluded that it was unlikely that any dose 
of aspirin could be completely selective for the inhibition of TXA2 synthesis. In keeping 
with this, in ‘at risk’ patients with severe atherosclerotic disease even at a dose of 50mg 
aspirin significantly reduced urinary levels of PGI2, as well as TXA2 [233]. These findings 
along with similar reports by others [226, 234, 235] strongly suggest that aspirin even at 
low doses leads to substantial inhibition of COX within the vasculature, both in platelets 
and in the vascular endothelium and so reduces PGI2 production [226, 236]. It is well 
recognised that reduction in PGI2 signalling in platelets causes increased in vivo 
activation but it is also becoming clear that aspirin therapy could potentially have 
additional deleterious effects within the cardiovascular system by disrupting the 
powerful interplays between platelets, the endothelium and P2Y12 receptor antagonists 
which, I describe below. 
 
1.8.2 P2Y12 receptor antagonists 
As mentioned previously, NO and PGI2 have long been recognised to synergise to 
produce powerful platelet inhibition [74]. Further key inhibitory relationships between 
P2Y12 receptor antagonists and the endothelial mediators NO and PGI2 have come to 
light in recent years. Importantly, in 2007 it was shown by Cattaneo et al that P2Y12 
receptor blockade potentiates the inhibitory effects of PGI2 on platelets [237]. 
Furthermore, in 2013 Kirkby et al demonstrated that there also exists a powerful 
synergistic interaction between NO and P2Y12 receptor blockade whereby, the blockade 
of P2Y12 receptors dramatically increases the inhibitory effects of NO on platelets [238]. 
This is because the P2Y12 receptor is a G-protein coupled receptor which is negatively 
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coupled to AC, a key regulator of cyclic nucleotides. P2Y12 receptor activation blocks the 
action of AC rapidly turning off the production of cAMP and countering the inhibitory 
signalling actions of cGMP. When P2Y12 receptors are blocked the effects of PGI2 and NO 
acting through the cAMP and cGMP signalling pathways are unimpeded and so their 
inhibitory effects are notably increased relative to P2Y12 receptor uninhibited platelets. 
PGI2 and NO have synergistically inhibitory effects upon platelets and the interaction 
with P2Y12 receptor blockers would theoretically provide a powerful three way 
synergistic effect: NO, PGI2 and P2Y12 receptor blockade are inhibitory individually, 
synergise with each other in individual pairs, and would synergise still further as a trio 
to provide far more potent platelet inhibition [239]. Thus, excitingly it could be that 
P2Y12 receptor antagonists exert part of their powerful antithrombotic effect through 
potentiation of the endogenous, endothelial derived inhibitors of platelet function, NO 
and PGI2. Accordingly, the important in vivo synergy between NO and PGI2 may serve to 
amplify the anti-thrombotic effects of P2Y12 inhibitors suggesting that the effectiveness 
of P2Y12 receptor antagonists could vary in individual patients depending on their 
endogenous production of inhibitory mediators and that endothelial function is actually 
key in determining the therapeutic potential of P2Y12 therapy. As a further layer of 
complexity, it should be noted that critically, a reduction in endothelial produced PGI2 
caused by the co-administration of aspirin could potentially hinder PGI2’s pivotal role in 
this powerful synergism. These vital concepts will be further investigated in this thesis 
following a brief review of current methods of both platelet and endothelial function 
testing. 
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1.9 Platelet function testing 
 
Platelets have an established role in maintaining normal haemostasis and are therefore, 
associated with both bleeding disorders and thrombotic events. Traditionally, platelets 
were tested for evidence of bleeding disorders in specialist centres but today with our 
increased understanding of the core role of platelets in atherothrombosis, platelet tests 
are also performed which aim to identify patients at risk of cardiovascular events and to 
monitor anti-platelet therapies in non-specialist centres. The increasing number of 
patients taking anti-thrombotic therapies has led to the advent of simpler platelet tests 
which are applied to identify patients at risk of bleeding during surgery or post trauma 
and also in transfusion medicine. 
 
The first in vivo platelet function test (PFT) to become established was the bleeding time 
assay by Duke in 1910. A cut would be made on the forearm and the time taken for 
cessation of bleeding recorded. More refined versions of this simple method remained 
established as the most reliable screening test until the 1990s. It has now been replaced 
by a screening bleeding history and more modern tests of platelet function as it is 
invasive, its reproducibility is low and it fails to identify subtle bleeding disorders. 
Essentially, it is not a useful predictor of the risk of bleeding in patients [240].  
 
1.9.1 Light transmission aggregometry 
In the 1960s, platelet testing was revolutionised by Gustav Born and John O’Brien who 
independently developed the concept of light transmission aggregometry (LTA) which 
remains the gold standard for assessment of various aspects of platelet functions in 
specialised laboratories today [241]. This test measures the ability of platelets in platelet 
rich plasma (PRP) to aggregate together following stimulation with an external agonist 
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in vitro. By adding a wide panel of agonists to PRP, a considerable amount of data can 
be obtained about the various pathways of platelet activation [242, 243]. The 
instrument consists of a light source and detector into which a cuvette containing PRP 
and a stirbar is placed. The test is based on detection of the increase in light transmission 
through the optically dense PRP with the precipitation of platelet aggregates following 
the addition of an exogenous platelet agonist. The aggregometer will record the rate 
and amount of maximal and final percentage aggregation (MA/FA) compared to the 
maximal optical density 0% (PRP) and minimal optical density 100%, platelet poor 
plasma (PPP).  
 
This technique is associated with drawbacks. It may be affected by different pre-
analytical conditions such as lipid plasma, haemolysis, or low platelet count. It requires 
relatively large volumes of blood, is labour intensive and time consuming, requiring 
skilled operators. Results may also be affected by procedural conditions such as PRP 
preparation and agonist concentration used. In an effort to improve and standardize the 
evaluation of platelet function, standardization processes and development of 
consensus guidelines on PFT have been developed, although these are more established 
in the bleeding rather than the thrombosis field [244]. LTA has been criticized for not 
representing a physiological test as platelets are not exposed to the endogenous factors 
that they would be in vivo, namely for example the endothelium, the extracellular matrix 
and the inhibitors PGI2 and NO. It also creates a circular low shear system as opposed to 
the high parallel shear which is encountered in blood vessels and is a closed 
environment with high concentrations of single agonists which is not representative of 
the physiological environment. Nonetheless using LTA, high rates of residual platelet 
reactivity to ADP and AA have been associated with the development of ischaemic 
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events in patients with cardiovascular disease, and arbitrary clinical research cut-off 
values for ADP and AA-induced platelet aggregation have been suggested. However, 
LTA’s predictive accuracy is only modest [245].  
 
1.9.2 Modified 96-well plate assay 
This technique is based on the same principles as LTA but is applied to a 96-well plate in 
order to test multiple platelet activation pathways [246, 247]. It is designed to be able 
to test multiple conditions at the same time, to reduce the labour intensity of LTA and 
also to reduce the amount of blood required. PRP and PPP are added to the plate to act 
as controls in a similar fashion to LTA. PRP is then added to incubation wells with 
agonists either coated or in solution, which will cause platelet aggregation upon stirring. 
The plate is typically stirred for 5 minutes before absorbance is measured in a 
conventional plate reader and represented as percentage aggregation.  
 
1.9.3 Lumi-aggregometry 
This technique is another modified assay based on LTA. It is essentially an assessment of 
platelet degranulation and secretion which contributes to the process of platelet 
activation. The release reaction is quantified by measuring the luminescence caused by 
the release of ATP, which is usually stored in dense granules [248]. This method is 
particularly useful in detecting disorders caused by storage pool and release disorders.  
 
1.9.4 Whole blood aggregometry 
Similarly to LTA, this method measures platelet aggregation however, rather than using 
optical detection it measures changes in impedance between two platinum wire 
electrodes as platelets aggregate in response to platelet agonists [249]. This is a useful 
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method as it bypasses the requirement for the separation of platelets from the rest of 
the blood which, is not only time consuming but removes other blood constituents 
which could affect platelet function [250]. However, the test is still time consuming and 
requires technical expertise.  
 
1.9.5 Flow cytometry based methods 
Flow cytometry is an extremely useful and resourceful technique for the study of 
platelets. It is used to measure platelet activation, to diagnose specific platelet 
disorders, measure reticulated platelets to monitor thrombopoiesis, monitor anti-
platelet agents and count platelets, to name but a few of its applications. Washed 
platelets, PRP or whole blood can be utilised for flow cytometric assays with the latter 
having the advantage that platelets are assessed in their physiological milieu. This 
technique requires very small volumes of blood and provides very sensitive and specific 
characteristics of a large number of cells. However, disadvantages are that the 
equipment is expensive and the assay preparation is complicated requiring specialised 
training. Briefly, samples to be analysed are diluted to reduce platelet aggregate 
formation. Depending on the complexity of the experiment a minimum of two 
antibodies conjugated with two different fluorophores will be added; one acting as a 
‘platelet identifier’ and the other recognising the antigen being tested. Following 
stimulation with a platelet agonist the samples are fixed and then assessed in the flow 
cytometer. Platelets can be recognised as they will exhibit the platelet identifier and 
characteristic light scatter.  
 
Platelet activation is commonly measured through use of the activation-dependent 
monoclonal antibody PAC-1 and through antibodies specific to granule proteins such as 
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P-selectin. PAC1 is directed against the fibrinogen binding site which is exposed 
following a conformational change in GPIIb/IIIa receptors of activated platelets and 
therefore, only binds when the platelet is activated [251]. P-selectin is an adhesion 
molecule which is present on the membrane of α-granules in resting platelets. P-selectin 
is only expressed on the platelet surface following α-granule secretion and therefore, P-
selectin specific monoclonal antibodies also only bind to activated platelets. P-selectin, 
via P-selectin glycoprotein ligand 1 (PSGL-1) mediates the adhesion of activated platelets 
to leukocytes. Flow cytometry can also be used to identify the interactions and binding 
of these cells to form multicellular aggregates as another marker of platelet activation.  
 
It is not only extracellular markers of platelet activation that can be detected through 
flow cytometric analysis but also phosphorylation of specific intracellular platelet 
proteins that can be detected and quantified using phosphorylation-specific monoclonal 
antibodies. This is indeed possible as permeabilisation disrupts the outer platelet 
membrane permitting antibodies to bind to intracellular proteins [252]. One widely-
studied example is phosphorylation of vasodilator-stimulated phosphoprotein (VASP). 
Under basal conditions VASP resides in a non-phosphorylated state. Prostaglandin E1 
however, though activation of cAMP leads to VASP phosphorylation. An action which is 
opposed by ADP binding to the P2Y12 receptor but permitted by an active P2Y12 receptor 
blocker. Therefore, the degree of VASP phosphorylation described as platelet reactivity 
index (PRI) will correlate with P2Y12 activity and VASP represents a sensitive method to 
measure the effectiveness of P2Y12 therapy [253].  
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1.9.6 Point of Care Analysis 
Despite DAPT, some patients will still experience further thrombotic events questioning 
the appropriateness of the ‘one size fits all’ approach to antiplatelet therapy. Due to this 
and the labour intensive, specialist centre nature of the PFT described above, simple and 
quick tests that give clear results indicating the efficacy of antiplatelet therapy have 
been developed. This has led to the proliferation of point-of-care (POC) tests, defined as 
diagnostic testing at or near the site of patient care with the potential of identifying 
patients with high on-treatment platelet reactivity (HTPR) or those at risk of bleeding 
during surgery. This would potentially allow for superior risk stratification in order to 
then tailor anti-platelet treatment to achieve therapeutic levels with a view to improving 
patient outcome. The PFA-100, Plateletworks, Impact cone and plate(let) analyser are 
all examples of POC tests. VerifyNow and Multiplate are the most widely used POC tests, 
which have been applied worldwide in cardiovascular research studies but are not 
currently recommended for routine use in clinical practice in the UK. The VerifyNow is 
described below as an example of a POC test. 
 
VerifyNow is a rapid, fully automated whole blood turbimetric-based assay, specifically 
developed to monitor the effects of antiplatelet drugs. It measures agonist induced 
agglutination of fibrinogen-coated beads by activated platelets expressing GPIIb/IIIa. 
Agonists used are AA, a combination of ADP and PGE1 or TRAP to test for the effects of 
aspirin, P2Y12 blockers and GPIIb/IIIa antagonists, respectively. The rate and extent of 
changes in light transmittance caused by the aggregating platelets is translated into 
P2Y12 reactivity units (PRU) in the context of P2Y12 antagonist therapy or aspirin 
reactivity units (ARU) and platelet aggregation units (PAU) respectively, for aspirin and 
GPIIb/IIIa cartridges [254]. In contrast to the more laborious “gold standard” in platelet 
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function testing, LTA, the ease of use of VerifyNow negates the need for skilled 
technicians and specialised laboratories and the results are not operator dependant 
[255]. It provides immediate information to facilitate prompt clinical decision making 
post PCI, for example. Importantly, it produces results which have been shown to 
correlate well with LTA [256] and in clinical trials such as ADAPT-DES, has provided 
biologically relevant results associated with adverse clinical outcomes such as ST [257]. 
Disadvantages include that it is inflexible and relatively expensive using disposable 
cartridges and only processing one sample at a time. It cannot be used for any other 
purpose than for monitoring the effects of three therapeutic agents. Factors such as 
platelet count, haematocrit, triglyceride and fibrinogen levels influence the 
performance of the assay, as does the time from blood sampling to testing [258], 
although this is true for most platelet function assays. 
 
The clinical application of VerifyNow however, along with other POC tests is vastly 
debated worldwide as the additional value of PFT above the standard clinical predictors 
of poor prognosis commonly used in daily cardiology practice is only minimal [245]. 
Furthermore, no single POC test has been advocated or has conclusively demonstrated 
reliability and definitive utility to enhance clinical outcome [259]. Although the negative 
predictive value to predict bleeding during surgical procedures is high, the positive 
predictive value of each of these tests in atherothrombosis remains limited. In addition, 
distinct POC assays provide slightly different information on diverse platelet functions 
leading to variability in the reproducibility, accuracy and correlation of these tests and 
not all assays correlate well when compared to traditional tests of platelet function. 
There are other important arguments against their use. They represent a relatively crude 
reflection of cardiovascular activity and risk. They are fundamentally only a test of in-
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vitro platelet function within a non-physiological environment and stimulus. They also 
only measure an isolated aspect of platelet function not reflecting the complicated 
nature of platelet physiology and the dynamic processes occurring in the vasculature. 
Furthermore, at present we cannot demonstrate that platelet reactivity ex vivo is a true 
representation of platelet activity in vivo and the precise HTPR thresholds that 
discriminate between patients with and without ischaemic events have not been 
determined. The next section will review the important clinical trials published in the 
area of PFT and clinical cardiovascular outcomes, before moving on to briefly describe 
tests of endothelial function. 
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1.10 Cardiovascular trials and personalised anti-platelet therapies  
 
DAPT with aspirin and a P2Y12 receptor antagonist is recommended for the secondary 
prevention of atherothrombotic events in patients with ACS or following PCI [127, 260, 
261]. However, this anti-platelet therapy regime is associated with increased bleeding 
regardless of the choice of P2Y12 inhibitor prescribed [129, 141, 145]. Clopidogrel has 
limitations which result in highly unpredictable P2Y12 receptor inhibition. The reasons 
for this widely variable pharmacological response are several fold. The principal reason 
for this is that clopidogrel undergoes a two-step metabolism process, leading to the 
generation of variable active metabolite, which can result in HTPR in 1 in 3 patients 
treated with clopidogrel [262]. Age, ethnicity, DM, renal insufficiency, ACS, obesity and 
drug-drug interactions are all additional factors that contribute to diminished 
clopidogrel response. The main pharmacokinetic and pharmacodynamics factors 
contributing to this inter-individual variability however, are not completely recognised 
[263]. 
 
Ticagrelor and prasugrel provide more reliable and more potent P2Y12 receptor 
inhibition and are effective in overcoming some of the limitations of clopidogrel 
treatment. Although recent studies have observed that HTPR can occur in response to 
prasugrel and ticagrelor treatment [144]. It has also been suggested that there may exist 
a ceiling effect even with these newer agents, as despite therapy there remains a 10% 
residual ischaemic event rate [264]. The pharmacodynamic benefits of these new agents 
have however, translated into significant clinical benefit but at a cost of increased 
bleeding. Optimal management of patients would ideally involve reduction of 
thrombotic and bleeding risks associated with P2Y12 therapy to balance efficacy and 
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safety and reduce adverse outcome. It had been hoped that monitoring platelet 
reactivity would improve patient survival by providing a valuable option to enable the 
risk stratification of patients according to their bleeding and thrombotic risk. As 
described in the previous chapter, there are several devices which test platelet reactivity 
during P2Y12 therapy. Unfortunately, this has not been the case and PFT has not been 
shown to be successful in reducing ischaemic complications and receives a class IIb 
recommendation in patients at high risk of poor clinical outcome where testing may 
alter management and a class III recommendation for routine use [265]. Therefore, 
currently despite this variability a one size fits all approach is still employed to DAPT in 
clinical practice. This is unfortunate as the concept of a therapeutic window of platelet 
reactivity is an attractive one, full of potential to improve patient outcomes in a similar 
manner to the INR utilised for warfarin. 
 
Despite this, HTPR is a firmly established independent risk factor for thrombosis [266, 
267] and there is accumulating evidence underscoring the importance of low on 
treatment platelet reactivity (LTPR) as a predictor of bleeding risk [268]. Several 
observational and larger outcome studies in patients undergoing PCI have reported 
HTPR to be linked to negative post-PCI thrombotic occurrences, with the strongest 
association demonstrating the link between short term outcomes post PCI, notably ST. 
These studies have been conducted employing various recognised laboratory methods, 
including LTA [269, 270], VerifyNow [245, 271], MEA [272] and VASP phosphorylation 
[273]. A meta-analysis also demonstrated the increased risk of cardiovascular mortality 
associated with clopidogrel non-responsiveness [267]. The prospective registry ADAPT-
DES, employing a PRU cut-off value of 208 also highlighted the importance of HTPR as a 
risk factor for ischaemic events, for example ST and MI at 1 year (p=0.005 and p=0.001, 
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respectively) [257]. In contrast, in non-PCI patients the association is less clear. The use 
of PFT to assess drug responsiveness in the ADRIE study in medically managed patients 
with stable CAD did not add any incremental predictive value of thrombotic events over 
conventional risk factors used in routine clinical practice [274].  Although, it is important 
to note that these clinical risk stratification scores are sometimes of limited use as many 
of the risk markers for thrombosis such as age, HTN and renal failure are also applicable 
as predictors of bleeding so do not discriminate between the two opposite ends of the 
spectrum outcomes.  
 
Despite the evidence linking HTPR to negative cardiovascular outcome, multiple large-
scale prospective, RCT have all failed to modify overall thrombotic risk by tailoring 
antiplatelet therapy to reduce platelet reactivity and improve patient outcomes. 
Although, it has been repeatedly cited that all of these individual trials were fraught with 
major limitations. 
 
The GRAVITAS study randomly assigned 2200 PCI patients with a PRU > 235 to receive 
either standard (300 mg LD, 75 mg MD) or high dose clopidogrel (600 mg LD, 150 mg 
MD) as treatment intervention based on a measure of platelet function to reduce post 
PCI thrombotic events. High dose clopidogrel treatment was ineffective in reducing 
composite ischaemic event occurrence [275].  
 
The ARCTIC triallists randomly assigned PCI patients to either a strategy of platelet 
function monitoring or to conventional therapy to establish whether the former strategy 
was effective in improving clinical outcomes. In poor responders, therapy was 
intensified to high dose clopidogrel or prasugrel. However, no improvements were 
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observed in the platelet function monitoring group as compared to the standard therapy 
group [276].  
 
TRIGGER-PCI sought to determine whether a strategy intervention of high dose 
clopidogrel based on a measurement of platelet function in PCI patients with HTPR 
optimised clinical outcomes. Unfortunately, the trial was pre-terminated due to lower 
than expected incidence of the primary endpoint of composite of ischaemic events 
[277]. 
 
Lastly, the TRILOGY trial conducted in medically treated ACS patients did demonstrate 
greater platelet inhibition by treatment intensification with prasugrel. However, not 
only did this not translate into event-free survival but the trial failed to show any firm 
link between HTPR and negative outcomes [278].  All of these trials put into question 
the use and prognostic relevance of PFT in patients undergoing PCI and therefore, it 
remains a vastly debated topic worldwide.   
 
There are several pertinent issues concerning the use of tests analysing platelet function 
which include the lack of standardization of some methods, notably LTA. Published cut-
offs for high and low platelet reactivity are highly heterogeneous and usually not 
validated outside of individual exploratory studies which, further fuels the controversy 
on the prognostic relevance of PFT in patients undergoing PCI. This means that currently 
there are no clinically validated thresholds distinguishing optimal platelet reactivity to 
enable precise risk stratification of patients following PCI. There are however, 
consensus-defined, uniform cut-offs for standardized platelet function assays which are 
based on exploratory studies and the best available evidence for each testing method. 
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These were reviewed in a recent collaborative analysis in 2015 on the role of platelet 
reactivity for risk stratification after PCI [279] where the following cut-offs were 
suggested for the VerifyNow, Multiplate analyser and VASP assay. LTPR-OTPR (Optimal 
on treatment platelet reactivity)-HTPR were defined as <95, 95-208, >208 PRU for 
VerifyNow, <19, 19-46, >46 U for Multiplate and <16, 16-50 and >50 for VASP assay. 
20,839 patients from 27 studies were included in the analysis which found 41% patients 
to have HTPR, 20% LTPR and 39% OTPR. Patients with HTPR when compared to OTPR 
were at higher risk of ST [RR:2.73 (2.03-3.69), p<0.00001] and had a reduced bleeding 
risk [RR:0.84 (0.71-0.99), p=0.04]. Those with LTPR in contrast, had a higher bleeding risk 
[RR:1.74 (1.47-2.06), p<0.00001] but no elevation in ST [RR:1.06 (0.68-1.65), p=0.78]. 
Interestingly, HTPR was linked with significantly higher mortality (p<0.05). Of note, the 
use of LTA was discouraged unless the tests above were not available, due to its lack of 
standardisation. 
 
Therefore, crucially no convincing relationship between the results of platelet testing 
and thrombotic events has been firmly established. Although there have been a few 
smaller scale studies that suggest that PFT and a therapy adjusted approach to PCI 
patient care could potentially be effective. Angiolillo et al demonstrated that a 
maintenance dose regimen of 150mg clopidogrel is associated with reduced platelet 
reactivity and enhanced platelet inhibition compared to that achieved with the 75mg in 
patients undergoing elective PCI [280]. Switching from clopidogrel to prasugrel has been 
shown to reduce HTPR [281] and also improved outcomes in the MADONNA study [272]. 
Bonello et al utilised VASP-P to tailor incremental loading doses of clopidogrel to below 
a set HTPR value to show significant reductions in ST and MACE [282]. In addition, a 
meta-analysis of 4213 patients by Aradi et al showed that the use of an intensification 
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of antiplatelet therapy protocol was associated with a significant reduction in 
cardiovascular mortality, ST and MI compared to conventional approach [283].  
 
Given these positive results, trials investigating the benefits of personalised therapy are 
ongoing and include TAILOR-PCI, ANTARCTIC and GIANT, the results of which are eagerly 
awaited. The trial design of these studies have been carefully optimised as previous large 
scale RCT have been criticized and some believe that this would have impacted on the 
negative results. It was found in the ARCTIC trial that amongst the poor responders only 
3.2% received prasugrel whereas 80.2% received high dose clopidogrel (600mg LD, 
150mg MD). In the GRAVITAS trial 40% of low responders remained so despite the 
increased dose of clopidogrel. Patient sample sizes have been questioned with some 
suggesting that many more, at least 17,000 would be required to show statistical 
differences in event rates [284]. Patient selection has been condemned with the 
exclusion of high-risk ACS patients and predominant inclusion of stable and elective PCI 
patients as it is suggested that intensified anti-platelet therapy might improve outcomes 
particularly in high risk patients but may not be so effective in low risk patients. There 
are also debates around study endpoints and the time of testing and randomisation. 
Also thought to be important is the course of intervention to reduce HTPR with third 
generation P2Y12 receptor antagonists now preferred to higher doses of clopidogrel. 
When considering alternative potential reasons for the failure of these studies, theories 
include that HTPR is a reliable method of risk stratification but not a variable to modify 
therapy [285]. That platelet reactivity is not solely a measure of drug response but also 
reflects the co-morbidities of the patient and PFT could be a poor substitute for the 
complex interactions taking place in vivo [286]. To this end, it has been suggested that 
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the addition of clinical variables and genotype to PFT could enhance risk prediction 
[287].  
 
An alternative theory and the one investigated in this thesis is that the weakness of 
these trials and PFT could be that they do not take into account the powerful 
interactions described in this thesis between anti-platelet therapies, endogenous 
platelet systems and the endothelium, specifically the strongly synergistic relationship 
between P2Y12 blockade, PGI2 and NO. This could potentially limit their interpretation of 
true in vivo platelet function, which would be better represented as a product of intrinsic 
platelet reactivity and endothelial function. This thesis will go on to highlight the 
importance of endothelial driven in vivo modulation of P2Y12 inhibition and introduce 
the concept of refining ex vivo PFT by incorporating an assessment of endothelial 
function to potentially better predict thrombotic outcomes in individual patients. Prior 
to this, the last section of this introduction comprises a short review of the tests 
available to assess endothelial function, some of which will be utilized in this thesis to 
start to test my hypothesis.  
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1.11 Endothelial function testing 
 
As reviewed above, the endothelium plays a pivotal role in cardiovascular haemostasis 
and disease. It regulates vascular tone and inflammation and its integrity is critical to 
prevent circulating platelets from being exposed to subendothelial matrix proteins to 
prevent arterial thrombosis. Cardiovascular risk factors such as DM and HTN lead to an 
excessive production of superoxide which leads to NO inactivation. This loss of NO 
bioavailabilty proceeds the development of atherosclerosis and is associated with 
morbidity and mortality [288]. Endothelial dysfunction is a well-established risk factor 
for cardiovascular disease characterized by an imbalance between vasodilatating and 
vasoconstricting substances [289]. It is a feature of atherosclerosis and proceeds it when 
only risk factors are present. 
 
Although the vascular endothelium has many functions the term ‘endothelial function’ 
is, in most cases, used to refer to the ability of the endothelium to release compounds 
that induce direct relaxation of smooth muscle cells within the vascular wall [290]. This 
is thought to largely reflect the bioavailability of NO but can also be representative of 
the bioavailability of PGI2 and other EDHFs. Therefore, reduced activity of NO and other 
EDHF’s can be detected through the assessment of endothelial function in a given 
individual. This is because endothelial dysfunction represents a syndrome with various 
clinical presentations rather than a localized vascular disorder [291]. This systemic 
nature has been demonstrated by the similar power of coronary and peripheral 
dysfunction in predicting cardiovascular events and that cardiovascular events can occur 
remotely from the site of dysfunction [292]. Assessment of the endothelium because of 
its location was previously limited. However, there are now several non-invasive, cost-
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effective and reproducible techniques that can be employed to assess endothelial 
function to help evaluate cardiovascular risk. These tests rely on two main principles; 
that endothelial dysfunction is a systemic disease which can be measured in different 
vascular beds and that certain stimuli will lead to NO release from the vascular 
endothelium to produce vasodilatation. This section describes the invasive and non-
invasive evaluation of endothelial function which are generally assessed by measuring 
vasomotion of conduit vessels or regional increases in blood flow, reflecting 
microvascular/resistance vessel function in the coronary or peripheral circulation [293]. 
 
1.11.1   Invasive tests of endothelial function 
The gold standard in the assessment of endothelial function is performed in the 
coronary circulation at coronary angiogram with intra-coronary Doppler for visualisation 
of the direct calculation of blood flow changes in vessel diameter and resistance. 
However, this technique is invasive and complex requiring expensive equipment and 
specialised expertise which limit its use although it is widely used in tertiary centres.  
 
Pharmacological stimuli such as ACh, serotonin or papaverine are delivered in increasing 
concentrations to assess epicardial coronary vasodilation. ACh is widely used as it is 
short acting and in atherosclerotic vessels it produces paradoxical vasoconstriction due 
to impaired muscarinic vasodilatation as a consequence of a poorly functioning 
endothelium, as reported by Ludmer et al in 1986 [294]. Adenosine and glycerlyl 
trinitrate (GTN) or sodium nitroprusside (SNP) are used to assess endothelium-
independent vasodilation in the microcirculation and compared to that due to the direct 
relaxation of smooth muscle cells, respectively. Coronary artery endothelial dysfunction 
has been shown to independently predict acute cardiovascular events in patients [295].  
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1.11.2   Non-invasive tests of endothelial function 
Similar principles to those applied to invasive testing are applicable to non-invasive 
endothelial testing. Healthy arteries will vasodilate in response to a pharmacological 
stimulus such as ACh or salbutamol (endothelium-dependent vasodilators) or reactive 
hyperaemia (RH) via NO release, as well as the release of other EDRFs [296]. Venous 
occlusion plethysmography (VOP) was developed over 100 years ago and is the oldest 
method to assess endothelial function. More commonly used techniques nowadays 
include ultrasound flow mediated dilatation (FMD) and pulse wave analysis (PWA) with 
inhaled salbutamol. Laser Doppler skin flowmetry (LDF) and digital pulse amplitude 
tonometry (PAT) are also used and focus on microvascular flow.      
 
1.11.2.1   Venous occlusion plethysmography 
Strain-gauge plethysmography (SGP), first described in 1951 is the most widely applied 
method of VOP which represents a non-invasive technique assessing peripheral blood 
volume. Tissue blood flow is measured by assessing tissue volume change following 
inflation of a proximal cuff to a pressure which occludes venous outflow but not arterial 
inflow leading to a volume change proportional to arterial inflow. Local infusion into the 
brachial artery allows for a minimally invasive additional assessment of the direct effect 
of drugs such as ACh on vascular tone. These agents are administered in escalating doses 
to cause local forearm vasodilatation but not systemic hypotension. Responses to these 
endothelial agonists are compared to those induced by direct smooth muscle relaxing 
agents in order to evaluate endothelium dependent vasodilatation. This technique is 
reproducible and has been widely used in research but its invasive nature does limit its 
use relative to more modern non-invasive techniques.  
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1.11.2.2   Flow mediated dilatation 
This technique involves the induction of a shear stress stimulus in the conduit brachial 
artery following a period of ischaemia induced by occlusion of forearm vessels for 5 
minutes [297]. It measures changes in conduit vessel diameter by ultrasound, changes 
which occur with increases in blood flow following dilatation of the microvasculature. 
These increases in vessel diameter occur through endothelium dependent mechanisms 
[298] which reflect endothelial-derived NO bioavailability [299]. The brachial artery is 
most often used with a blood pressure cuff placed 1-2 cm above the antecubital fossa 
inflated to suprasystolic pressure. When released, RH results. The artery is measured at 
the end of diastole to assess the vessel response to increased flow which is expressed 
as percentage change from vessel baseline. FMD has been shown to be associated with 
cardiovascular events in patients with and without overt cardiovascular disease [300, 
301] and also to the presence of cardiovascular risk factors. 
  
1.11.2.3   Pulse wave analysis and pulse wave velocity 
Arterial stiffness depends partly on smooth muscle tone [302]. Predominantly NO but 
also ET-1 and natriuretic peptides are known to contribute to the functional regulation 
of artery stiffness [303]. Analysis of the arterial waveform and velocity provides 
information about stiffness in arteries and the amount of wave reflection in the arterial 
system [303]. This can be assessed noninvasively by using PWA. Wave reflection occurs 
at sites of impedance mismatch usually occurring at branch points within the 
cardiovascular system. It is quantified using augmentation index (Aix) by determining 
the difference between at least two consecutive systolic peaks which, will decrease with 
vasodilatation and increase with vasoconstriction [304]. Increased arterial stiffness 
increases the velocity of both forward arterial blood flow, as well as reflected waves 
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causing central pressure augmentation [305]. It is possible by recording the shape of the 
arterial waveform following the administration of GTN (an endothelium independent 
stimulus) and after salbutamol (an endothelium dependent stimulus) to make an 
assessment of endothelial function [306]. PWV is another classic index of aortic stiffness 
which has been related to vessel dispensability. Aortic PWV is measured between the 
carotid and femoral arteries by synchronically detecting arrival of the wave in these two 
areas and measuring the distance between them. It is easy to measure non-invasively 
and is highly reproducible [307]. PWV has a strong correlation with cardiovascular 
events and has been shown to be an independent predictor of all-cause and 
cardiovascular mortality [308, 309]. PWA has been used to identify endothelial 
dysfunction in a variety of disorders including PAD where salbutamol-induced changes 
in Aix were significantly reduced in PAD patients while GTN-produced changes were not 
different [310]. Aix has also been found to correlate with traditional CAD risk factors and 
atherosclerosis [311]. 
 
1.11.2.4   Peripheral artery tonometry 
This technique uses a finger plethysmography cuff which records finger arterial pulsatile 
volume changes. The EndoPAT device assesses post-ischaemic vasodilator response 
compared to baseline flow to assess endothelial function as the PAT signal is modulated 
by the bioavailability of NO [312]. A finger on each hand is monitored and a pressure 
cuff placed on one of the upper arms to allow for a hyperaemic response to take place 
with the other finger acting as a control. The EndoScore is calculated as a ratio of the 
PAT signal over the baseline signal. Endothelial assessments with PAT have been shown 
to demonstrate patterns of abnormality similar to that of brachial artery ultrasound 
assessment of FMD [313]. Digital vasodilator function was related to multiple traditional 
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and metabolic cardiovascular risk factors such as male sex, body mass index (BMI), ratio 
of total to high-density lipoprotein (HDL) cholesterol, DM and smoking in a Framingham 
heart study of third generation cohort participants [314]. Low RH signals, indicating 
endothelial dysfunction detected by EndoPAT have also been associated with higher 
adverse event rates during follow-up and provided incremental value to the 
Framingham risk score [315]. 
 
1.11.2.5   Laser Doppler flowmetry 
LDF is a technique which monitors skin microvascular blood flow. This is because the 
response observed in the cutaneous circulation is thought to mirror the responses taking 
place in other vascular beds [316]. In contrast to the techniques detailed above it 
provides an assessment of the microvasculature. The laser light beam will change when 
it comes into contact with moving tissues. The fraction and magnitude of light shifted is 
dependent on the concentration of moving red blood cells and on their average velocity, 
respectively [317]. 
 
The direct delivery of ACh and SNP through iontophoresis and post-occlusive reactive 
hyperaemia (PORH) are techniques which are associated with LDF for the non-invasive 
measurement of endothelial function. RH will lead to an increase in both the 
concentration and velocity of red bloods cells following the release of a pneumatic cuff 
inflated to supra-systolic blood pressure reflecting NO and prostanoid availability. 
Iontophoresis is a technique describing the migration of charged substances through the 
skin by means of delivering a small continuous galvanic current. This allows very small 
amounts of drugs to be administered non-invasively. ACh can be used to induce 
vasodilatation reflecting NO and prostaglandin participation and SNP to test smooth 
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muscle dependent pathways of vasodilation [318]. LDF assessed ACh iontophoresis is 
impaired in several pathologies linked to cardiovascular disease including hypertension 
and hypercholesterolaemia [319].  
 
1.11.3   Novel assays 
In recent years novel diagnostic tools for assaying endothelial function have been 
developed. These include ELISA-based quantification of circulating biomarkers such as 
vWF, ET-1, t-PA, thrombomodulin, soluble VCAM-1 and ICAM-1 and E-selectin. 
Techniques evaluating and phenotyping circulating endothelial cells and endothelial-
derived microparticles are also being tested. These remain very much investigational 
methods of endothelial function testing at present.  
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1.12 Summary 
 
An often explored hypothesis is that in at risk patients the chances of experiencing a 
thrombotic event is associated with the level of platelet blockade: i.e. those individuals 
with less effective blockade provided by aspirin and, particularly, P2Y12 receptor 
blockers are more at risk of thrombotic events. However, studies have failed to show 
any benefits from ex vivo monitoring of platelet function and subsequent tailoring of 
treatment in patients receiving DAPT. This failure is possibly because the ex vivo platelet 
tests used in these trials do not consider the environment in which platelets reside in 
vivo. Namely, that within the circulation endothelium-derived autacoids NO and PGI2 
reduce platelet reactivity and prevent inappropriate platelet activation. Taking account 
of the above observations, I hypothesise that within the circulation the levels of 
endothelium-derived mediators are an important determinant of the efficacy of DAPT. 
The strong synergies between P2Y12 inhibitors and the cAMP and cGMP signalling 
systems mean that the in vivo platelet reactivity in patients receiving DAPT will be a 
function of the level of P2Y12 receptor blockade and the levels of endothelial-derived NO 
and PGI2. This provides an explanation for different thrombotic outcomes in the 
presence of similar levels of platelet blockade; i.e. individual patients with different 
levels of endothelial function, or indeed disease-driven endothelial dysfunction, would 
have different levels of in vivo platelet inhibition for the same level of DAPT activity, as 
determined by ex vivo testing and why even allowing for differences dependent upon 
adherence to therapy, individuals on DAPT may in fact present rather a more 
homogenous level of platelet inhibition than can be associated to different clinical 
outcomes. A schematic diagram of the ideas so far put forward in this thesis is 
represented in figure 1.3. 
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Figure 1.3: Summary of the interactions between the endothelium and P2Y12  
antagonism 
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1.13 Aims  
 
This thesis investigates the complex interplay between P2Y12 receptor blockade and the 
endothelial inhibitors NO and PGI2.   
 
This approach is structured into the following specific aims: 
1. To investigate in vitro the interaction between P2Y12 blockade, NO and PGI2. 
2. To demonstrate the anti-platelet effects of NO and PGI2 in the presence of strong 
P2Y12 receptor blockade in healthy volunteers ex vivo. 
3. To consider the effects of cardiovascular disease on the relationship between NO, 
PGI2 and P2Y12 blockade in patients with PAD. 
4. To develop a reproducible method of endothelial function testing in healthy 
volunteers in order to start to consider the role of the endothelium in platelet 
reactivity in patients. 
5. To research the respective roles of platelets and the coagulation system in 
thrombus formation and the effects of aspirin, P2Y12 antagonist and DAPT 
therapies. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
 
Acetylcholine     Sigma, UK 
Acetylsalicylic acid (aspirin)   Sigma, UK 
Adenosine diphosphate    Labmedics, UK 
Alexa647-conjugated secondary antibody  Invitrogen, UK 
Anti-P-selectin-PE     eBioscience  
Arachidonic acid    Sigma, UK 
Ascorbic acid      Sigma, UK 
Bovine serum albumin    Sigma, UK 
Calcium Ionophone A23187   Sigma, UK 
CHRONO-LUME     Labmedics, UK     
CD61-APC     eBioscience, UK 
CountBright Absolute counting beads  Invitrogen, UK 
Epinephrine     Labmedica 
Diclofenac     Sigma, UK 
DEA/NONOate     Sigma, UK 
Dimethyl Sulphoxide     VWR, UK 
Epinephrine     Labmedics, UK 
Ethanol      VWR, UK 
FITC-conjugated anti-CD42b    eBioscience, UK 
 
Formalin     Sigma, UK 
Heparin     CP pharmaceuticals Ltd, UK 
Horm Collagen     Takeda Austria 
Lipopolysaccharide    Sigma, UK 
Methanol-free formaldehyde    Fisher Scientific 
PAC-1-FITC      BD Bioscience, UK 
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Prostaglandin I2 / Prostacyclin   Tocris, UK    
Phosphate buffered saline   Sigma, UK 
Prasugrel active metabolite    Daitchi Sankyo, Japan 
Ristocetin     Helena Bioscience, UK 
Saline      Baxter, UK 
Sodium Chloride     Sigma, UK 
Sodium Nitroprusside    Sigma, UK 
Tri-sodium citrate    Sigma, UK 
Triton X-100       Sigma, UK 
 
TRAP-6 amide     Bachem, UK 
U46619      Enzo 
VASP-P(Ser239) primary antibody   Enzo Life-sciences, UK  
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2.2 Methods 
 
Methods detailed below are applicable to several chapters of this thesis. Additional 
methods are described in the relevant chapter. 
 
2.2.1 Ethics and consent 
All experiments were approved by St Thomas’s Hospital Research Committee  
(Ref. 07/Q0702/24) and all volunteers gave verbal and written consent before entering 
the studies. 
 
2.2.2 Recruitment of study participants  
All participants were screened for potential participation and after providing written 
consent a health status was carried out. Those volunteers deemed appropriate were 
recruited to participate in studies. 
 
2.2.3 Blood collection 
Blood was obtained by venepuncture performed in the ante-cubital fossa using a 19 
gauge butterfly needle into a syringe containing 3.2% tri-sodium citrate, unless stated 
otherwise. Final ratios of anti-coagulant and blood were 1:9 to give a final concentration 
of 0.109 M. 
 
2.2.4 Preparation of PRP and PPP 
PRP was obtained by centrifugation of citrated whole blood at 175 × g for 15 minutes at 
25°C. The PRP fraction was carefully removed as to not disturb the red blood cells or 
buffy coat. PPP was obtained by centrifugation of PRP at 1300 × g for 2 minutes. 
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2.2.5 Preparation of platelet agonists 
ADP, TRAP-6 and U46619 were all prepared from 1 mM stock diluted in PBS. AA  
(100 mM stock in 100% ethanol) and epinephrine (1 mM) were diluted in 0.1% w/v 
ascorbic acid in PBS. Horm collagen (1 mg/ml) was diluted in isotonic glucose. 
Lyophilized ristocetin was reconstituted to 30 mg/ml in distilled H2O. All agonists were 
prepared at concentrations 10 times the required final concentrations and added 1:10 
to PRP.    
 
2.2.6 Preparation of platelet inhibitors  
DEA/NONOate (100 mM stock) and PGI2 (10 mM stock) were diluted in NaOH (0.01 M) 
and also prepared at a concentration 10 times that required and added 1:10 to PRP.  
 
2.2.7 Platelet aggregation 
Platelet aggregation was measured by LTA, 96-well plate aggregation or optimul plate. 
 
2.2.7.1   LTA 
Aggregation responses were measured using a Bio/Data PAP-8E turbidimetric 
aggregometer (Alpha Laboratories, Eastleigh, UK). Prior to measuring aggregation 
response channels were blanked using a 250 µl sample of PPP (200 or 225 µl) plus a 
diluent (25 or 50 µl). Aggregation experiments were carried out at 37 °C with constant 
stirring at 1200 rpm. Cuvettes containing a stirrer bar were prepared with PRP (200 or 
225 µl) and incubated for 2 minutes. 25 µl inhibitor solution was added to PRP (200 µl) 
samples testing inhibitory conditions and incubated for a further 1 minute. 25 µl agonist 
solution was then added (10:1 final concentration) to test maximal and final aggregation 
(MA and FA) responses measured over 5 minutes using 340 nm-light.      
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2.2.7.2   96-well plate aggregation 
This modified light transmission method was used to assess platelet aggregation, as 
previously described [246]. 10 µl of agonist or vehicle were added to individual wells of 
a 96-well plate at 10 × final concentration. Four wells containing PRP and four previously 
prepared PPP wells served as controls corresponding to 100% and 0% aggregation, 
respectively. 100 µl samples of PRP were placed into individual wells containing agonists. 
The plate was then placed on a Tecan Sunrise (Tecan Trading AG, Switzerland) 
absorbance plate reader, set to measure absorbance at 595 nm in order to determine 
levels of platelet aggregation.   
 
2.2.7.3   Optimul  
Platelet aggregation was assessed using a previously reported methodological approach 
providing a standardised optical detection of platelet aggregation (optimul method) 
based upon 96-well plate aggregometry [247]. 4 wells containing PRP and 4 wells of PPP 
acted as control wells. 40 µl of PRP was added to each test well and the plate was then 
placed on a bioshaker at 1200 rpm at 37 ° C for 5 minutes. Platelet aggregation was 
determined immediately by changes in light absorbance detected at 595 nm by a Tecan 
Sunrise absorbance set (Tecan Trading AG, Switzerland). 
 
2.2.8 ATP + ADP Release 
Experiments were conducted in a lumi-aggregometer (560 CA, Chronolog, Havertown, 
PA, USA) to measure ADP + ATP secretion. Blank samples were prepared (200 µl PPP, 25 
µl CHRONO LUME and 25 µl diluent) to set the baseline, acting as a reference range 
corresponding to 100% aggregation. Test samples (200 µl PRP, 25 µl CHRONO LUME and 
25 µl diluent) containing stirrer bars were incubated for 2 minutes at 37 °C before being 
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stimulated with collagen (4 µg/ml) or TRAP-6 (25 µM). Chart v4.2 (AD Instruments, UK) 
was used to record aggregation and luminescence traces over 5 minutes at which point 
4 nmol ATP was injected to act as a reference range for quantifying ATP release.  
 
2.2.9 Flow cytometry 
Flow cytometric analysis was used to quantify P-selectin and PAC-1 expression post-
activation. CD61 was used to identify platelets. To make the antibody mix, 1 µl CD61 
APC, 1.5 µl CD62p PE and 1.5 µl PAC-1-FITC were added to 46.5 µl saline per volunteer. 
PRP samples were incubated and then stimulated with TRAP-6 (25 µM) in a 96-well 
plate. After gentle mixing at 37 °C, reactions were stopped through the addition of 10-
fold excess of cold saline. Platelets were immediately stained with anti-CD61-
allophycocyanin, PAC-1-FITC (BD Bioscience, Oxford, UK), and anti-P-selectin-PE 
(eBioscience) for 15 minutes at 4 °C and then fixed in 2% (v/v) formalin. PAC-1-FITC and 
anti-P-selectin-PE immunoreactivity were acquired on a FACSCalibur instrument (Becton 
Dickson, UK) using CellQuest software (Becton Dickinson, UK).  
 
2.2.10   Statistical analyses 
Data were analysed using Prism 6.0e (GraphPad Software, La Jolla, CA, USA). For tests of 
platelet aggregation, statistical significance was determined by two-way ANOVA with 
Dunnett’s post-hoc test unless otherwise stated. Flow data were analysed using FlowJo 
v8.7 (Treestar, Ashland, USA) where the ‘single platelet’ population was gated based on 
forward scatter and CD61-APC immunoreactivity (FL-4 mean fluorescence intensity). 
Data sets are presented (Mean±SEM) and considered different if p<0.05. Additional 
statistical analyses are described in the relevant chapter. 
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Chapter 3: The in vitro synergy between P2Y12 blockade, 
PGI2 and NO  
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3.1 Introduction 
 
It is well known that NO and PGI2 independently amplify each other’s effects and more 
recently it has been elucidated that the inhibitory actions of NO and PGI2 are both 
independently potentiated by blockade of P2Y12 receptors in platelets [237, 238]. In this 
first results chapter, I start to explore the hypothesis that the three-way synergy 
between PGI2, NO and P2Y12 receptor antagonism produces much more powerful 
platelet inhibition than P2Y12 receptor blockade alone and hence, platelet function in 
vivo is a product of intrinsic platelet reactivity which can be modified by DAPT but also 
by the influence of the endothelial mediators, NO and PGI2. Due to the mechanisms of 
action of these endothelial mediators, I also propose that there will be close associations 
of these anti-platelet agents to platelet cyclic nucleotide systems. 
 
This relationship is firstly investigated using PRP from healthy volunteers treated with 
prasugrel active metabolite (PAM) in vitro to produce P2Y12 blockade with and without 
aspirin. To these, NO or PGI2 individually and in combination will be added to 
demonstrate their independent and combined effects on platelet inhibition using an 
array of tests of platelet function. Aggregation and ATP release experiments will be 
conducted and then flow cytometry to consider the downstream effects of P2Y12 
blockade, NO and PGI2 by investigating levels of VASP phosphorylation, a downstream 
marker of PKG and PKA activation representative of cyclic nucleotide activity. I will then 
concentrate on the platelet cyclic nucleotide systems which are strongly effected by 
both PGI2 and NO. Importantly, I will seek to define whether these interactions are 
synergistic in nature with the true potential of powerfully influencing platelet inhibition 
to a far greater extent than P2Y12 blockade alone.  
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3.2 Methods 
 
3.2.1    Recruitment of healthy volunteers 
Potential blood donors aged 18-40, both male and female provided written consent and 
were subsequently screened. This process involved a detailed medical history, physical 
examination and observations including blood pressure, pulse rate and temperature. 
Those fulfilling the inclusion criteria with normal health profiles were recruited. 
 
3.2.2 Preparation of platelet solutions  
Blood was obtained by venepuncture and both PRP and PPP were prepared from whole 
anti-coagulated blood, as described in sections 2.2.3 and 2.2.4. 
 
3.2.3 Treatment of PRP with anti-platelet drugs 
Aspirin (ASA) was prepared in ethanol to a concentration of 100 mM and then diluted in 
PBS to a concentration of 3 mM. This was subsequently diluted in PRP 1:100 to obtain 
the required final concentration of 30 µM. PAM was prepared to a concentration of 10 
mM in DMSO and diluted in PBS to a concentration of 600 µM. To achieve final 
concentrations of 1.5, 3 and 6 µM PAM solution this was further diluted 1:400, 1:200 
and 1:100 in whole blood, respectively. PRP treated with PAM and/or ASA or vehicle was 
incubated at 37 °C for 30 minutes in a water bath before use in assays. 
 
3.2.4 LTA 
Platelet aggregation was determined by LTA, as described in section 2.2.7.1. Initially, 
PGI2 (1-100 nM) or vehicle were added to vehicle or PAM (6 µM) treated PRP for 1 
minute at 37 °C and stimulated with Horm collagen (30 µg/ml) or TRAP-6, specific for 
PAR-1 (30 µM). Aggregation experiments were repeated but with the addition of 
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DEA/NONOate (0.1-1000 nM) rather than PGI2. These experiments were then repeated 
again but with the addition of either vehicle or both PGI2 (1-8 nM) and DEA/NONOate 
(1-1000 nM) in PRP treated with either vehicle or PAM (6 µM) and stimulated with 
collagen (30 µg/ml) or TRAP-6 (30 µM). Following this, in PRP treated with vehicle or 
PAM (6 µM) with or without ASA (30 µM), aggregations to TRAP-6 (25 µM) and collagen 
(4 µg/ml) were measured after pre-incubation of PRP with vehicle (NaOH 0.01 M) 
DEA/NONOate (100 nM) or PGI2 (1 nM) individually or the combination of DEA/NONOate 
and PGI2 for 1 minute at 37 °C.   
 
3.2.5 Isobolographic analysis 
Inhibitory concentration curves for PGI2 (1-8 nM) or DEA/NONOate (10 nM-1 µM) 
against aggregation induced by TRAP-6 (30 µM) or collagen (30 µg/mL), in the presence 
of vehicle or PAM (6 µM) were constructed with data fitted to a logistic equation using 
least-squares method. Derived data was used to generate isobolograms [320]. 
 
3.2.6 ADP + ATP Release 
ADP + ATP release from platelets was assessed by lumi-aggregometry, as described in 
section 2.2.8. PRP treated with vehicle or PAM (6 µM) with or without ASA (30 µM) was 
pre-incubated with either vehicle, DEA/NONOate and/or PGI2 as described above. ADP 
+ ATP secretion was evaluated by luminescence in the presence of Chrono-Lume reagent 
after stimulation with TRAP-6 (25 µM) or Horm collagen (4 µg/ml). 
 
3.2.7    VASP phosphorylation 
PRP was pre-incubated with vehicle, ASA (30 µM), PAM (6 µM) or ASA+PAM and 
stimulated with collagen (4 µg/ml) or TRAP-6 (25 µM) in the presence of PGI2 and/or 
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DEA/NONOate or vehicle. After 4 minutes the reaction was stopped with methanol-free 
formaldehyde (2% final). Platelets were permeabilized using 0.2% Triton X-100 and 
incubated with anti-VASP-P(Ser239), Alexa647-conjugated secondary antibody and FITC-
conjugated anti-CD42b, for 30 minutes each in turn. The platelet pellet was then 
resuspended in 0.9% saline. VASP-P (Ser239) immunoreactivity was measured by flow 
cytometry, using a FACS-Calibur instrument.  
 
3.2.8 cAMP and cGMP measurements 
PAM (6 µM), ASA (30 µM), PAM+ASA or vehicle-treated PRP was stimulated with 
collagen (4 µg/mL) or TRAP-6 (25 µM) in the presence of PGI2 and/or DEA/NONOate or 
vehicle. After 4 min, platelets were lysed with Triton-X-100 (0.625%) and treated with 
iso-butylmethylxanthine (IBMX; 500 μM) to inhibit phosphodiesterase activity. 
Potassium fluoride (0.5 M) was added to increase fluorophore stability in the 
homogenous time-resolved fluorescence (HTRF) based competitive immunoassays 
(Cisbio) used to determine cAMP and cGMP concentrations. HTRF combines 
fluorescence resonance energy transfer technology (FRET) with time-resolved 
measurement (TR). FRET is a technique based on the interactions between biomolecules 
assessed by coupling each with a fluorescent label and detecting the level of energy 
transfer. Proximity of two fluorophores is responsible for the specific signal emission. 
Elimination of background fluorescence is achieved by the addition of time-resolved 
measurement. In brief, as previously described by Degorce et al, the competitive cAMP 
assay combines anti-cAMP Ig labeled with a cryptate donor (anti-cAMP cyrptate 
conjugate) and cAMP labeled with acceptor d2 (cAMP d2 conjugate). Donor and 
acceptor are brought into proximity range by the binding of anti-cAMP Ig to cAMP. 
Energy is transferred from donor to acceptor on excitation of donor occurring at 337 nm 
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leading to donor and acceptor to generate emission at 620 nm and 665 nm, respectively. 
The level of cAMP generated is measured by competing with the cAMP d2 for antibody 
binding [321].  
 
 
3.2.9   Heat map generation and scaling 
The heat maps were created in Microsoft excel. Conditional formatting was applied to 
the cells containing the data range. A colour scale was chosen to allow visual 
representation of the underlying data. At one end of the scale, red represents 100% 
aggregation of platelets or maximal platelet ATP release. On the other end of the scale, 
green represents 0% platelet aggregation or no ATP release. There is a gradual change 
in the colour scale from red to dark red to brown to dark green through to green 
corresponding to decreasing percentage values. Dark brown represents the mid-way 
point (50%. The colour gradient was applied to the range of cells containing the data 
thus indicating where each data point falls within the data set. This allows a quick and 
powerful visual representation of my data alongside the other graphical resources and 
written text. The red (100%) and green (0%) are immediately differentiated and data 
points in between can be judged in conjunction with the underlying data and scale 
represented below.   
The colour scale is as follows:  
 
 
  
0 100% 
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3.3 Results 
 
3.3.1 Interactions between PGI2 and P2Y12 blockade with PAM on platelet 
aggregation  
PRP pre-incubated with PAM (6 µM) or vehicle and treated with PGI2 or vehicle was 
tested in the LTA to investigate the interactions between PGI2 and P2Y12 blockade. PGI2 
was added to PRP at concentrations of 1 nM, 10 nM or 100 nM before the PRP was 
stimulated with either ADP (20 µM), TRAP-6 (30 µM) or collagen (30 µg/ml) in the LTA 
(representative traces displayed in figure 3.1). In the presence of vehicle, full 
aggregation (>60%) was observed for all 3 agonists in PRP. For PRP stimulated with ADP 
(20 µM) the addition of PGI2 (1 nM) reduced aggregation, which was abolished with 
higher concentrations of PGI2. Pre-treatment of PRP with PAM (6 µM) however, led to 
near complete blockade of aggregation even in the presence of vehicle, while in the 
presence of all concentrations of PGI2 aggregation was abolished. Aggregation induced 
by TRAP-6 (30 µM) in vehicle PRP was reduced by PGI2 (10 nM), but not by PGI2 at lower 
concentrations. In PAM treated PRP, however, aggregation was reduced by all 3 
concentrations of PGI2 (1 nM, 10 nM and 100 nM). In vehicle PRP, Collagen (30 µg/ml) 
caused strong aggregation in samples treated with vehicle or PGI2 (1nM). The addition 
of PGI2 (1 nM) to PAM (6 µM) treated PRP reduced aggregation, while under the same 
conditions both PGI2 (10 and 100 nM) abolished aggregation. In vehicle treated PRP only 
the addition of PGI2 (100 nM) fully inhibited platelet aggregation (Figure 3.2).     
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Figure 3.1: Influence of PAM and PGI2 on platelet aggregation. LTA traces following stimulation 
with (A) ADP (20 µM), (B) TRAP-6 (30 µM) or (C) collagen (30 µg/ml) in PRP pre-incubated with 
PAM (6 µM) or vehicle with the addition of PGI2 (1 nM, 10 nM or 100 nM) or vehicle. 
 
 
 
Figure 3.2: Influence of PAM and PGI2 on platelet aggregation. Platelet aggregation in LTA 
following stimulation with (A) ADP (20 µM), (B) TRAP-6 (30 µg/ml) or (C) collagen (30 µM) in PRP 
pre-incubated with PAM (6 µM) or vehicle with the addition of PGI2 (1 nM, 10 nM or 100 nM) or 
vehicle. N=1. 
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3.3.2 Interactions between NO and P2Y12 blockade with PAM on platelet 
aggregation  
PRP pre-incubated with PAM (6 µM) or vehicle and treated with DEA/NONOate, or 
vehicle was tested in the LTA to investigate the interactions between NO and P2Y12 
blockade. DEA/NONOate was added to PRP at concentrations of 0.1 nM, 10 nM and 
1000 nM before the PRP was stimulated with either ADP (20 µM), TRAP-6 (30 µM) or 
collagen (30 µg/ml) in the LTA (representative traces displayed in figure 3.3). In the 
presence of vehicle, full aggregation (>60%) was observed for all 3 agonists in vehicle 
treated PRP. For PRP stimulated with ADP (20 µM) only the addition of DEA/NONOate 
(1000 nM) inhibited aggregation. Pre-treatment of PRP with PAM (6 µM) led to near 
complete blockade of aggregation in the presence of vehicle and all concentrations of 
DEA/NONOate. In vehicle treated PRP aggregation induced by TRAP-6 (30 µM) was only 
minimally reduced by DEA/NONOate (1000 nM). Pre-treatment with PAM (6 µM) 
however, led to near complete blockade of aggregation in the presence of 
DEA/NONOate (1000 nM). Collagen (30 µg/ml) caused strong aggregation in PRP treated 
with vehicle and all three concentrations of DEA/NONOate. The addition of 
DEA/NONOate (1000 nM) to PAM (6 µM) nearly fully inhibited platelet aggregation 
(Figure 3.4).  
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Figure 3.3: Influence of PAM and NO on platelet aggregation. LTA traces following stimulation 
with (A) ADP (20 µM), (B) TRAP-6 (30 µM) or (C) collagen (30 µg/ml) in PRP pre-incubated with 
PAM (6 µM) or vehicle with the addition of DEA/NONOate (0.1 nM, 10 nM or 1000 nM) or 
vehicle. 
 
 
 
Figure 3.4: Influence of PAM and NO on platelet aggregation. Platelet aggregation in LTA 
following stimulation with (A) ADP (20 µM), (B) TRAP-6 (30 µM) or (C) collagen (30 µg/ml) in PRP 
pre-incubated with PAM (6 µM) or vehicle with the addition of DEA/NONOate (0.1 nM, 10 nM 
or 1000 nM) or vehicle. N=1. 
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3.3.3 Interactions between PGI2, NO and P2Y12 blockade with PAM on platelet 
aggregation  
PRP pre-incubated with PAM (6 µM) or vehicle and treated with DEA/NONOate, PGI2 or 
vehicle was tested in the LTA to investigate the interactions between PGI2, NO and P2Y12 
blockade. DEA/NONOate was added to PRP at concentrations of 1-1000 nM to which 
PGI2 (1-8 nM) or vehicle was added before the PRP was stimulated with either collagen 
(30 µg/ml) (Figure 3.5) or TRAP-6 (30 µM) (Figure 3.6). DEA/NONOate (1 nM) had little 
effect on collagen induced platelet aggregation. In vehicle PRP, DEA/NONOate (1000 
nM) also had minimal effect however, in the presence of PGI2 aggregation was reduced. 
PGI2 (1-8 nM) increased platelet inhibition but pre-treatment with PAM led to much 
higher levels of platelet inhibition in all concentrations tested. In fact, aggregation was 
near abolished in PAM treated PRP in conditions of DEA/NONOate (10nM) and PGI2 (2 
nM) and above. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Influence of PAM, PGI2 and NO on platelet aggregation. Platelet aggregation in LTA 
following stimulation with collagen (30 µg/ml). Platelets pre-incubated in PAM (6 µM) or vehicle 
and treated with PGI2 (1 nM-8 nM) and DEA/NONOate (1 nM-1000 nM). Data are presented as 
final aggregation (%, mean±SEM). N=4  
 
 
TRAP-6 induced full aggregation (>60%) in the presence of DEA/NONOate (1 nM) in both 
vehicle and PAM (6 µM) treated PRP. The addition of DEA/NONOate (1000 nM) to 
130 
vehicle PRP also led to high levels of aggregation which was reduced by PGI2 (1-8 nM). 
In contrast, DEA/NONOate (1000 nM) led to markedly reduced platelet inhibition in PRP 
pre-incubated with PAM which was further reduced by PGI2 (1-8 nM). Pre-treatment 
with PAM dramatically reduced platelet aggregation in all conditions tested. In vehicle 
PRP, aggregation was abolished by DEA/NONOate (1000 nM) and PGI2 (8 nM). However 
DEA/NONOate (10 nM) and PGI2 (4 nM) abolished aggregation in PAM (6 µM) treated 
PRP. 
 
 
 
 
 
 
 
 
 
Figure 3.6: Influence of PAM, PGI2 and NO on platelet aggregation. Platelet aggregation in LTA 
following stimulation with TRAP-6 (30 µM). Platelets pre-incubated in PAM (6 µM) or vehicle and 
treated with PGI2 (1 nM-8 nM) and DEA/NONOate (1-1000 nM). Data are presented as final 
aggregation (%, mean, ±SEM). N=4. 
 
 
3.3.4   Synergy between PGI2, NO and P2Y12 blockade 
Isobolographic analyses indicated strong synergistic inhibition between DEA/NONOate 
and PGI2 against platelet aggregation induced by both collagen (30 µg/mL; Figure 
3.7A/B) and TRAP-6 amide (30 µM; Figure 3.7C/D), with isoboles curving strongly 
towards the axes.  P2Y12 blockade caused a further powerful (4-fold and 10-fold, 
respectively) enhancement in the synergy between DEA/NONOate and PGI2 for the 
inhibition of aggregations induced by collagen (Figure 3.7B) and TRAP-6 (Figure 3.7D). 
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Figure 3.7: Synergism between NO, PGI2 and PAM. IC50 isobolograms were generated by 
analyzing combinations of DEA/NONOate and PGI2 required to produce a 50% inhibition of 
platelet aggregation stimulated by collagen (30 μg/ml) in the (A) absence and (B) presence of 
PAM (6 μM) and by TRAP-6 (30 μM) in the (C) absence and (D) presence of PAM (6 μM). The 
linear relationship is predicted by the arithmetic sum of the effect of either DEA/NONOate or 
PGI2 alone, as described in the methods, and the experimental line curving towards the axes 
indicates a strong, synergistic relationship. n = 4 for each point. 
 
3.3.5   Effects of PGI2 and NO on platelet aggregation in the presence of submaximal 
P2Y12 antagonism 
PRP was taken from healthy volunteers and pre-incubated in vitro with PAM (1.5 µM, 3 
µM and 6 µM) to represent 25%, 50% and 100% of the concentration of PAM required 
for total P2Y12 receptor inhibition. Samples were treated with vehicle (NaOH, 0.01 M), 
DEA/NONOate (100 nM), PGI2 (1 nM) or DEA/NONOate + PGI2 and stimulated with ADP 
(20 µM), collagen (4 µg/ml) or TRAP-6 (25 µM). Aggregation in response to ADP (20 µM) 
was increasingly inhibited with increasing levels of PAM: control, 79±5%; PAM-25%, 
70±5%; PAM-50%, 48±15%; PAM-100%, 4±1% (p<0.05).  
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Maximum platelet aggregation to collagen (4 µg/ml) in the presence of PAM-100% was 
reduced by the addition of DEA/NONOate (74±4% to 23±9%, p<0.05), PGI2 (74±4% to 
22±6%, p<0.05) and DEA/NONOate+PGI2 (50±10% to 4±1%, p<0.05). Similarly, TRAP-6 
(25 µM) induced aggregation was reduced in the presence of DEA/NONOate (70±2% to 
36±6%, p<0.05), PGI2 (67±2% to 35±3%, p<0.05) and DEA/NONOate+PGI2 (63±3% to 
4±2%, p<0.05). Indeed, even with submaximal, PAM-50% and PAM-25% P2Y12 receptor 
inhibition, significant inhibition of platelet aggregation was found following addition of 
DEA/NONOate+PGI2. Following collagen stimulation, DEA/NONOate+PGI2 reduced 
aggregation (50±10% to 6±2%, p<0.05) and (50±10% to 21±10%, p<0.05) in the context 
of PAM-50% and PAM-25% receptor inhibition, respectively, compared to PAM-100% 
with vehicle (69±2% to 59±3%). DEA/NONOate+PGI2 also reduced TRAP-6 induced 
aggregation in both PAM-25% (63±3% to 39±10%, 0<0.05) and PAM-50% (63±3% to 
20±6%, p<0.05) receptor inhibition compared to PAM-100% plus vehicle (69±2% to 
59±3%). These results are displayed in graph form in figure 3.8A-F and are also expressed 
as heatmaps in figure 3.10A to aid visualisation of results (red represents maximum 
aggregation and green minimum aggregation). 
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Figure 3.8: The in vitro effects of PAM on platelet aggregation. PRP from healthy 
volunteers was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 25%, 50% and 
100% maximum concentration for total P2Y12 receptor inhibition, respectively. Bar 
charts showing % final aggregation in response to (A/C/E) collagen (4 µg/mL) and (B/D/F) 
TRAP-6 (25 µM) in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM) or 
NO + PGI2. Data are presented as final aggregation (%, mean, ±SEM). Significance is shown as * 
p<0.05 for pre- versus post-PAM. Significance is shown † p<0.05 vehicle versus inhibitor 
treatment. Significance is shown ‡ p<0.05 versus PAM+PGI2-treated. N=4.  
 
3.3.6   Effects of PGI2 and NO on platelet aggregation in the presence of submaximal 
P2Y12 antagonism and aspirin 
PRP from healthy volunteers was pre-treated in vitro with PAM (1.5 µM, 3 µM and 6 µM) 
to represent 25%, 50% and 100% of the concentration of PAM required for total P2Y12 
receptor inhibition in the presence of aspirin (ASA). Samples were treated with vehicle 
(NaOH, 0.01 M), DEA/NONOate (100 nM), PGI2 (1 nM) or DEA/NONOate + PGI2 and 
stimulated with ADP (20 µM), collagen (4 µg/ml) or TRAP-6 (25 µM).  Aggregation in 
response to ADP (20 µM) was increasingly inhibited with increasing levels of PAM+ASA: 
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control, 73±5%; ASA, 51±7%; ASA+PAM-25%, 33±11%; ASA+PAM-50%, 23±8%; 
ASA+PAM-100%, 7±1% (p<0.05). Maximum platelet aggregation to collagen (4 µg/ml) in 
the presence of ASA+PAM-100% was reduced by the addition of DEA/NONOate (66±8% 
to 3±2%, p<0.05), PGI2 (64±8% to 5±2%, p<0.05) and DEA/NONOate+PGI2 (43±10% to 
2±1%, p<0.05). Similarly, TRAP-6 (25 µM) induced aggregation was reduced in the 
presence of DEA/NONOate (72±4% to 31±12%, p<0.05), PGI2 (71±4% to 46±7%, p<0.05) 
and DEA/NONOate+PGI2 (67±5% to 15±7%, p<0.05). Again, in the context of 
submaximal, PAM-50% and PAM-25% P2Y12 receptor inhibition, the addition of 
DEA/NONOate and PGI2 led to significant inhibition of platelet aggregation. Although 
ASA alone plus DEA/NONOate+PGI2 inhibited collagen-induced platelet aggregation, 
TRAP-6-induced aggregation was only significantly inhibited with the addition of 
DEA/NONOate+PGI2 to ASA+PAM-100% (67±5 to 15±7%, p<0.05), ASA+PAM-50% 
(67±6% to 33±15%, p<0.05), and even ASA+PAM-25% (67±5% to 36±13%, p<0.05) as 
compared to ASA (67±5% to 50±13%) and vehicle with ASA+PAM-100% (75±4% to 
56±3%). Again, to aid in visualisation of results these data are expressed as heatmaps in 
figure 3.10B and also below in graph form in figure 3.9A-H. 
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Figure 3.9: The in vitro effects of aspirin and PAM on platelet aggregation. PRP from 
healthy volunteers was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 25%, 
50% and 100% maximum concentration for total P2Y12 receptor inhibition, respectively. 
Bar charts showing % final aggregation in response to (A/C/E/G) collagen (4 µg/mL) and 
(B/D/F/H) TRAP-6 (25 µM) in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 
(1 nM) or NO + PGI2 in the presence of aspirin (30 µM). Data are presented as final 
aggregation (%, mean, ±SEM). Significance is shown as * p<0.05 for pre- versus post-PAM. 
Significance is shown † p<0.05 vehicle versus inhibitor treatment. Significance is shown ‡ p<0.05 
versus PAM+PGI2-treated. N=4. 
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Figure 3.10: The in vitro effects of PAM with and without aspirin on platelet aggregation. PRP 
from healthy volunteers (n = 4) was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 
25%, 50% and 100% maximum concentration for total P2Y12 receptor inhibition, respectively. 
Heatmaps showing % final aggregation in response to ADP (20 µM), collagen (4 µg/mL) and 
TRAP-6 (25 µM) in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM) or NO + 
PGI2 were generated in the (A) absence and (B) presence of aspirin (30 µM). Red represents 
maximum aggregation and green shows minimum aggregation with each cell representing data 
from 4 subjects. 
 
3.3.7 Effects of PGI2 and NO on ATP release in the presence of submaximal P2Y12 
antagonism  
Collagen (4 µg/mL) induced ATP release was significantly inhibited by 
DEA/NONOate+PGI2 in the presence of full and partial P2Y12 receptor inhibition; PAM-
100% (6.0±1.3 nM to 2.3±0.5 nM, p<0.05), PAM-50% (6.0±1.3 nM to 4.0±1.8 nM, p<0.05) 
and PAM-25% (6.0±1.3 nM to 4.1±1.7 nM, p<0.05), but not by DEA/NONOate or PGI2 
alone. These results compare to (10.8±3.3 to 8.2±2.0) for PAM-100% receptor inhibition 
0 100% 
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with vehicle. DEA/NONOate+PGI2 also reduced ATP release following TRAP-6 (25 µM) 
stimulation in the context of full P2Y12 receptor inhibition PAM-100% (9.7±1.5 nM to 
3.0±1.5 nM, p<0.05). Althou+PGI2 did not significantly reduce ATP release in the context 
of partial P2Y12 receptor blockade, PAM-50% (6.0±1.3 nM to 4.0±1.8 nM) and PAM-25% 
(6.0±1.3 nM to 4.11.7), ATP release was lower in these sub-optimal P2Y12 blockade 
conditions as compared to PAM-100% plus vehicle (13.0±1.0 nM to 11.7±3.7 nM). Figure 
3.11A-F displays these results in bar graph format and figure 3.13A as heatmaps. 
 
 
Figure 3.11: The in vitro effects of PAM on ATP release. PRP from healthy volunteers 
was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 25%, 50% and 100% 
maximum concentration for total P2Y12 receptor inhibition, respectively. Bar graphs 
showing ATP release in response to (A/C/E) collagen (4 µg/mL) and (B/D/F) TRAP-6 (25 
µM) in the presence of vehicle (NaOH, 0.01 M), NO (10 0 nM), PGI2 (1 nM) or NO + PGI2. 
Data are presented as ATP release (nmole, mean, ±SEM). Significance is shown as * p<0.05 for 
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pre- versus post-PAM. Significance is shown † p<0.05 vehicle versus inhibitor treatment. 
Significance is shown ‡ p<0.05 versus PAM+PGI2-treated.N=4. 
 
 
3.3.8   Effects of PGI2 and NO on ATP release in the presence of submaximal P2Y12 
antagonism and aspirin 
Similarly to the above results for PAM alone, DEA/NONOate+PGI2 reduced collagen 
induced ATP release in the presence of submaximal levels of P2Y12 blockade (ASA+PAM-
0%, 3.3±0.2 nM; ASA+PAM-25%, 1.9±0.3 nM, p<0.05; ASA+PAM-50%, 2.1±0.3, p<0.05; 
ASA+PAM-100%, 1.8±0.2 nM, p<0.05). Following TRAP-6 (25 µM) stimulation, even in 
the presence of full P2Y12 inhibition, neither DEA/NONOate nor PGI2 alone reduced ATP 
release. However, in combination ATP release was significantly reduced in the presence 
of full P2Y12 blockade (ASA+PAM-100%, 4.9±1.1 nM, p<0.05) and in the presence of 
partial P2Y12 blockade (ASA+PAM-50%, 5.3±1.2 nM, p<0.05; ASA+PAM-25%, 6.7±1.1 nM, 
p<0.05). Notably, aspirin therapy alone did not produce a significant reduction in ATP 
release (ASA+PAM-0%, 7.7±1.2 nM). Figure 3.12A-H display these results as bar graphs 
and figure 3.13B.  
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Figure 3.12: The in vitro effects of aspirin and PAM on ATP release. PRP from healthy 
volunteers was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 25%, 50% and 
100% maximum concentration for total P2Y12 receptor inhibition, respectively. 
Bargraphs showing ATP release in response to (A/C/E/G) collagen (4 µg/mL) and 
(B/D/F/H) TRAP-6 (25 µM) in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 
(1 nM) or NO + PGI2 in the presence of aspirin (30 µM). Data are presented as ATP release 
(nmole, mean, ±SEM). Significance is shown as * p<0.05 for pre- versus post-PAM. Significance 
is shown † p<0.05 vehicle versus inhibitor treatment. Significance is shown ‡ p<0.05 versus 
PAM+PGI2-treated.N=4. 
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Figure 3.13: The in vitro effects of PAM with and without aspirin on ATP release. PRP from 
healthy volunteers (n = 4) was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 25%, 
50% and 100% maximum concentration for total P2Y12 receptor inhibition, respectively. 
Heatmaps showing ATP release in response to collagen (4 and 10 µg/mL) and TRAP-6 (25 µM) in 
the presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM) or NO + PGI2 were generated 
in the (A) absence and (B) presence of aspirin (30 µM). Red represents maximum ATP release 
and green shows minimum ATP release with each cell representing data from 4 subjects. 
 
 
3.3.9 Effects of P2Y12 blockade, PGI2 and NO on VASP-phosphorylation  
To further investigate the effects of P2Y12 blockade on the downstream pathways of PGI2 
and NO the levels of phospho (Ser239)-VASP, a downstream marker of PKG and PKA 
activation, were measured. Figure 3.14 illustrates representative control data for TRAP-
6 (25 µM) induced VASP phosphorylation experiments. This was done in PRP incubated 
with PAM (6 µM) and/or ASA (30 µM) or vehicle, treated with vehicle NaOH (0.01 M), 
DEA/NONOate (100 nM), PGI2 (1 nM), or DEA/NONOate + PGI2 and stimulated with 
collagen (4 µg/ml) or TRAP-6 (25 µM) (Figure 3.15).  
0 100% 
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Figure 3.14: Representative control data for VASP phosphorylation experiments. VASP 
phosphorylation (Ser239) in the (A) absence and (B) presence of DAPT was measured in TRAP-6 
(25 μM) stimulated PRP treated with vehicle NaOH (0.01 M), DEA/NONOate (100 nM), PGI2 (1 
nM), or DEA/NONOate + PGI2 by flow cytometry. Histograms are representative of n = 4.  
 
Following collagen stimulation, VASP phosphorylation remained unchanged and no 
significant changes were found in any of the conditions studied (Figure 3.15A). Following 
TRAP-6 stimulation, however, in all the treatment conditions tested in the presence of 
PAM, VASP-phosphorylation was increased. This increase was notable in the presence 
of PGI2, 28±5 to 47±15 units (p<0.05). However, the largest significant increase in VASP-
phosphorylation was detected in the DEA/NONOate+PGI2 treated group (27±4 to 46±11 
units, p<0.05). DEA/NONOate+PGI2 also significantly affected VASP levels in platelets 
pre-treated with DAPT (27±4 to 34±4, p<0.05) (Figure 3.15B).  
 
142 
 
Figure 3.15: The in vitro effects of aspirin and PAM on VASP phosphorylation. PRP from healthy 
volunteers (n = 4) was treated with aspirin (30 μM), PAM (6 μM), both or vehicle followed by 
addition of vehicle (NaOH, 0.01 M), DEA/NONOate (100 nM), PGI2 (1 nM) or DEA/NONOate + 
PGI2. Following stimulation by (A) collagen (4 μg/ml) or (B) TRAP-6 (25 μM) phospho (Ser239) 
VASP levels were then determined by flow cytometry as a composite of cGMP and cAMP 
responses. Significance is shown as * p < 0.05 vs. non-treated. 
 
3.3.10 Involvement of cAMP and cGMP in the synergistic effects of P2Y12 blockade, 
PGI2 and NO 
No significant changes were found in cGMP levels in platelets in response to 
DEA/NONOate and/or PGI2 after incubation with ASA, PAM or ASA+PAM during platelet 
aggregation stimulated by collagen (4 µg/ml; Figure 3.16C) or TRAP-6 (25 µM; Figure 
3.16D). In collagen-stimulated platelets, basal cAMP levels (0.8±0.1 nM) were not 
altered by DEA/NONOate, but were significantly increased by PGI2 (2.6±0.3 nM, p<0.05) 
and even more so by the combination of DEA/NONOate+PGI2 (4.9±0.6 nM, p<0.05). 
However, neither PAM, ASA nor PAM+ASA altered the cAMP responses of collagen 
stimulated platelets (Figure 3.16A). In contrast, in TRAP-6-stimulated platelets, 
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DEA/NONOate, PGI2 and their combination did not elevate cAMP levels in vehicle or ASA 
groups, but PGI2 did in the presence of PAM (1.0±0.1 nM to 2.3±0.2 nM, p<0.05) and 
PAM+ASA (1.4±0.5 nM to 2.2±0.4 nM, p<0.05). This response was further enhanced by 
addition of PGI2+DEA/NONOate (PAM, 3.4±0.6 nM; PAM+ASA, 3.5±0.6 nM; p<0.05; 
Figure 3.16B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: The in vitro effects of aspirin and PAM on cyclic nucleotide levels. PRP from healthy 
volunteers (n = 4) was treated with aspirin (30 μM), PAM (6 μM), both or vehicle followed by 
addition of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM) or NO + PGI2. cAMP levels were 
then measured following stimulation by (A) collagen (4 μg ml) and (B) TRAP-6 (25 μM) as were 
cGMP levels following (C) collagen (4 μg ml) and (D) TRAP-6 (25 μM). Significance is shown as * 
P < 0.05 vs. non-treated and † p < 0.05 PGI2 with corresponding PAM or aspirin + PAM.  
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3.4 Discussion  
 
It is well known that NO and PGI2 synergise to inhibit platelets [74] and it has been 
demonstrated that P2Y12 antagonists potentiate the inhibitory actions of both PGI2, 
dependent upon cAMP [237], and NO, dependent upon cGMP generation [238]. I 
therefore, reasoned that differences in the levels of NO and PGI2 in the presence of the 
same levels of P2Y12 receptor blockade will produce different levels of platelet inhibition 
in an individual patient. Furthermore, that the strong synergies between P2Y12 inhibitors 
and the cAMP and cGMP signaling systems mean that the in vivo platelet reactivity in 
patients receiving DAPT will be a function of the level of P2Y12 receptor blockade and 
the levels of endothelial-derived NO and PGI2.  
 
Here, I have started to investigate this hypothesis in vitro using PAM with and without 
aspirin to show that strong interactions between P2Y12 receptor blockade and 
endothelial derived mediators produce profound inhibitory effects upon platelets, far 
more than P2Y12 blockade acting alone. These studies highlight that the interactions of 
NO, PGI2 and P2Y12 receptor blockade in inhibiting platelets are markedly synergistic as 
noted by isobolographic analysis and measures of aggregation, ATP release, VASP 
phosphorylation and cyclic nucleotide expression.  
 
Firstly, the results show that blockade of platelet P2Y12 receptors markedly enhances 
the antiplatelet potency of both PGI2 and NO individually, causing a 10- to 1000-fold 
increase in inhibitory activity against platelet aggregation in response to activation of 
receptors for either thrombin, collagen or ADP, and that this is even further enhanced 
when PGI2 and NO are applied in combination. This was demonstrated over a range of 
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concentrations of NO (0.01-1000 nM) and PGI2 (1 nM- 100 nM). High concentrations of 
thrombin (30 µM), collagen (30 µM) and ADP (20 µM) were used in order to display the 
true potency of these powerful interactions in the context of full P2Y12 blockade which 
is achieved using PAM (6 µM).  
 
To establish whether the interactions observed between NO, PGI2 and P2Y12 blockade 
for inhibition of thrombin and collagen induced platelet aggregation were additive or 
synergistic, isobolographic analyses were conducted [320]. To do this, matched 
aggregation studies were performed by LTA, using high concentrations of the platelet 
agonists collagen (30 µg/ml) and TRAP-6 (30 µM). Aggregation was measured in the 
absence and presence of full P2Y12 receptor blockade using PAM (6 µM). From these 
data, isobolograms were constructed indicating the concentrations of DEA/NONOate 
and PGI2 required, in combination, to produce 50% inhibition of platelet aggregation 
with and without PAM (6 µM). A simple additive relationship is indicated on an 
isobologram by a straight line, i.e. a relationship where a reduction in concentration of 
one inhibitor necessitates a linear increase in the concentration of the other to maintain 
the same level of inhibition. However, the isobolograms generated here displaying the 
interaction between DEA/NONOate and PGI2 indicate a powerful synergy between these 
two inhibitors with the isoboles curving markedly toward the axes. Importantly, for both 
agonists tested the blockade of P2Y12 receptors led to a further powerful enhancement 
of platelet inhibition. In fact, in the presence of PAM (6 µM), TRAP-6 induced aggregation 
was further inhibited 10-fold and collagen 4-fold further, highlighting the synergistic 
relationship between the three mediators. 
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Selecting inhibitory concentrations of PGI2 (1 nM) and DEA/NONOate (100 nM), I further 
explored the effects of full P2Y12 receptor inhibition with PAM (6 µM) with both PGI2 and 
NO individually and in combination on platelet aggregation and then also the additional 
effects of aspirin on the powerful three-way synergy that was observed between the 
aforementioned mediators. Following incubation with PAM (6 µM), aggregation was 
significantly reduced by both PGI2 and NO alone. However, much stronger inhibition was 
observed in the presence of the combination for both agonists tested, collagen (4 µg/ml) 
and TRAP-6 (25 µM). Interestingly, the addition of aspirin did not further reduce 
aggregation in the presence of PAM (6 µM) and PGI2+NO following collagen stimulation. 
In TRAP-6 stimulated samples aspirin did not have any additional inhibitory action to 
that of PAM (6 µM) in the presence of PGI2 or NO individually or in combination. 
Aggregation in response to collagen was reduced by PGI2+NO and aspirin therapy alone, 
but there was no reduction in the response to TRAP-6 with no evidence of the powerful 
three-way synergy that was observed between P2Y12 blockade and these inhibitors. 
These data support the hypothesis that the level of platelet inhibition in vivo will be 
dramatically affected by the presence and activity of these endothelially produced 
endogenous platelet inhibitors in the presence of P2Y12 receptor antagonist therapy.   
 
Next, continuing with an in vitro approach, I modelled events in the presence of 
suboptimal levels of P2Y12 receptor blockade by using concentrations of PAM that were 
50% and 25% of the effective concentration.  Under these conditions it was noted that 
relative to consensus levels of DAPT there was no significant reduction in platelet 
aggregation. Notably, however, in the presence of NO and PGI2 effective levels of 
inhibition were achieved, even when platelets were exposed to only 25% of the effective 
concentration of PAM. As expressed in heat maps, there is a clear interaction between 
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P2Y12 blockade and the endothelial mediators that move platelets from reactive (‘red’) 
to unreactive (‘green’). Interestingly, these comparisons indicate that 25% of the 
effective concentration of PAM plus NO and PGI2 produces a stronger inhibition in LTA, 
the ‘gold standard test’, than 100% of the effective concentration of PAM in the absence 
of NO and PGI2 (i.e. the normal conditions for testing ex vivo platelet responsiveness).  
Similarly, while NO, PGI2 or P2Y12 blockade alone had relatively little effect upon platelet 
granule release, determined as ATP release, when combined they caused more than 
50% inhibition. These results indicate that even in the presence of effective P2Y12 
blockade, the presence of NO and PGI2 lead to very much higher levels of platelet 
inhibition. Again, even in the presence of only partial 25% and 50% P2Y12 receptor 
blockade, the addition of the combination of PGI2 and NO caused more effective platelet 
inhibition than 100% of the effective concentration of PAM in the absence of these 
endothelial inhibitors. This suggests that in individuals in whom suboptimal P2Y12 
inhibition is achieved, such as poor clopidogrel metabolisers, anti-platelet efficacy may 
be particularly sensitive to any changes in endothelial function.  
 
The in vitro data also demonstrate that the triple synergy between P2Y12 blockade, NO 
and PGI2 can be explained by changes in cAMP signalling, which is consistent with known 
interactions between NO and PGI2 [322], and between PGI2 and P2Y12 [237]. The most 
pronounced increases in cAMP, but not cGMP, were seen with NO+PGI2 together with 
P2Y12 blockade following TRAP-6 stimulation. This increase in cyclic nucleotide activity 
was confirmed through measurement of VASP phosphorylation, a major substrate for 
cAMP- and cGMP-regulated protein kinases, which was increased following TRAP-6 
stimulation in the presence of PAM in all cases but markedly so in the presence of PGI2 
and also DEA/NONOate+PGI2. 
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In this first chapter I show that the endothelial inhibitors PGI2 and NO influence the 
efficacy of P2Y12 receptor blockade in inhibiting platelet function. Whilst PGI2 and NO 
had little effect on their own, they caused almost complete inhibition of platelets 
treated with PAM. While NO and PGI2 were added exogenously they are surrogates for 
the effects of endogenous NO and PGI2 and other elevators of platelet cyclic nucleotides 
such as adenosine. This initial data suggests that following standard DAPT the level of 
platelet reactivity is a function of the level of P2Y12 receptor blockade and the levels of 
NO and PGI2 and in vivo platelet function is a product of both internal platelet responsive 
signalling reactivity and the external influence of the endothelium. Having 
demonstrated this is in vitro, in the next chapter I will further investigate these 
interactions by testing platelets ex vivo from healthy volunteers treated with standard 
anti-platelet therapies. 
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Chapter 4: The efficacy of P2Y12 receptor antagonist 
therapy is strongly determined by endothelial mediators 
in healthy volunteers ex vivo 
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4.1 Introduction 
 
In the previous chapter I described a potent three way synergy between P2Y12 receptor 
blockade and the endothelial mediators, NO and PGI2. A synergy much more powerful 
than those previously described between NO and PGI2 [74], and both NO and PGI2 
individually with P2Y12 blockade [238] [237]. I outlined that the inhibitory effects of both 
NO and PGI2 are powerfully potentiated by P2Y12 receptor blockade in vitro which, is 
suggestive that in vivo platelet function is a product of intrinsic platelet reactivity, 
modifiable by DAPT and the endogenous inhibitory endothelial mediators NO and PGI2. 
This implies that for individual patients endothelial mediator production is an important 
determinant of the efficacy of DAPT, and that for individual patients in vitro measures 
of platelet reactivity do not accurately predict the in vivo effectiveness of DAPT due to 
the confounding of differences in endothelial mediator production. Here, my studies 
continue to test the hypothesis that within the circulation levels of endothelium-derived 
mediators are an important determinant of the efficacy of DAPT by adding exogenous 
NO and PGI2 to standard ex vivo tests of platelet function in blood taken from healthy 
volunteers receiving anti-platelet therapies.  
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4.2 Methods 
 
4.2.1 Study participants 
24 healthy, non-smoking male volunteers (aged 18-40 years) were recruited and 
participated in the study. Health status was determined though medical history and 
physical examination, including blood pressure, pulse rate, blood chemistry and 
urinalysis. Volunteers with normal clinical profiles were included in the study. 
 
4.2.2 Study protocol 
Healthy volunteers abstained from aspirin, NSAIDs and any other anti-platelet therapy 
for 14 days before commencing the study. The volunteers were divided into three 
groups of 8. The first group received aspirin (75 mg, o.d.), the second prasugrel (10 mg, 
o.d.) and the third both aspirin (75 mg, o.d.) and prasugrel (10 mg, o.d.), to represent 
DAPT, for 7 days. Adherence was assessed by interview at each study visit. Blood and 
urine samples were collected before and after drug treatment on day 0 and day 7. 
 
4.2.3 Blood collection and preparation of PRP/PPP 
Blood was collected by venepuncture as described in section 2.2.3 and PRP/PPP was 
prepared as described in section 2.2.4. 
 
4.2.4 LTA 
Baseline aggregations to AA (1 mM), ADP (5 and 20 µM), Horm collagen (0.4, 4 and 10 
µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were determined, as described in section 
2.2.7.1. Aggregations to TRAP-6 (25 µM) and Horm collagen (4 µg/ml) were measured 
after pre-incubation of PRP with vehicle (NaOH 0.01 M,) DEA/NONOate (100 nM) or PGI2 
(1 nM) individually or in combination with DEA/NONOate and PGI2 for 1 minute at 37 °C. 
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4.2.5 ADP + ATP Release 
ADP + ATP release from platelets was assessed by lumi-aggregometry, as described in 
section 2.2.8. PRP was pre-incubated with vehicle or DEA/NONOate and/or PGI2 as 
described above. ADP + ATP secretion was evaluated by luminescence in the presence 
of Chrono-Lume reagent after stimulation with collagen (4 µg/ml) or TRAP-6 (25 µM). 
 
4.2.6 Flow cytometry 
PRP was incubated with PGI2 and/or DEA/NONOate or vehicle and then activated with 
TRAP-6 (25 µM). P-selectin and PAC-1 expression were measured using flow cytometry, 
as described in section 2.2.9.  
 
4.2.7 cAMP and cGMP measurements 
PRP was stimulated with collagen (4 µg/mL) or TRAP-6 (25 µM) in the presence of PGI2 
and/or DEA/NONOate or vehicle. After 4 min, platelets were lysed with Triton-X-100 
(0.625%) and treated with iso-butylmethylxanthine (IBMX; 500 μM) and potassium 
fluoride (0.5 M). cAMP and cGMP concentrations were determined by HTRF-based 
competitive immunoassays. 
 
4.2.8   Heat map generation and scaling  
The heat maps were created in Microsoft excel. Conditional formatting was applied to 
the cells containing the data range. A colour scale was chosen to allow visual 
representation of the underlying data. At one end of the scale, red represents 100% 
aggregation of platelets or maximal platelet ATP release. On the other end of the scale, 
green represents 0% platelet aggregation or no ATP release. There is a gradual change 
in the colour scale from red to dark red to brown to dark green through to green 
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corresponding to decreasing percentage values. Dark brown represents the mid-way 
point (50%. The colour gradient was applied to the range of cells containing the data 
thus indicating where each data point falls within the data set. This allows a quick and 
powerful visual representation of my data alongside the other graphical resources and 
written text. The red (100%) and green (0%) are immediately differentiated and data 
points in between can be judged in conjunction with the underlying data and scale 
represented below.   
The colour scale is as follows:  
 
 
 
 
  
0 100% 
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4.3 Results 
 
4.3.1  LTA responses to standard agonists following monotherapy aspirin or 
prasugrel and DAPT 
In baseline studies, high pre-treatment levels of platelet reactivity were observed, with 
final aggregation values of over 60% for all agonists tested, as is normal in naïve healthy 
volunteers [244, 323, 324]. Following treatment with aspirin or prasugrel there was 
powerful inhibition of platelet responses to AA or ADP, respectively, (see below) in 
keeping with the mode of action of these agents [244, 324]. 
 
In individuals taking aspirin, standard LTA responses to AA (1 mM) were strongly 
inhibited (74±7% to 2±1%), as were responses to collagen (0.4 µg/ml). Responses to ADP 
(5 µM) were also significantly reduced although to a lesser degree (74±6 to 46±8%), 
while those to U46619 (10 µM) were unaffected (Figure 4.1A). In individuals taking 
prasugrel, aggregatory responses to AA (67±5% to 12±6%), collagen (0.4 µg/ml) (69±2% 
to 17±4%), ADP (5 µM) (70±2% to 2±1%) and U46619 (72±2% to 50±5%) were all 
significantly reduced (Figure 4.1B). Aggregations induced by AA, collagen (0.4 µg/ml) and 
ADP (5 µM and 20 µM) were abolished in individuals taking DAPT (aspirin plus prasugrel) 
while responses to U46619 (71±1% to 29±10%) and collagen (10 µg/ml) (69±2% to 
44±3%) were strongly reduced (Figure 4.1C). 
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Figure 4.1: Standard platelet aggregation tests. Standard LTA responses to AA (1 mM), ADP (5 
and 20 µM), collagen (0.4 and 10 µg/mL) and U46619 (10 µM) in healthy volunteers before and 
following treatment with (A) aspirin (75 mg), (B) prasugrel (10 mg), or (C) DAPT (aspirin, 75 mg 
+ prasugrel, 10 mg) for 7 days. N=8 for all.  Significance is shown as * p<0.05 treated vs non-
treated. 
 
 
4.3.2 The individual and combined effects of PGI2, NO and DAPT on platelet 
aggregation 
Representative LTA traces are displayed in figure 4.2. In control PRP neither 
DEA/NONOate nor PGI2 individually or in combination had an effect on platelet 
aggregation responses following collagen (4 µg/ml) or TRAP-6 (25 µM) stimulation 
(Figure 4.2.A/C).  
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Following DAPT treatment, collagen (4 µg/ml) induced aggregation was reduced for all 
conditions tested; vehicle, 70% to 39%; DEA/NONOate, 68% to 29%; PGI2 70% to 21% 
and PGI2+DEA/NONOate, 64% to 11%. In TRAP-6 (25 µM) stimulated PRP following 
DAPT, aggregation was minimally reduced in the presence of vehicle (75% to 61%) but 
more so in the presence of DEA/NONOate (76% to 52%) and PGI2 (76% to 49%). The 
greatest reduction in platelet aggregation was observed in platelets exposed to the 
combination of PGI2+DEA/NONOate (70% to 20%) (Figure 4.2.B/D).  
Figure 4.2: The effect of DAPT on platelet aggregation. Representative LTA traces of PRP before 
and after DAPT (aspirin, 75 mg + prasugrel, 10 mg) treatment in the presence of vehicle (NaOH, 
0.01 M), DEA/NONOate (100 nM), PGI2 (1 nM), or DEA/NONOate+PGI2 following (A/B) collagen 
(4 μg/mL) or (C/D) TRAP-6 amide (25 μM) stimulation. Traces representative of n=1.  
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4.3.3 The individual and combined effects of PGI2 and NO on aspirin or prasugrel 
monotherapy and DAPT on platelet aggregation following collagen stimulation 
PRP from each therapy group was tested with the addition of PGI2 and/or NO. Before 
therapy, PGI2 (1 nM) or DEA/NONOate (100 nM) had little effect upon platelet 
aggregation in response to collagen (4 µg/ml), whilst NO+PGI2 produced some inhibition 
(Figure 4.3.A/B/C). Following DAPT, aggregation in the presence of vehicle was 
significantly reduced from 73±2% to 31±2% (p<0.05; Figure 4.3.A), as seen previously 
with a lower concentration of collagen (0.4 µg/mL; Figure 4.1.C). Inhibition of platelet 
aggregation was increased by the addition of either PGI2 (14±2%) or DEA/NONOate 
(17±3%), but further still by the combination of PGI2+DEA/NONOate (5±1%) (Figure 
4.3.A). A similar pattern, i.e. the highest levels of platelet inhibition were seen with the 
addition of PGI2+DEA/NONOate post therapy, were observed in both aspirin and 
prasugrel monotherapy treated groups (Figure 4.3.B/C). Of note, in these 
PGI2+DEA/NONOate treated samples the highest net reduction in platelet aggregation 
was noted following DAPT (Native PRP: 56±6% to post DAPT: 5±1%, net reduction: 51%), 
as compared to that observed for prasugrel (Native PRP: 28±8% to post prasugrel: 1±1%, 
net reduction: 27%) and the smallest net reduction following aspirin therapy (Native 
PRP: 16±6% to post aspirin 2±1%, net reduction 14%) (Figure 4.3.A/B/C).  
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Figure 4.3: Interactions of NO and PGI2 with DAPT, aspirin and prasugrel: platelet 
aggregation following collagen stimulation. Bar graphs of platelet aggregation in 
response to collagen (4 µg/ml). Aggregometry was conducted before and after 7 days of 
DAPT (aspirin, 75 mg + prasugrel, 10 mg), aspirin (75mg) or prasugrel (10mg). 
Aggregometry was conducted in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), 
PGI2 (1 nM), or NO + PGI2. Data are presented as final aggregation (%, mean±SEM). 3 data set 
comparisons have been performed. Significance is shown as * p<0.05 for pre- (red) versus post- 
(blue) anti-platelet therapy. Significance is shown † p<0.05 post- (blue) anti-platelet therapy, 
vehicle versus inhibitor treatment. Significance is shown ‡ p<0.05 post- (blue) anti-platelet 
therapy vs post therapy PGI2-treated. N=8 for all.  
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4.3.4 The individual and combined effects of PGI2 and NO on aspirin or prasugrel 
monotherapy and DAPT following TRAP-6 stimulation 
The addition of PGI2, DEA/NONOate or DEA/NONOate+PGI2 had negligible effects upon 
platelet aggregation induced by TRAP-6 (25 µM) in native PRP (Figure 4.4). However, 
TRAP-6 (25 µM)-induced aggregation was significantly reduced by DAPT in the presence 
of vehicle, PGI2 or DEA/NONOate (74±3% to 57±4%, 70±3% to 48±6% and 71±3% to 
49±6%, respectively). Whilst when DEA/NONOate+PGI2 was present in the presence of 
DAPT it was much reduced still further (67±3% to 19±6%, p<0.05; Figure 4.4.A). A similar 
pattern was observed in the prasugrel monotherapy group, in which prasugrel 
significantly reduced platelet aggregation (p<0.05) in the presence of either PGI2 (70±1% 
to 43±6%) or DEA/NONOate (72±1% to 50±5%) but the highest levels of inhibition were 
observed with the addition of PGI2+DEA/NONOate (63±3% to 7±3%) (Figure 4.4.C). This 
pattern was not noted in the aspirin monotherapy group where aspirin treatment only 
moderately reduced platelet aggregation significantly in the presence of 
PGI2+DEA/NONOate (69±5% to 28±9%). Aspirin therapy did not reduce platelet 
aggregation in the presence of either PGI2 or DEA/NONOate alone (Figure 4.4.B). 
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Figure 4.4: Interactions of NO and PGI2 with DAPT, aspirin and prasugrel: platelet aggregation 
following TRAP-6 stimulation. Bar graphs of platelet aggregation in response to TRAP-6 (25 µM). 
Aggregometry was conducted before and after 7 days of DAPT (aspirin, 75 mg + prasugrel, 10 
mg), aspirin 75mg or prasugrel 10mg. Aggregometry was conducted in the presence of vehicle 
(NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented as final aggregation 
(%, mean±SEM). 3 data set comparisons have been performed. Significance is shown as * p<0.05 
for pre- (red) versus post- (blue) anti-platelet therapy. Significance is shown † p<0.05 post- (blue) 
anti-platelet therapy, vehicle versus inhibitor treatment. Significance is shown ‡ p<0.05 post- 
(blue) anti-platelet therapy vs post therapy PGI2-treated. N=8 for all. 
 
4.3.5 Heat maps displaying the effects of PGI2 and NO on platelet aggregation 
following aspirin or prasugrel monotherapy and DAPT  
To make data readily accessible results are presented in the form of heat maps that 
move from red to green, indicating movement from full platelet aggregation in red to 
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no platelet activation in green. These heat maps express a clear interaction between 
anti-platelet therapies and PGI2 and NO that move platelets from reactive (‘red’) to 
unreactive (‘green’). This is observable for both primary agonists tested, collagen (4 
µg/ml) (Figure 4.5.A) and TRAP-6 (25 µM) (Figure 4.5.B). Though a weak effect of this 
transition is observed following aspirin therapy the effects are much more marked 
following both prasugrel monotherapy and DAPT. In the context of P2Y12 receptor 
blockade through DAPT and prasugrel therapy, both PGI2 and NO alone reduced platelet 
aggregation although it is the combination of the two which inhibited aggregation most 
strongly. Aspirin therapy only decreased aggregation when combined with the 
combination of NO+PGI2, with these effects being most evident in the collagen (4 µg/ml) 
as opposed to TRAP-6 (25 µM) stimulated platelets. 
 
 
 
 
 
 
 
Figure 4.5: Heatmaps representing interactions of NO and PGI2 with aspirin, prasugrel and 
DAPT. Heatmaps of platelet aggregation in response to (A) collagen (4 µg/ml), and (B) TRAP-6 
amide (25 µM). Aggregometry was conducted before and after 7 days of aspirin (75 mg), 
prasugrel (10 mg) or DAPT (aspirin, 75 mg + prasugrel, 10 mg) in the presence of vehicle (NaOH, 
0.01 M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented as heatmaps indicating 
maximum final aggregation with red and minimum final aggregation with green. N = 8 for all. 
 
0 100% 
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4.3.6 The individual and combined effects of PGI2, NO and DAPT on ADP + ATP release 
To further characterise the effects of PGI2 and NO on platelets, ADP + ATP release in the 
lumi-aggregometer was determined as a measure of dense granule secretion. 
Representative lumi-aggregometry traces are displayed below in figure 4.6. In native 
PRP there was a reduction in ATP release only in the presence of PGI2+DEA/NONOate. 
DAPT alone did not cause a reduction in ATP release, however the addition of either 
DEA/NONOate or PGI2 did reduce ATP release. The lowest ATP release was observed 
following DAPT in the presence of DEA/NONOate+PGI2.  
 
 
Figure 4.6: The effect of DAPT on platelet ATP release. Representative lumi-aggregometry 
traces before and after DAPT (aspirin, 75 mg + prasugrel, 10 mg) treatment in the presence of 
vehicle (NaOH, 0.01 M), DEA/NONOate (100 nM), PGI2 (1 nM), or DEA/NONOate+PGI2 following 
TRAP-6 amide (25 μM) stimulation.  Traces representative of n=1.  
 
 
4.3.7 The individual and combined effects of PGI2 and NO together with aspirin or 
prasugrel monotherapy and DAPT on ADP + ATP release 
In native PRP, PGI2+DEA/NONOate caused variable levels of collagen-induced ATP 
release in the three groups tested; ATP release in the DAPT group was not affected by 
the addition of PGI2+DEA/NONOate (3.8±0.8 to 3.5±0.8 nM) however, in the aspirin and 
prasugrel monotherapy groups ATP release was reduced (6.8±0.9 to 2.4±0.9 nM) and 
(8.6±0.5 to 3.1±0.4 nM) by PGI2+NONOate (Figure 4.7.A/C/D). DAPT reduced ATP release 
with the addition of PGI2 (3.8±0.8 to 0.9±0.15 nM, p<0.05) (Figure 4.7.A). Aspirin therapy 
also significantly reduced ATP release in the presence of PGI2 (Figure 4.7.C). Prasugrel 
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therapy significantly reduced (p<0.05) ATP release in all conditions tested. ATP was also 
significantly reduced (p<0.05) by DEA/NONOate and PGI2 individually and in 
combination compared to vehicle (vehicle, 8.6±0.5 to 5.2±0.4; DEA/NONOate, 7.3±0.5 
to 1.4±0.2; PGI2, 6.6±0.3 to 0.9±0.15 and PGI2+NO 3.1±0.4 to 1±0.3 nM) (Figure 4.7.D). 
In platelets stimulated with TRAP-6 (25 µM), ATP release was not affected by DAPT in 
the presence of vehicle (pre-treatment, 7.5±1.7; post-treatment, 7.7±0.6 nM) or by the 
addition of PGI2 and/or DEA/NONOate (Figure 4.7.B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Interactions of NO and PGI2 with DAPT, aspirin and prasugrel: platelet ADP/ATP 
release. Bar graphs of platelet ADP/ATP release in response to (A/C/D) collagen (4 µg/ml), and 
(B) TRAP-6 amide (25 µM). Lumi-aggregommetry experiments were conducted before and after 
7 days of DAPT (aspirin, 75 mg + prasugrel, 10 mg), aspirin (75mg) or prasugrel (10mg), in the 
presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented 
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as ATP release (nmole, mean±SEM). 3 data set comparisons have been performed. Significance 
is shown as * p<0.05 for pre- (red) versus post- (blue) anti-platelet therapy. Significance is shown 
† p<0.05 post- (blue) anti-platelet therapy, vehicle versus inhibitor treatment. Significance is 
shown ‡ p<0.05 post- (blue) anti-platelet therapy vs post therapy PGI2-treated. N=8 for all. 
 
 
4.3.8 Heat maps displaying the effects on ATP release of PGI2 and NO in control 
conditions or in the presence of aspirin or prasugrel monotherapy and DAPT 
As previously, the results in 4.3.7 are represented in the form of heat maps transitioning 
from red to green to indicate movement from high platelet ATP release in red to low 
platelet ATP release in green. A transition of red to green was observed with the addition 
of PGI2, NO and PGI2+NO following treatment with all three anti-platelet therapy 
regimes in platelets stimulated with collagen (4 µg/ml; Figure 4.8.A) or TRAP-6 (25 µM; 
Figure 4.8.B). 
 
 
 
 
 
 
 
 
 
Figure 4.8: Heat maps representing interactions of NO and PGI2 with aspirin, prasugrel and 
DAPT. Heat maps of platelet ATP release in response to (A) collagen (4 µg/ml), and (B) TRAP-6 
amide (25 µM). Lumi-aggregometry was conducted before and after 7 days DAPT (aspirin, 75 mg 
+ prasugrel, 10 mg), aspirin (75 mg) or prasugrel (10mg) in the presence of vehicle (NaOH, 0.01 
M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented as heat maps indicating 
maximum ATP release with red and minimum ATP release with green. N = 8 for all. 
 
0 100% 
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4.3.9 P-selectin expression and GPIIb/IIIa activation in the presence of PGI2 and NO 
together with aspirin or prasugrel monotherapy and DAPT 
To further characterise the effects of PGI2 and NO on platelets, PAC-1 and P-selectin 
expression were determined. Representative histograms of the effects of DAPT and 
endothelial inhibitors are displayed below. In native PRP, there was a reduction in PAC-
1 and P-selectin expression in the presence of PGI2 and PGI2+DEA/NONOate. DAPT 
reduced PAC-1 and P-selectin expression in all conditions tested (Figure 4.9).  
 
 
 
 
 
 
 
 
Figure 4.9: Representative histograms of the effects of DAPT on platelet P-selectin and 
GPIIb/IIIa expression. GPIIb/IIIa activation by PAC-1 binding in the (A) absence and (B) presence 
of DAPT and P-selectin expression in the (C) absence and (D) presence of DAPT as measured by 
flow cytometry in PRP stimulated with TRAP-6 (25 μM) in the presence of vehicle (NaOH, 0.01 
M), DEA/NONOate (100 nM), PGI2 (1 nM), or DEA/NONOate + PGI2.  
 
In native PRP, TRAP-6 induced expression of P-selectin and GPIIb/IIIa produced  a similar 
pattern in all 3 volunteer groups with mild reductions caused by PGI2 and DEA/NONOate 
individually, and moderate reductions caused by PGI2+DEA/NONOate (Figure 4.10). Both 
P-selectin expression and GPIIb/IIIa activation following DAPT were strongly reduced in 
all conditions tested. For both markers, PGI2+DEA/NONOate further significantly 
reduced expression (p<0.05) compared to vehicle treated PRP (Figure 4.10.A/B). Aspirin 
therapy caused no significant reductions in either P-selectin or GPIIb/IIIa activation 
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(Figure 4.10.C/D). In the presence of prasugrel therapy, P-selectin expression was 
reduced in the vehicle treated group (25±6 MFI to 9±3 MFI). GPIIb/IIIa activation was 
significantly reduced by prasugrel in all conditions tested and also further by 
DEA/NONOate, PGI2 and PGI2+DEA/NONOate: vehicle, 19±4 to 1.6±0.3 MFI; 
DEA/NONOate, 10±2 to 0.4±0.2 MFI; PGI2, 13±2 to 0.5±0.2 MFI and NO+PGI2, 5±1 to 
0.2±0.2 MFI (Figure 4.10.E/F).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Interactions of NO and PGI2 with DAPT, aspirin and prasugrel: platelet P-selectin 
and GPIIb/IIIa expression. Bar graphs of P-selectin expression (A/C/E) and PAC-1 activation 
(B/D/F) stimulated with TRAP-6 amide (25 µM). Flow cytometry experiments were conducted 
before and after 7 days of DAPT (aspirin, 75 mg + prasugrel, 10 mg), aspirin 75mg or prasugrel 
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10mg. Flow cytometry was conducted in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), 
PGI2 (1 nM), or NO + PGI2. Data are presented as mean fluorescence index (MFI, mean±SEM). 3 
data set comparisons have been performed. Significance is shown as * p<0.05 for pre- (red) 
versus post- (blue) anti-platelet therapy. Significance is shown † p<0.05 post- (blue) anti-platelet 
therapy, vehicle versus inhibitor treatment. Significance is shown ‡ p<0.05 post- (blue) anti-
platelet therapy vs post therapy PGI2-treated. N=8 for all. 
 
4.3.10   Heat maps displaying the effects on P-selectin and GPIIb/IIIa expression of 
PGI2 and NO in the presence of aspirin or prasugrel monotherapy and DAPT  
In native PRP, predominantly red cells are present in the matrix representing high levels 
of platelet activation. With the addition of PGI2+DEA/NONOate there is a weak transition 
to green. These results are largely mirrored in the aspirin treated group for both ADP 
and TRAP-6. Results for P-selectin (Figure 4.11.A) and GPIIb/IIIa expression (Figure 
4.11.B) in the DAPT and prasugrel treated groups are markedly different, with all cells in 
the matrix displaying green representing high levels of platelet inhibition for both ADP 
and TRAP-6.  
 
 
 
 
 
 
 
 
 
Figure 4.11: Heat maps representing interactions of NO and PGI2 with aspirin, prasugrel and 
DAPT. Heat maps of (A) P-selectin expression and (B) PAC-1 activation in response to ADP (20 
µM) and TRAP-6 amide (25 µM). Flow cytometry was conducted before and after 7 days DAPT 
0 100% 
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(aspirin, 75 mg + prasugrel, 10 mg), aspirin or prasugrel in the presence of vehicle (NaOH, 0.01 
M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented as heat maps indicating 
maximum MFI with red and MFI with green. N = 8 for all. 
 
4.3.11 Involvement of cAMP and cGMP in the synergistic effects of P2Y12 blockade, 
PGI2 and NO 
I found no significant changes in cGMP levels in platelets in response to 
DEA/NONOate+PGI2 following treatment with DAPT (Figure 4.12.C/D). In collagen-
stimulated platelets following DAPT, cAMP levels (0.42±0.12 nM) were significantly 
increased (p<0.05) by DEA/NONOate+PGI2 (4.42±0.98 nM) (Figure 4.12.A). A significant 
increase (p<0.05) was also observed in platelets stimulated with TRAP-6 (0.34±0.1 to 
2±0.35 nM) (Figure 4.12.B).  
 
 
 
 
 
 
 
 
 
 
Figure 4.12:  Interactions of NO + PGI2 with DAPT with prasugrel (10 mg) plus aspirin (75 mg): 
platelet cyclic AMP and GMP release. Bar graphs of cAMP release (A/B) following stimulation 
of platelets with (A) collagen (4 µg/ml) and (B) TRAP-6 amide (25 µM). Bar graphs of cGMP 
release (C/D) following stimulation with (C) collagen (4 µg/ml) and (D) TRAP-6 amide (25 µM). 
Experiments were conducted before and after 7 days of DAPT (aspirin, 75 mg + prasugrel, 10 
mg) in the presence of vehicle (NaOH, 0.01 M) or NO + PGI2 (100 nM + 1 nM). Data are presented 
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as nanomolar (nM, mean±SEM). Significance is shown as * p<0.05 vs non-treated, † p<0.05 vs 
NaOH-treated. N=8 for all experiments. 
 
To further validate these results, cyclic nucleotide levels were also measured in platelets 
from healthy volunteers pre and post treatment with another P2Y12 antagonist, 
ticagrelor. Similarly to the results obtained for DAPT with prasugrel plus aspirin, DAPT 
with ticagrelor plus aspirin did not alter the cGMP response in either collagen-stimulated 
(4 µg/ml) or TRAP-6 (25 µM) stimulated platelets. There was also no change in cGMP 
formation following the addition of PGI2+DEA/NONOate (Figure 4.13.C/D). In contrast, 
in collagen-stimulated platelets the combination of PGI2+DEA/NONOate significantly 
elevated cAMP levels following treatment with aspirin plus ticagrelor (0.32±0.13 nM to 
3.51±1.13 nM, p<0.05) (Figure 4.13.A).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Interactions of NO + PGI2 with DAPT with ticagrelor (90 mg) and aspirin (75 mg): 
platelet cyclic AMP and GMP release. Bar graphs of cAMP release (A/B) following stimulation 
with (A) collagen (4 µg/ml) and (B) TRAP-6 amide (25 µM). Bar graphs of cGMP release (C/D) 
following stimulation with (C) collagen (4 µg/ml) and (D) TRAP-6 amide (25 µM). Experiments 
were conducted before and after 7 days of DAPT (aspirin, 75 mg, plus ticagrelor, 90 mg) in the 
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presence of vehicle (NaOH, 0.01 M) or NO + PGI2 (100 nM + 1 nM). Data are presented as 
nanomolar (nM, mean±SEM). Significance is shown as * p<0.05 vs non-treated, † p<0.05 vs 
NaOH-treated. N=8 for all. 
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4.4 Discussion 
 
The data presented here show in healthy individuals receiving standard P2Y12 receptor 
antagonist therapy producing consensus levels of platelet inhibition, that ex vivo 
responses to the strong primary platelet activators collagen and TRAP-6 are powerfully 
influenced by the presence of NO and PGI2. It is well known that NO and PGI2 synergise 
to inhibit platelets [74] and it has been demonstrated that P2Y12 antagonists potentiate 
the inhibitory actions of both PGI2, dependent upon cAMP [237], and NO, dependent 
upon cGMP generation [238]. In the studies presented here, through measures of 
aggregation, ATP release, activation of GP IIb/IIIa receptors and P-selectin expression, I 
demonstrate that these strong interactions between P2Y12 receptor blockade and 
endothelial derived mediators produce profound inhibitory effects upon platelets tested 
ex vivo.  
 
I firstly established that the drug regime given in these studies elicited satisfactory 
reduction in baseline reactivity therefore, establishing effectiveness of P2Y12 and/or COX 
inhibition in accordance with suggested analytical cut-offs [264]. These reductions were 
against high pre-treatment levels of platelet reactivity (>70% response to 5 µM ADP) 
[123]. In these studies care was taken to include the standard measures of platelet 
function as determined in consensus statements [325]. Then to make data readily 
accessible, results were additionally presented in the form of heat maps that move from 
red to green, indicating movement from full platelet activation to no platelet activation.  
 
In volunteers taking DAPT, it was noted that inhibition of LTA responses to ADP and AA 
were in keeping with consensus statements of effective DAPT; i.e. in this study the drugs 
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were working to an effective level of clinical efficacy. Despite this level of effective 
inhibition, high concentrations of the strong primary platelet activators, TRAP-6 or 
collagen, still caused notable platelet aggregation in all three groups. Addition of low 
concentrations of NO or PGI2 individually had little effect on their own pre-treatment, 
nor did they affect aggregation to TRAP-6 following aspirin therapy. However, in the 
presence of P2Y12 blockade by prasugrel or DAPT, the addition of NO or PGI2 significantly 
reduced aggregation reflecting the known individual synergies between P2Y12 blockade 
and PGI2 and NO. Addition of low concentrations of NO and PGI2 in combination, to 
model the environment within the blood vessel, had little effect on their own pre-
treatment but led to almost complete inhibition of activation in platelets from 
individuals treated with DAPT (19±6) or prasugrel (7±3%), demonstrating the three-way 
synergy between these inhibitors and P2Y12 blockade. The combination of NO+PGI2 did 
reduce aggregation post-aspirin therapy but not to such a powerful degree (28±9%). 
PGI2 and NO are known to synergise powerfully leading to platelet inhibition so we can 
well expect to see some inhibitory effect in platelets from individuals treated with 
aspirin. However, without the additional three way synergy of P2Y12 receptor blockade 
this level of inhibition is far inferior to that seen in platelets from individuals treated with 
prasugrel.  
 
With regard to collagen-induced aggregation, a similar pattern was observed for all 
three treatment groups post treatment, in that platelet aggregation was reduced 
individually by NO and PGI2 but very much greater reductions were observed in the 
presence of the two inhibitors in combination. DAPT significantly reduced aggregation 
in all conditions tested and also in the presence of NO, PGI2 and NO+PGI2. These effects 
were stronger than those seen following monotherapy with aspirin or prasugrel alone 
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where aggregation was only significantly reduced with the addition of PGI2 or PGI2+NO. 
Of note, far greater net reductions in aggregation were observed in the DAPT (51%) and 
prasugrel (27%) groups in the presence of NO+PGI2 as compared to aspirin (14%). These 
results are in keeping with the fact that DAPT has more powerful anti-platelet effects 
than aspirin or prasugrel alone, that collagen is a weaker platelet agonist than TRAP-6 
and also a lower concentration of agonist was used so the inhibitory effects of PGI2 and 
NO were more pronounced. Platelet activation was also assessed by collagen induced-
ADP release where DAPT led to low levels of ATP release in all conditions tested. 
Prasugrel therapy alone also had a potent effect causing significant reductions in ATP 
release in all conditions tested. Notably, all three inhibitor combinations were 
significantly reduced compared to pre-treatment and also compared to vehicle. 
Following aspirin treatment, I observed a reduction in ATP release only in the presence 
of the combination of NO+PGI2. 
 
The interactions of PGI2 and NO with either DAPT, aspirin or prasugrel therapies were 
also studied using flow cytometry by assessing both PAC-1 and P-selectin expression 
following TRAP-6 (25 µM) stimulation. For DAPT, both P-selectin and PAC-1 expression 
were very greatly reduced in all conditions tested. Notably, the addition of PGI2+NO 
caused further significant decreases in the expression of both markers as compared to 
vehicle (P-selectin, 96% and PAC-1, 97%). Interestingly, aspirin therapy did not 
significantly reduce P-selectin or PAC-1 expression in any condition tested, or with the 
addition of NO and/or PGI2 individually or in combination as compared to vehicle. 
Prasugrel monotherapy however, followed a similar pattern to DAPT producing greatly 
reduced expression of both markers. Significant reductions of PAC-1 expression were 
observed post therapy as compared to pre-treatment in all conditions tested and all 
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three inhibitor combinations were significantly reduced compared to vehicle. Prasugrel 
therapy in addition to NO and PGI2 individually and in combination all reduced PAC-1 
expression by 94%.  
 
These results, using several methods of platelet testing indicate that even in the 
presence of effective P2Y12 blockade, i.e. within consensus guidelines, the presence of 
NO and PGI2 lead to very much higher levels of platelet inhibition. Similar patterns of 
inhibition were observed following DAPT and prasugrel therapy in aggregation, dense 
granule release and flow cytometry experiments. Whilst PGI2+NO caused some 
inhibition in the presence of aspirin therapy, this was only in collagen induced 
aggregation and ATP release experiments. However, the effects on aspirin monotherapy 
were much less than those observed in the context of P2Y12 receptor blockade where 
the potent three way synergy with PGI2 and NO led to high levels of platelet inhibition 
in all methods tested.  
 
Lastly, the effects of the various inhibitor combinations on the effector molecules of PGI2 
and NO, cAMP and cGMP, were tested. No significant differences in cGMP levels were 
found under any of the conditions tested. There were however, significant increases in 
levels of cAMP in both the aspirin plus prasugrel and aspirin plus ticagrelor groups 
following TRAP-6 and collagen stimulation. DAPT (aspirin plus prasugrel) with vehicle did 
not increase cAMP, nor did the addition of PGI2+NO to pre-treatment PRP. However, the 
combination of all three significantly increased cAMP expression by 91% following 
collagen stimulation and 61% following TRAP-6 stimulation. I also noted a significant 
91% increase in cAMP in the aspirin plus ticagrelor group treated with NO+PGI2 following 
stimulation with collagen.   
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To conclude, this chapter highlights further the strong interactions between P2Y12 
receptor inhibition, PGI2 and NO and the potential involvement of the cAMP and cGMP 
signalling systems. These results indicate that this synergy is mostly cAMP-related. The 
strong synergies between P2Y12 inhibitors and the cAMP and cGMP signaling systems 
suggest strongly that the in vivo platelet reactivity in patients receiving DAPT will be a 
function of the level of P2Y12 receptor blockade and the levels of endothelial-derived NO 
and PGI2. This provides an explanation for different thrombotic outcomes in the 
presence of similar levels of platelet blockade; i.e. individual patients with different 
levels of endothelial function, or indeed disease-driven endothelial dysfunction, would 
have different levels of in vivo platelet inhibition for the same level of DAPT activity, as 
determined by ex vivo testing. This hypothesis will be further explored in patients with 
endothelial dysfunction in the next chapter. 
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Chapter 5: Endothelial function is a vital determinant of 
the therapeutic efficacy of P2Y12 receptor antagonists in 
patients with peripheral arterial disease  
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5.1 Introduction 
 
Having established in healthy volunteers that the endothelial mediators NO and PGI2 
influence platelet responses to P2Y12 therapies, I sought to apply these findings to the 
clinical environment in patients with cardiovascular disease. I focused firstly on patients 
with a diagnosis of PAD, a common condition with a 12% prevalence in the general 
population [326] and 20-30% in the diabetic population [327]. Interestingly, despite 
dramatic improvements in revascularisation therapies there remains a very high 
morbidity and mortality associated with PAD with a mortality rate of up to 30% at 5 
years [328].  
 
There are several other reasons for choosing to study this particular patient group. 
Notably, both European and American PAD guidelines recommend a range of anti-
platelet therapies for treatment which opens up the possibility of comparing and 
contrasting platelet responses to different therapies in this patient group. The 
ACCF/AHA guidelines give a 1A recommendation to the prescription of anti-platelet 
therapies to patients with symptomatic PAD [328]. More specifically, class 1B guidance 
is applied to both the use of aspirin (75mg-325mg) and clopidogrel (75mg) in these 
patients. The ESC guidelines specify a 1C recommendation for the use of anti-platelet 
agents in symptomatic PAD [329]. This is based on data from 9706 patients in 42 studies 
used in a meta-analysis by the antithrombotic trialists’ collaboration which found a 23% 
reduction in vascular death, MI and stroke associated with the use of anti-platelet 
therapies in patients with peripheral arterial bypass, angioplasty or intermittent 
claudication [111]. Interestingly, low dose aspirin was found to be as efficacious as 
higher doses. The effectiveness of clopidogrel against aspirin was evaluated in a 
subgroup of 6452 patients with lower extremity arterial disease in the CAPRIE trial. At 
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follow-up at one year, there was a significant 23.8% reduction in events in those patients 
on clopidogrel as compared to aspirin with respective event rates of 3.9% and 4.9% 
[135]. The use of DAPT for the treatment of PAD however, is not indicated in this group 
as the small benefits associated with this therapy do not justify the increase in bleeding. 
One exception to this is patients with recent peripheral percutaneous revascularization, 
to the superior femoral artery or the iliac artery, for example, who may be prescribed 
DAPT for between 1 to 3 months as they may benefit from this intensified therapy [330]. 
However, definitive randomised data are lacking. Importantly, some patients with 
concomitant PAD and IHD will find themselves on DAPT following an ischaemic cardiac 
event or PCI.   
 
Intriguingly, this latter patient group have a significantly worse prognosis following an 
ACS alongside other patient groups such as those with chronic kidney disease (CKD), DM 
and the elderly. This is reported in several observational studies but the reasons for this 
are not clear; it could be hypothesized that DAPT has reduced efficacy in this patient 
group. The PAMISCA study indicated PAD as a major predictor of adverse outcome in 
patients after ACS and that those patients with subclinical PAD also have an increased 
risk of cardiovascular mortality, MI, HF and angina compared to those without PAD 
[331]. They also suggest that the total atherosclerotic burden and more diffuse arterial 
damage in different arterial territories is associated with worse clinical outcomes. In a 
PAD subgroup analysis of the PLATO study at one year CV death, MI or stroke occurred 
in 19.3% of patients with PAD compared to 10.2% without PAD (p<0.001). The primary 
endpoint in those PAD patients treated with ticagrelor was 18% compared to those 
treated with clopidogrel 20.6%, which was not significantly different [332].  
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Thirdly, both PGI2 and NO pathways are implicated in the pathogenesis of PAD. PAD 
patients have reduced endothelial function as a result of widespread PAD and associated 
disturbances in their endogenous production of NO and PGI2 Reduced NO bioavailability 
has been demonstrated in patient with PAD, with diffuse vascular damage in different 
territories and elevated ADMA and SDMA levels predicting worse patient outcome [333] 
[331].  PGI2 deficiency has also been implicated in the pathogenesis of PAD [68] [334]. 
This suggests that P2Y12 receptor antagonist therapies may not be as effective in 
reaching their full therapeutic potential in vivo due to suboptimal endogenous inhibitor 
production and so reduce the three way synergy identified and discussed in previous 
chapters of this thesis. Moreover, in these patients the co-administration of aspirin with 
P2Y12 receptor antagonists might be especially detrimental as it could potentially further 
reduce vascular PGI2 production from already dysfunctional endothelial cells.  
 
Taking into account the ideas elucidated above, it is most interesting to assess platelet 
reactivity in patients with PAD and to look at a range of individuals; treatment naïve 
patients, as well as those on the anti-platelet therapies, aspirin and clopidogrel 
monotherapy, and DAPT with aspirin plus clopidogrel. It is also of interest to define the 
patients’ platelet function and responsiveness to endothelial mediators as compared to 
healthy volunteers.  
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5.2 Methods 
 
5.2.1    Study participants 
Male and female patients with stable PAD aged 18-85 years were recruited for 
participation in the study. Health status was determined though medical history and 
patient notes. Patients with PAD Fontain classification I-III were included in the study. 
Exclusion criteria included an acute cardiovascular event (< 4 weeks) and concomitant 
anticoagulation therapy. 
 
5.2.2 Study protocol 
Patients were recruited in the out-patient clinic where blood and urine samples were 
collected. Adherence to medication was assessed by interview during the visit.  
 
5.2.3 Blood collection and preparation of PRP/PPP 
Blood was obtained by venepuncture performed in the ante-cubital fossa using a 19 
gauge butterfly needle into pre-filled vacutainers containing 3.2% tri-sodium citrate to 
a final ratio of anti-coagulant and blood of 1:9. PRP/PPP was prepared as described in 
section 2.2.4. 
 
5.2.4 LTA 
Baseline aggregation to AA (1 mM), ADP (5 and 20 µM), Horm collagen (0.4, 4 and 10 
µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were determined, as described in section 
2.2.7.1. Aggregations to TRAP-6 amide (25 µM) and Horm collagen (4 µg/ml) were 
measured after pre-incubation of PRP with vehicle (NaOH 0.01 M,) DEA/NONOate (100 
nM) or PGI2 (1 nM) individually or the combination of DEA/NONOate + PGI2 for 1 minute 
at 37 °C. 
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5.2.5 Optimul  
Platelet aggregation was assessed using the optimul method described in 2.2.7.3. 
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5.3 Results 
 
5.3.1 PAD patient treatment groups  
Blood and urine samples were collected from 42 patients with a proven diagnosis of 
stable PAD. Patients were prescribed a range of therapies (Table 5.1). In keeping with 
published guidelines, the majority of patients were prescribed monotherapy aspirin or 
clopidogrel and a smaller number were prescribed DAPT. A surprising proportion of 
patients did not take any regular anti-platelet therapy. Interestingly, two patients were 
prescribed cilostazol, a PDE inhibitor alongside DAPT. Cilostazol is highlighted in 
treatment guidelines as adjuvant therapy indicated in patients with lifestyle limiting 
intermittent claudication due to lower extremity PAD and receives a 1A 
recommendation to improve symptoms and increase walking distance [328, 329]. 
However, it is often poorly tolerated by patients due to side effects such as dizziness, 
headaches and diarrhoea. It is also contra-indicated in several patient groups such as 
those with congestive cardiac failure (CCF), severe tachyarrhythmias, recent MI or 
coronary intervention in the previous 6 months. Due to the low number of patients this 
data is not reported below. Baseline patient characteristics are described below (Table 
5.2). 
 
Therapy Number of patients 
Naïve 10 
Aspirin 16 
Clopidogrel 10 
Aspirin + Clopidogrel 6 
 
Table 5.1: Treatment groups of patients with PAD. 
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Characteristic   Number Percentage 
  Median Age   64   
  Male   36 86% 
  Smoker  Yes 24 57% 
    Ex 7 17% 
    No 11 26% 
  Ethnicity Caucasian 25 60% 
    Asian 13 31% 
    Black 3 7% 
  Femoral angioplasty   6 14% 
  Myocardial infarction   6 14% 
  Diabetes Mellitus   20 48% 
  Hypertension   20 48% 
 Ischaemic heart disease  13 31% 
 Hypercholesterolaemia  13 31% 
  CABG   5 12% 
  Coronary stent   6 14% 
  Heart failure   4 10% 
  CVA   6 14% 
  Iliac stent   2 5% 
  Carotid artery stenosis   4 10% 
  COPD   11 26% 
  Chronic renal failure   1 2% 
  TIA   2 5% 
  AAA   1 2% 
  AF   1 2% 
          
Table 5.2: Patients baseline characteristics 
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5.3.2 Characterisation of platelet responses to standard agonists by LTA 
AA induced aggregation was significantly reduced in the aspirin therapy group compared 
to those patients that were not prescribed anti-platelet agents; 15±6 compared to 
74±4% (p<0.05). Aggregation was further reduced in patients taking DAPT (1%±1%, 
p<0.05). Interestingly, aggregation was also significantly decreased by clopidogrel 
therapy (44±8%, p<0.05) (Figure 5.1.A). Aggregation following stimulation with ADP (5 
µM) was not significantly reduced by aspirin therapy (naïve, 67±4%; aspirin, 49±6%). 
However, a significant reduction was seen in the clopidogrel and DAPT groups; 13±4% 
and 18±9%, respectively (p<0.05) (Figure 5.1.B). A similar pattern was observed with 
ADP (20 µM) whereby aggregation was significantly reduced by clopidogrel 
monotherapy and DAPT but not by aspirin therapy: naïve, 77±4%; aspirin, 64±5%; 
clopidogrel, 28±6% and DAPT, 21±8% (Figure 5.1.C). Collagen (0.4 µg/ml) induced 
44±10% aggregation in naïve PRP. This was significantly reduced by clopidogrel (11±4%) 
but not by aspirin (23±7%) or DAPT (18±10%) (Figure 5.1.D). Following stimulation with 
collagen (4 µg/ml), aggregation was significantly decreased by DAPT (24±13% compared 
to 77±6% in naïve, p<0.05) but not by aspirin (56±7%) or clopidogrel (55±7%) (Figure 
5.2.A). There were no significant differences in aggregation between treatment groups 
with collagen (10 µg/ml) (Figure 5.2.B). TRAP-6 induced aggregation in naïve PRP was 
80±4%. This was not altered by aspirin or clopidogrel therapies (80±5% and 75±5%), but 
was reduced by DAPT (59±10%, p<0.05) (Figure 5.2.C). A similar pattern of aggregation 
was seen following stimulation with U46619 whereby aggregation was only significantly 
reduced in the DAPT group as compared to naive patients (57±8% compared to 80±4%). 
Neither clopidogrel (57±8%) nor aspirin significantly affected aggregation (79±4%) 
(Figure 5.2.D).  
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Interestingly, only aggregation induced by collagen (0.4 µg/ml) was significantly reduced 
in treatment naïve patients with PAD as compared to healthy volunteers. No significant 
differences were found between the two groups for any of the other agonists tested 
(Figures 5.1 and 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Standard agonist induced platelet aggregation in LTA for PAD patient subgroups. 
Standard LTA responses to A) AA (1 mM), B) ADP (5 µM), C) ADP (20 µM) and D) collagen (0.4 
µg/mL) in patients with PAD and healthy volunteers. Data are presented as final aggregation 
(%, mean±SEM). Significance is shown as * p<0.05 between different PAD anti-platelet therapy 
groups and as † p < 0.05 between healthy volunteers and naïve PAD patients. N=50. 
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Figure 5.2: Standard agonist induced platelet aggregation in LTA for PAD patient subgroups. 
Standard LTA to A) collagen (4 µg/ml), B) collagen (10 µg/ml), C) TRAP-6 (25 µM) and D) U46619 
(10 µM) in patients with PAD and healthy volunteers. Data are presented as final aggregation 
(%, mean±SEM). Significance is shown as * p<0.05 between different PAD anti-platelet therapy 
groups and as † p < 0.05 between healthy volunteers and naïve PAD patients. N=50. 
 
5.3.3 Characterisation of optimul aggregation curves for patients with PAD on and 
off anti-platelet therapies 
DAPT resulted in the lowest levels of platelet aggregation in response to all agonists 
tested. Clopidogrel also caused marked reductions in platelet responses to ADP, 
epinephrine, TRAP-6 and U46619, as did aspirin to platelet responses to AA, ristocetin 
and collagen (Figure 5.3).  
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Figure 5.3: Standard optimul aggregation curves for PAD patients. Optimul plate aggregation 
traces for PAD patients; treatment naïve and those on standard anti-platelet therapies of aspirin 
(75 mg), clopidogrel (75 mg) and DAPT with aspirin and clopidogrel plotted against healthy 
controls. Agonists tested are shown A) AA, B) ADP, C) Collagen, D) Epinephrine, E) Risocetin, F) 
TRAP-6, F) U46619. Data are presented as final aggregation (%, mean±SEM). N=50. 
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5.3.4 The individual and combined effects of PGI2 and NO following collagen 
stimulation 
In treatment naïve patients, high levels of platelet aggregation were observed in 
response to collagen (4 µg/ml; 77±3%). This was not significantly reduced by the addition 
of PGI2 or NO, 70±7% and 56±10%, respectively. There was a significant reduction 
however, following the addition of PGI2+NO (35±10%, p<0.05) (Figure 5.4.A). Similar 
results were observed for the healthy control group (vehicle, 73±2% and PGI2+NO, 
56±6%, p<0.05) (Figure 5.4.E). In the aspirin treated group aggregation was significantly 
reduced by PGI2 and PGI2+NO (59±5% to 34±6% and 24±5% respectively, p<0.05) but not 
by NO (50±5%) (Figure 5.4.B). All three inhibitor combinations led to significant 
reductions in responses in clopidogrel treated patients (vehicle, 66±6%; NO, 46±7%; PGI2 
22±5% and PGI2+NO, 9±2%, p<0.05) (Figure 5.4.C). DAPT with aspirin plus clopidogrel 
reduced aggregation to 29±15% in the presence of vehicle, with no further reduction 
following the addition of NO (29±15%). In the presence of PGI2 and PGI2+NO 
aggregations were 10±6% and 8±4%, respectively but these were not significantly 
different to vehicle (Figure 5.4.D).  
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Figure 5.4: Interactions of NO and PGI2 in anti-platelet treated and non-treated PAD patient 
groups and healthy controls: platelet aggregation following collagen stimulation. Bar graphs 
of platelet aggregation in response to collagen (4 µg/ml). Aggregometry was conducted in A) 
treatment naive PAD patients as well as those prescribed B) aspirin (75 mg), C) clopidogrel (75 
mg), D) aspirin (75mg) plus clopidogrel (75 mg) and in E) healthy volunteer controls. 
Aggregometry was conducted in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 
nM), or NO + PGI2. Data are presented as final aggregation (%, mean±SEM). Significance is shown 
as * p<0.05. N=50. 
 
Comparing the effects of respective endothelial inhibitors across different treatment 
groups (Figure 5.5), following collagen (4 µg/ml) stimulation high levels of platelet 
aggregation were observed in vehicle treated naive PAD patients (77±3%) and healthy 
volunteers (73±2%). Aggregation was significantly reduced by vehicle only in the DAPT 
treated patients (29±15%, p<0 05) compared to these. A similar pattern was observed 
in NO treated samples with only DAPT reducing aggregation (29±16, p<0.05) compared 
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to treatment naïve PAD patients and healthy volunteers (70±7% and 69±2%, 
respectively). Addition of PGI2 led to significant reductions (p<0.05) in clopidogrel 
(22±6%) and DAPT (10±6%) treated groups whereas, aggregation remained high in naïve 
PAD patients (56±10%) and healthy volunteers (68±2%). Incubation with PGI2+NO still 
led to high levels of aggregation in healthy volunteers (56±6%) but not in treatment 
naïve PAD patients (35±10%). PGI2+NO significantly decreased aggregation in 
clopidogrel and DAPT patients; 8±2% and 8±4%, respectively. Importantly, aspirin 
therapy did not result in significant levels of platelet inhibition in any inhibitor condition 
tested (Figure 5.5).  
 
 
 
 
Figure 5.5: Effects of NO, PGI2 and PGI2+NO in PAD patient therapy sub-groups and healthy 
controls: platelet aggregation following collagen stimulation. Bar graphs of platelet 
aggregation in response to collagen (4 µg/ml). Aggregometry was conducted in treatment naive 
PAD patients, as well as those prescribed aspirin (75 mg) clopidogrel (75 mg), aspirin (75mg) plus 
clopidogrel (75 mg) and in healthy volunteer controls. Aggregometry was conducted in the 
presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented 
as final aggregation (%, mean±SEM). Significance is shown as * p<0.05 in inhibitor subgroups 
compared to naïve PAD patients. N=50. 
 
5.3.5 The individual and combined effects of PGI2 and NO following TRAP-6 
stimulation 
In samples from patients taking aspirin, addition of PGI2 (73±5%) or NO (67±5%) alone 
did not inhibit platelet responses to TRAP-6 but the combination did (vehicle, 77±5 to 
59±4%, p<0.05) (Figure 5.6.B). 
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In clopidogrel treated patients, aggregation was significantly reduced by the addition of 
PGI2+NO (74±5% to 36±9%, p<0.05), but not by PGI2 or NO alone (48±8% and 66±5%, 
respectively) (Figure 5.6.C). There were no significant differences observed for the DAPT 
patient group; vehicle, 59±10%; NO, 54±11%, PGI2 34±12% and PGI2+NO 31±12% 
(Figures 5.6.D). Neither did inhibitors reduce aggregation in PAD naïve or healthy 
volunteers compared to vehicle (Figures 5.6.A/E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Interactions of NO and PGI2 in treated and non-treated PAD patient groups and 
healthy controls: platelet aggregation following TRAP-6 (25 µM) stimulation. Bar graphs of 
platelet aggregation in response to TRAP-6 (25 µM). Aggregometry was conducted in A) 
treatment naive PAD patients, as well as those prescribed B) aspirin (75 mg), C) clopidogrel (75 
mg), D) aspirin (75mg) plus clopidogrel (75 mg) and in E) healthy volunteer controls. 
Aggregometry was conducted in the presence of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 
nM), or NO + PGI2. Data are presented as final aggregation (%, mean±SEM). Significance is shown 
as * p<0.05. N=50. 
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On comparing the effects of corresponding endothelial inhibitors across different 
treatment groups following TRAP-6 (25 µM) stimulation (figure 5.7), I found no 
significant differences between those samples treated with vehicle or NO. PGI2 
treatment however, significantly reduced aggregation in DAPT patients (34±12%, 
p<0.05) compared to treatment naïve patients (67±5%) and healthy controls (69±3%).  
Aggregation remained high in samples from healthy controls and naïve PAD patients 
treated with NO+PGI2; 66±6% and 67±3%, respectively. However, aggregation was 
significantly reduced (p<0.05) by both clopidogrel and DAPT with NO+PGI2; 36±9% and 
31±12%, respectively. Notably, again aspirin therapy did not reduce aggregation with 
any inhibitor combination tested. 
 
 
 
 
 
 
 
Figure 5.7: Effects of NO, PGI2 and PGI2+NO in PAD patient therapy sub-groups and healthy 
controls: platelet aggregation following TRAP-6 stimulation. Bar graphs of platelet aggregation 
in response to TRAP-6 (25 µM). Aggregometry was conducted in treatment naive PAD patients 
as well as those prescribed aspirin (75 mg), clopidogrel, (75 mg), aspirin (75mg) plus clopidogrel 
(75 mg) and in healthy volunteer controls. Aggregometry was conducted in the presence of 
vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented as final 
aggregation (%, mean±SEM). Significance is shown as * p<0.05 in inhibitor subgroups compared 
to naïve PAD patients. N=50. 
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5.3.6 Comparison of platelet responses to standard agonists in PAD patients and 
healthy volunteers prescribed aspirin therapy 
Lastly using LTA, platelet aggregation in PAD patients treated with aspirin was compared 
to that in healthy volunteers prescribed aspirin for 7 days. Interestingly, AA induced 
15±6% aggregation in PAD patients compared to 2±1% in healthy volunteers. However, 
this did not reach statistical significance. Nor were any significant differences found 
between the two groups for other agonists tested (Figure 5.8). 
 
 
 
 
 
 
 
 
Figure 5.8: Standard LTA agonist induced platelet aggregation for patients with PAD and 
healthy volunteers prescribed aspirin therapy. Standard LTA responses to AA (1 mM), ADP (5 
and 20 µM), collagen (0.4 and 4 µg/mL), U46619 (10 µM) and T6-amide (25 µM) in patients with 
PAD and healthy volunteers treated with aspirin therapy. Data are presented as final 
aggregation (%, mean±SEM). Significance is shown as * p<0.05. N=24. 
 
5.3.7 The effects of PGI2 and NO in PAD patients and healthy volunteers prescribed 
aspirin therapy 
For both TRAP-6 (25 µM) and collagen (4 µg/ml), responses to PGI2+DEA/NONOate were 
significantly different between the two treatment groups. Collagen induced aggregation 
was higher in the PAD patients (21±5%) compared to healthy volunteers (2±1%). TRAP-
6 also induced higher levels of aggregation in the PAD aspirin treated patients as 
compared to aspirin-treated healthy volunteers (60±4% versus 28±9%) (Figure 5.9). 
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Figure 5.9: Responses to NO and PGI2 in patients with PAD and healthy volunteers prescribed 
aspirin therapy. Bar graphs of platelet aggregation in response to A) collagen (4 µg/ml) and B) 
TRAP-6 (25 µM). Aggregometry was conducted in aspirin (75 mg) treated PAD patients, as well 
as healthy volunteers prescribed aspirin (75 mg). Aggregometry was conducted in the presence 
of vehicle (NaOH, 0.01 M), NO (100 nM), PGI2 (1 nM), or NO + PGI2. Data are presented as final 
aggregation (%, mean±SEM). Significance is shown as * p<0.05. N=24. 
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5.4 Discussion  
 
In this chapter, I investigated platelet responses in patients with a diagnosis of PAD, a 
patient group associated with high morbidity and mortality and significantly worse 
outcome following ACS. I firstly sought to establish baseline reactivity in the 4 PAD 
patient groups (naïve, aspirin, clopidogrel and DAPT with aspirin plus clopidogrel) and 
compare these to healthy volunteer controls. In treatment naïve PAD patients I 
observed high levels of platelet aggregation (>70%) to all agonists tested other than 
collagen (0.4 µg/ml). Interestingly, collagen (0.4 µg/ml) induced aggregation was 
actually significantly reduced in PAD patients compared to healthy volunteers. There 
were however, no other significant differences found between FA values in these two 
groups, suggesting that despite being more prone to thrombosis in vivo the platelets of 
this patient group are not inherently more reactive than those from healthy volunteers. 
This supports the idea that it could be the in vivo environment which is vital in 
determining platelet reactivity and the presence or absence of the endothelial 
inhibitors, NO and PGI2. 
 
In aspirin treated PAD patients, AA induced aggregation was 15±6%, compared to 74±4% 
in non-treated PAD patients. A reduction in keeping with consensus statements of 
effective aspirin therapy (aspirin resistance previously defined as >20% aggregation 
when tested in LTA [335]). This level of aggregation was higher than that observed in 
healthy volunteers prescribed aspirin monotherapy for a week (2±1%), in chapter 4 of 
this thesis, but not significantly different. Together these data suggest that when tested 
in vitro aspirin, albeit a weak inhibitor of platelet activity, produces similar levels of 
platelet inhibition in PAD patients and healthy volunteers.  
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In those PAD patients taking clopidogrel, aggregation to ADP 5 µM (13±4%) and ADP 20 
µM (28±6%), were in keeping with consensus statements of effective P2Y12 therapy 
(clopidogrel resistance previously defined as >46% and >59% aggregation to ADP 5 µM 
and ADP 20 µM by LTA [336]). Interestingly, compared to data from the healthy 
volunteer studies, platelet aggregation in these patients was found to be significantly 
higher to only AA (44±8% versus 12±6%) and ADP 20 (28±6% versus 2±2%) as compared 
to those volunteers who had taken prasugrel therapy for one week. There were no 
differences in responses to collagen, TRAP-6 or U46619. PAD patients taking DAPT were 
also within consensus statements (ADP 5, 18±9% and ADP, 20 21±8%), although 
responses to ADP were significantly higher than those in healthy volunteers prescribed 
DAPT with aspirin plus prasugrel (ADP 5, 1±1%; ADP 20, 2±1%).  No differences were 
seen for other agonists tested. However, direct comparisons between clopidogrel-
treated PAD patients and prasugrel-treated healthy volunteers are difficult to make as 
prasugrel is a more powerful and reliable inhibitor of ADP. 
 
I also investigated the effects of PGI2 and NO individually and in combination on platelets 
from the PAD patients. Following TRAP-6 (25 µM) stimulation, the addition of PGI2 
and/or NO did not significantly affect platelet aggregation in PRP from treatment naïve 
PAD patients or those prescribed DAPT. Both clopidogrel and aspirin therapy 
significantly reduced platelet aggregation in the presence of PGI2+NO compared to 
vehicle (77±5% to 59±4%, p<0.05). This reduction was greater in clopidogrel treated 
patients (74±5% to 36±9%, p<0.05) highlighting the additional synergy of P2Y12 blockade 
beyond that of PGI2 and NO alone. Interestingly, on comparing the effects of PGI2+NO 
on different treatment groups to naïve patients (66±6%), clopidogrel and DAPT led to 
significant reductions in platelet aggregation (clopidogrel, 36±9%; aspirin + clopidogrel, 
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31±12%, p<0.05). Aspirin therapy alone however, did not (aspirin, 59±4%) further affect 
aggregation, providing additional evidence of the powerful three-way synergy between 
NO, PGI2 and P2Y12 receptor blockade. 
 
I also investigated the effects of PGI2 and/or NO on platelet aggregation in response to 
collagen (4 µg/ml). In healthy volunteers and treatment naïve PAD patients, NO or PGI2 
alone did not reduce aggregation however, the combination did (healthy volunteers; 
vehicle 73±2%, PGI2+NO 56±6%, p<0.05: treatment naïve; 77±3%, PGI2+NO 35±10%, 
p<0.05). PGI2+NO (24±5%) also significantly reduced aggregation compared to vehicle 
(59±5%) following aspirin treatment however, not to the same extent as following 
clopidogrel treatment (vehicle, 66±6%; PGI2+NO, 8±2%). In this latter case, aggregation 
was also reduced by NO (46±7%) and PGI2 (22±5%) individually, explained by P2Y12 
blockade potentiating the effects of both NO and PGI2 individually and more strongly 
together. DAPT led to similarly reduced aggregation with PGI2+NO, 8±4%. When 
comparing the effects of different endothelial inhibitors on anti-platelet regimes, I found 
DAPT significantly reduced aggregation in all inhibitor conditions tested compared to 
samples from treatment naïve patients. Both clopidogrel and DAPT reduced aggregation 
in samples treated with PGI2 (naïve, 56±10%; clopidogrel, 22±5% and DAPT, 10±6%) and 
with PGI2+NO (naïve, 35±10%; clopidogrel, 8±2% and DAPT, 8±3%). Therefore, for both 
TRAP-6 and collagen stimulation significant interactions between PGI2+NO and P2Y12 
blockade were noted with clopidogrel in both the absence or presence of aspirin. 
Notably, these interactions were not observed in samples taken from patients treated 
solely with aspirin. The synergistic relationship between PGI2+NO and P2Y12 blockade 
produced by far the highest levels of platelet inhibition in these samples.  
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In this chapter, I studied the effects of common anti-platelet therapies used at standard 
doses in PAD patients. This is important to note, as there is the potential during in vitro 
studies to employ drug concentrations that do not reflect that seen in clinical use, 
particularly when using pharmacokinetically short-lived drugs such as aspirin and 
clopidogrel. The data collected demonstrated that whilst aspirin and clopidogrel therapy 
significantly reduce aggregation induced by AA and ADP, respectively, high levels of 
platelet aggregation are still observed following stimulation with the primary agonists 
TRAP-6 and collagen. This is suggestive that in vivo these strong pro-thrombotic 
pathways would still be able to act and could lead to thrombosis despite apparently 
effective therapeutic intervention. However, similarly to what was seen in healthy 
volunteers, the endothelial mediators NO and PGI2 strongly interact with P2Y12 blockade 
to inhibit platelet activation, even that induced by primary agonists.  The effectiveness 
of the anti-platelet therapies in vivo may therefore be strongly dependent upon PGI2 
and NO production.  
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Chapter 6: Endothelial function testing in healthy 
volunteers 
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6.1 Introduction 
 
As outlined in section 1.11 there are several non-invasive, cost-effective and 
reproducible techniques that can be employed to assess endothelial function to help 
evaluate cardiovascular risk. Amongst these techniques is laser Doppler flowmetry 
(LDF), a technique which monitors skin microvascular blood flow. The skin response 
reflects responses taking place in other vascular beds and provides an assessment of the 
microvasculature [316]. Combining this technique with iontophoresis or post-occlusive 
hyperaemia (PORH) are effective ways of calculating endothelial function. Reactive 
hyperaemia (RH) involves the release of a pneumatic cuff following a period of occlusion 
produced by inflating the cuff to supra-systolic blood pressure and is believed to reflect 
NO and prostanoid availability. Iontophoresis is a technique describing the migration of 
charged substances through the skin by means of delivering a small continuous galvanic 
current to allow very small amounts of drugs to be administered non-invasively. The 
administration of acetylcholine (ACh) can be used to induce endothelial-dependent 
vasodilatation reflecting NO and prostaglandin participation and sodium nitroprusside 
(SNP) to test smooth muscle dependent, non-endothelial pathways of vasodilation 
[318]. Both these techniques are dependent on NO bioavailability although other factors 
such as prostaglandins and adenosine are also involved. Here, I have applied these 
methods to test endothelial function in healthy volunteers with a view to using an 
estimation of endothelial function as an adjuvant to ex vivo platelet function testing to 
better represent the net in vivo platelet function in patients. 
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6.2  Methods 
 
6.2.1 Recruitment of healthy volunteers 
Potential volunteers aged 18-40, both male and female underwent a health screen and 
gave verbal and written consent to participate. This process involved a detailed medical 
history, physical examination and observations including blood pressure, pulse rate and 
temperature. Those fulfilling the inclusion criteria with normal health profiles were 
recruited. 
 
6.2.2 Study period 
Microvascular perfusion and vasodilator responses were measured in a temperature-
controlled room (22-25 °C) according to a standardised protocol on study days. 
Measurements were undertaken during the day (10:00–16:00), with participants asked 
to refrain from smoking and ingesting any food, tea or coffee for 2 hours prior to the 
experiment. Subjects were lying in the supine position with their forearm supported at 
heart level. Following a 20-min equilibration period, the forearm area was cleaned with 
alcohol and dried. 
 
6.2.3 Iontophoresis 
Two iontophoresis chambers were positioned over healthy skin (avoiding any area of 
lipodermatosclerosis, excessive hair follicles or superficial veins) 10 cm apart on the 
medial surface of the forearm and 5 cm from the antecubital fossa. 1% ACh and 1% SNP 
diluted in sodium chloride (NaCl) were injected into the anodal and cathodal 
iontophoresis chambers, respectively. Drug concentration and current were chosen to 
minimise nonspecific vasodilatory effects [337]. The laser Doppler probe was positioned 
through the centre of each chamber and LDF measurements were made using a DRT4 
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(Moor Instruments, UK) including skin temperature, flux and microvascular dose-
response curves for each of the five iontophoretic challenges. 
 
After achieving a stable recording of baseline flux, LDF responses to ACh and SNP were 
measured using a modified incremental-dose iontophoresis protocol, as previously 
described [338]. In brief, dose response curves for ACh and SNP induced vasodilation 
were characterised using the following procedure in order to apply incremental charge 
stimuli: 50 μA applied for 10 s (500 μCb), 75 μA for 10 s (750 μCb), 100 μA for 10 s (1000 
μCb), 100 μA for 20 s (2000 μCb and 100 μA for 30 s (3000 μCb), with a 3 minute 
recording period between each dose. Measurements were repeated with the chambers 
at exactly the same site on a separate occasion to test for reproducibility of the 
technique. 
 
6.2.4 PORH  
Following a 10 minute recovery period, the chambers were repositioned and RH 
performed. A standard probe was mounted on the medial aspect of the right forearm 
10 cm from the antecubital fossa. After a 120 second basal perfusion recording, 180 
seconds of supra-systolic pressure occlusion (180 mmHg) of the forearm was followed 
by sudden release of the cuff and recording for 180 seconds. Resting perfusion level, 
peak hyperaemic response and duration of RH were measured. 
 
6.2.5 Data analysis and statistical analysis 
Data was obtained using a commercial software system (MoorVMS-PC Ver3.1, Moor 
Instruments, UK) before being transferred to a database (Excel 97) and analysed using 
statistical software GraphPad Prism v5.  
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6.3 Results 
 
6.3.1 Responses to PORH and iontophoresis assessed by LDF 
Endothelial function testing was conducted by two approaches, PORH and iontophoresis 
using LDF. For PORH, baseline and occlusion perfusion were easily recorded, as were the 
responses to occlusive hyperaemia. Figure 6.1 depicts a representative PORH chart for 
one of the healthy volunteer subjects tested while figure 6.2 and table 6.1 demonstrate 
the variables measured.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Representative PORH chart assessed by laser Doppler perfusion measurements of 
the forearm skin in a healthy volunteer. Channel 1 shows the resting level and biological zero 
at occlusion followed by the responses to occlusive hyperaemia including the maximal 
hyperaemic response following cuff release and the times to recovery, to maximal level, to half 
decay and to full decay. 
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Figure 6.2: PORH - terminology and variables tested 
 
Variable 
 
Description 
Resting level (RL) 
 
The average level before inflation 
Biological zero (BZ) 
 
The average value during the second 
half of pressure holding 
Maximum level (ML) 
 
Maximum value after release of cuff 
pressure 
Time to recovery (TR) 
 
Interval between trace and restoring to 
RL 
Time to maximal level (TM) 
 
Interval between release and maximum 
value 
Time to half decay (TH) 
 
Interval from release to mid-decay 
value after maximum 
 
Table 6.1: PORH - terminology and variables tested  
 
Figure 6.3 highlights a representative trace obtained following iontophoresis of both 
ACh and SNP. The currents applied were imperceptible to most subjects while a slight 
tingling sensation was described by some. Compared to basal skin perfusion, graded 
iontophoretic administration of ACh and SNP resulted in successive perfusion increases. 
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Figure 6.3: Representative trace of iontophoretic responses following administration of ACh 
and SNP assessed by laser Doppler perfusion measurements of the forearm skin in a healthy 
volunteer. Channel 1 represents iontophoresis of ACh and channel 2 administration of SNP with 
current bursts also displayed. Periods of iontophoresis are indicated: 0.50 mC (50 µA for 10 s), 
0.75 mC (75 µA for 10 s), 1 mC (100 µA for 10 s), 2mC (100 µA for 20 s) and 3mC (100 µA for 30 
s). 
 
 
6.3.2 PORH testing by LDF in healthy volunteers 
To be able to conduct endothelial function testing in future healthy volunteer platelet 
studies and in patients with cardiovascular disease the methodology was first tested in 
healthy controls to establish reproducibility. This was done in 10 healthy volunteers 
where the maximum value after release of cuff pressure (ML) response was recorded 
and repeated to give a total of two recordings per individual. The mean of the two peak 
hyperaemic recordings in these individual volunteers are displayed in perfusion units 
(PU) in figure 6.4 to demonstrate their normal distribution. The minimum mean ML 
recorded was 33 PU and the highest 129 PU. Mean ML+SEM for the group of 10 
volunteers was 75±8 PU. Mean resting perfusion (RL) was 13±1 PU.  
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Figure 6.4: Distribution of mean peak hyperaemic values for the 10 healthy volunteers tested 
 
Peak hyperaemic responses were repeated a total of two times to test the 
reproducibility of the technique. Repeated recordings are shown in the graphs in figure 
6.5 below. The mean % difference between the two ML for the 10 individuals was 
11±3%. The 25th percentile, median, 75th percentile and maximum % differences were 
5, 10, 17 and 30%, respectively. Results for % difference per individual healthy volunteer 
are tabulated in Table 6.2 below.  
ML 1 ML 2 % difference 
72 86 17 
45 52 14 
76 81 6 
88 84 5 
64 87 30 
73 72 1 
36 30 18 
93 80 15 
62 59 5 
127 131 3 
 
Table 6.2: PORH - maximum values. ML 1 recorded on visit one and ML 2 recorded on visit two 
in each health volunteer. % difference between values ML 1 and ML 2.  
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Figure 6.5: Individual maximum hyperaemic responses in healthy volunteers. ML recorded by 
LDF on two separate occasions to demonstrate reproducibility of the technique in healthy 
volunteers. 
 
 
6.3.3 Forearm skin perfusion responses following graded iontophoresis of ACh and 
SNP determined by laser Doppler perfusion measurements in healthy volunteers 
In 6 healthy volunteers endothelial function was assessed by iontophoresis of ACh (1%) 
and SNP (1%) through the skin using the following periods of iontophoresis: 0.50 mC (50 
µA for 10 s), 0.75 mC (75 µA for 10 s), 1 mC (100 µA for 10 s), 2 mC 4, (100 µA for 20 s) 
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and 3 mC (100 µA for 30 s). Basal skin perfusion and successive increases in perfusion 
were recorded following this graded iontophoretic administration of ACh and SNP. 
Experiments were repeated twice in each volunteer. The mean basal skin perfusion 
response to SNP in all volunteers was 14±2 PU. This increased to 21±6, 32±8, 38±10, 
66±12 and 84±10 PU with each application of SNP. For ACh, mean basal skin perfusion 
was 15±2 PU. With each application of ACh this increased to 23±4, 34±5, 45±5, 66±8 and 
85±10 PU. Figure 6.6 represents the ACh and SNP traces obtained in my subject group. 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Laser Doppler perfusion measurements following graded iontophoresis of ACh 
(above) and SNP (below) in healthy controls. Data are presented as laser Doppler perfusion 
(Arbitrary units, mean±SEM). N=6.. Iontophoresis periods: 0.50 mC (50 µA for 10 s), 0.75 mC 
(75 µA for 10 s), 1 mC (100 µA for 10 s), 2 mC 4, (100 µA for 20 s) and 3 mC (100 µA for 30 s) 
 
When represented as % change from baseline, SNP led to a 45±15, 126±24, 177±35, 
349±58 and 645±69% increase in perfusion. ACh increased skin perfusion 66±14, 
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137±26, 258±46, 443±81 and 640±123% compared with basal levels. Detailed results are 
shown in figure 6.7 as % increase from baseline for each individual healthy volunteer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Laser Doppler perfusion measurements following graded iontophoresis of ACh and 
SNP displayed as % increase from baseline 
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6.4  Discussion 
 
In this chapter I conducted pilot two tests of approaches to measure endothelium-
dependent and endothelium-independent vasodilation in healthy volunteer subjects. 
The approaches used were laser Doppler techniques coupled with iontophoresis and 
PORH. These are recognised to be reliable methods of testing endothelial function and 
have previously been applied in clinical studies across a range of patient groups including 
those with hypertension [339], heart transplants [340], diabetes and venous 
insufficiency [338], and coronary artery disease, as well as healthy volunteer cohorts 
[341]. However, these approaches have not been previously used an adjuvant to 
assessing platelet reactivity.  
 
The PORH studies were well tolerated by study subjects and baseline, occlusion and 
post-occlusive responses were easily recorded. PORHmax (ML) was chosen as my study 
variable as it has previously been shown to be a reproducible parameter for measuring 
microvascular reactivity during RH. In fact, in some studies it has been demonstrated to 
be the most reproducible index [342]. Although not fully standardised, PORH protocols 
are less variable than other methods used to test endothelial function. Most studies will 
use a pneumatic cuff inflated to a supra-systolic pressure (between 20 mmHg above 
systolic and 300 mmHg) with an occlusion time of 3 to 5 minutes. The studies reported 
here were based on a previous study establishing PORH using laser Doppler perfusion of 
the forearm as a sensitive and valid method to measure microvascular function. Keymel 
et al found that 3 minutes of forearm occlusion was sufficient to induce maximal 
vasodilation during PORH as indicated by maximal increase in perfusion unit (PU) 
amplitude that did not further increase after a total of five-minute occlusion [341]. In 
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these experiments it was therefore, decided to inflate the cuff to 180 mmHg for 3 
minutes. 
 
Using this method the PORHmax responses were found to follow a normal distribution, 
as one might expect. The mean PORHmax response was found to be 75±8 PU which is 
in keeping with previous studies in healthy controls reporting a population mean of 
88±17 PU relative increase in perfusion post 180 second occlusion [341]. Reproducibility 
was high with a mean intra-individual variability of 11±3% and a range of 1-30%. This is 
comparable to previous studies reporting intra-individual variabilities of 12-21% [341]. I 
observed a wide range in inter-individual values of 33 to 129 PU which is higher than 
perhaps might be expected in healthy volunteers, previous studies have reported inter-
individual variance rates of 14-26%. However, the present study cohort included males 
and females of both Asian and Caucasian race, aged between 23 and 38 with different 
life style factors and therefore, some variability in endothelial function could be 
expected. Some day-to-day and diurnal variation can also be expected which was more 
difficult to control in this pilot study although I did attempt to reduce diurnal and 
positional variability as best as possible. 
 
Iontophoresis coupled with LDF allows for assessment of real-time changes of skin blood 
flow after the administration of different vasoactive substances without systemic 
effects. In recent years, iontophoresis drug delivery accompanied by laser Doppler 
technology has been increasingly used to measure endothelial function. Importantly, 
Hansell et al found a significant correlation between vascular responses to endothelial-
dependent vasodilatation in the skin microvasculature and large arteries (brachial 
artery), using LDF and FMD, respectively [343]. My technique was well tolerated by 
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subjects with a tingling sensation perceived by some. One volunteer did suffer a very 
mild but completely reversible local allergic reaction to SNP and skin irritations have 
previously been reported in some individuals [344]. As is good practice, I carried out mild 
epidermal stripping on the iontophoresis area to clear away any surface lipids or 
keratinocytes in order to subsequently lower skin resistance and facilitate drug delivery.  
 
As previously mentioned, ACh introduced into the skin by iontophoresis causes 
endothelium-dependent vasodilation, which can be compared with the endothelium 
independent vasodilator effect of SNP, a NO donor. Unfortunately, iontophoresis 
protocols are not standardised. Protocols from different laboratories vary widely in 
design and most are complicated and time consuming. There is a need for a simple, 
reproducible method but as this is not established I optimised the protocol using 
previously published literature. After achieving a stable recording of baseline flux, LDF 
responses to ACh and SNP were measured using a modified incremental-dose 
iontophoresis protocol, as previously described by Klonizakis et al in both healthy 
volunteer and patient studies [338, 345]. Most groups prefer to obtain a dose response 
curve by changing the duration of a constant current (e.g., 100 μA) or by a gradual 
increase in current over time (10-100 μA). The latter has the advantage that it looks at 
the vascular response to an agonist at low currents minimising nonspecific, current-
induced galvanic responses [346]. 
 
Drug concentrations and currents were chosen so as to minimize nonspecific 
vasodilatory effects, in particular reducing galvanic effects which are thought to occur 
due to current induced release of neuropeptides (e.g., substance P, bradykinin, 
calcitonin gene-related peptide) [337]. A range of vehicles have been used to dilute 
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drugs for iontophoresis including deionized water, tap water, and NaCl. These vehicles 
have at times been found to induce dermal vasodilation, referred to as a “galvanic 
response” [346]. This so called ‘galvanic response’ leads to local vasodilation, initiated 
by C-fibre activation which can be due to differing pH changes caused by electrolysis of 
water and/or acidosis sensed at the anode and alkalosis at the cathode [347]. I used 
NaCl as the iontophoresis vehicle solution as it has been shown to have a negligible 
vasodilator effect [348] and I observed acceptable day to day reproducibility using this. 
Whilst reproducibility was acceptable, it could have been higher but laser Doppler 
coupled with iontophoresis has in fact, been associated with poor reproducibility 
previously and mean day to day variances in ACh response between 6.4%-42% have 
been reported. This is thought to be explained by the spatial heterogeneity of skin blood 
flow and movement artefacts. Drug delivery is also influenced by skin resistance, which 
varies significantly between individuals and across different skin areas. Ramsay et al 
found that higher skin resistance is associated with smaller vasodilator responses for 
both SNP and ACh [344]. 
 
Traditional data analysis methods measure the magnitude of the change in flux. 
Maximum perfusion is affected by the duration of endothelial and smooth muscle cell 
exposure to specific stimuli and is affected by the duration and the value of electrical 
current. Similar basal perfusion rates were observed for both ACh and SNP, 15±2 and 
14±2 PU, respectively. The 5 applications of ACh and SNP each led to increased skin 
perfusion with the final level of skin perfusion obtained by each drug being similar, 
85±10 PU for ACh and 84±10 PU for SNP. The iontophoresis of ACh elicited significant 
increases (p<0.05) in perfusion at every stage of iontophoresis. SNP elicited a significant 
increase from the third period of iontophoresis onwards (1 mC to 3 mC). Represented 
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as % increase from baseline, ACh induced skin perfusion at the end of the iontophoresis 
period was increased 640±123%. A similar increase in perfusion following SNP 
iontophoresis was observed, with levels increasing 645±69% in my heathy volunteers. 
This value of maximum vasodilation is similar to values of 700-800% change obtained in 
healthy control groups in other published studies. The matching values of ACh and SNP 
maximal perfusion is suggestive of similar endothelial and non-endothelial dependent 
reactions in my healthy controls, as would be expected in those without endothelial 
dysfunction. Generally, the relative contributions of endothelial factors to these 
vasodilator responses is not well understood with some suggesting that prostanoid-
dependent mechanisms do not significantly contribute to endothelium-dependent 
vasodilation [349] and others suggesting that cutaneous vasodilatation is mainly driven 
by a prostanoid-dependent mechanism [350]. SNP, on the contrary does not stimulate 
endogenous NO production but rather reacts with tissue sulfhydryl groups under 
physiologic conditions to produce NO directly and thereby stimulate SMC relaxation 
[346]. SNP is therefore, used as an endothelium dependent control. A reduction in 
vascular response in ACh with no concurrent reduction in SNP response is indicative of 
endothelial dysfunction. A reduction in SNP response can be interpreted as a structural 
change within the vessel or as a reduction in NO activity or availability caused by, for 
example, high oxidative stress. 
 
My future work will use laser Doppler combined with iontophoresis and/or PORH to 
assess microvascular function in patients at risk of and with established cardiovascular 
disease and in healthy volunteers pre- and post-intervention with agents such as 
naproxen, aspirin and P2Y12 receptor antagonists that affect both endothelial and 
platelet function. This technique is a particularly attractive approach to try to 
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understand the net influences on platelet and endothelial function, as the 
microcirculation may well be the initial site of endothelial damage in subjects at risk of 
cardiovascular disease [351].  
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Chapter 7: Platelets influence clot microstructure as 
assessed by fractal analysis of viscoelastic properties  
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7.1 Introduction 
 
As described in chapter 1, there exists a complex interplay of platelets and coagulation 
in atherothrombosis. Platelets are critical to the processes of atherothrombosis, driving 
thrombus formation through a cascade of complex intracellular signalling pathways and 
powerful positive feedback loops [95]. Platelets also have a central role in the cell-based 
regulation of the coagulation system [352-354]. Because of the fundamental 
involvement of platelets in atherothrombosis, anti-platelet drugs that target amplifying 
secondary platelet agonists are the standard of care for the prevention of thrombotic 
events in patients with cardiovascular disease. 
 
Coagulation pathway changes also play a central role in clot propagation, a process that 
is affected by many factors both genetic and environmental [355]. Configuration of the 
fibrin network has been shown to be a vital determinant of clot stability and 
susceptibility to fibrinolysis [356, 357] with clot permeability being the rate limiting 
factor for the activity of plasmin, the fibrin network degradation enzyme. Clots 
composed of compact thin fibres are associated with thrombotic events [358, 359] and 
clot microstructure appears unfavourably altered in CAD and other conditions 
associated with thrombosis [360-363] and is also associated with adverse events 
following PCI. Despite the interwoven nature of platelet activation and the coagulation 
system in thrombosis however, few studies relate both analysis of protein and cellular 
parts of coagulation in the same population.   
 
The following chapter investigates the complex interplay of platelets and coagulation 
pathways in clot microstructure.  This is of relevance as it has been suggested that there 
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is a definitive diagnostic potential in characterising clot microstructure and modulation 
of clot architecture as a possible treatment for thrombosis [364]. However, many 
techniques that assess the mechanics and quality of clot architecture rely on processed 
samples using altered blood in remote laboratories, limiting their clinical use.  
 
Viscoelastic properties have been shown to be sensitive measures of fibrin 
polymerisation and blood clot structure [365] and these properties can be quantified 
using small amplitude oscillatory shear rheometry to measure gel point (GP) [366]. GP 
is a multi-faceted biomarker that defines the transition between viscoelastic fluid and 
viscoelastic solid states during gelation and in coagulating blood GP marks the 
establishment of the incipient clot. GP provides three related biomarkers all calculated 
from the one measurement; time taken to reach GP or gel time (TGP), clot strength (G’GP) 
and the fractal dimension (df) of the incipient clot, which provide a quantitative 
assessment of clot microstructure. Structure of the early clot, as quantified by df has 
been established as providing a template for the mature clot when analysed based on 
viscoelastic and imaging data and quantified by fractal analysis [367], a technique used 
in biology and medicine to characterize nonlinear growth in branching network 
structures Reduced df is associated with more permeable, less branched and 
mechanically weaker clots and a raised df corresponds to a tightly packed, highly 
branched clot that is stronger and less permeable. The value of TGP and df as new 
biomarkers of haemostasis has been highlighted in several recent studies [368-371]. TGP 
and df are used as parameters to investigate clot architecture in this chapter. Clot 
microstructure is further investigated by projecting random fractal aggregates (RFAs) as 
a function of df, representative of ensuing clot development which I then related to 
platelet reactivity. To produce these assessments of platelet function, standard tests of 
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aggregation and activation were used to determine the effects of individual anti-platelet 
therapies on platelets taken from healthy volunteers treated with standard anti-platelet 
therapies. The influences of these therapies on clot structure were then determined 
using advanced rheological analyses of incipient fibrin clots. Together these approaches 
provided an insight into the complex interplay of platelets in the formation of clot 
microstructure. 
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7.2 Methods 
 
7.2.1   Study participants 
16 healthy, male volunteers (aged 18-40 years) participated in an initial single anti-
platelet therapy study. Health status was determined though medical history and 
physical examination, including blood pressure, pulse rate, blood chemistry and 
urinalysis. Volunteers with normal clinical profiles were included in the study. 
Subsequently, a further 20 healthy volunteers were recruited in an identical manner for 
a follow-up DAPT study. 
 
7.2.2 Study protocol 
All healthy volunteers abstained from aspirin, NSAIDs and any other anti-platelet 
therapy for 14 days before commencing the studies. Two groups of 8 volunteers 
received monotherapy aspirin (75 mg) or prasugrel (10 mg) for 7 days. Subsequently, 
two groups of 10 volunteers received DAPT with either aspirin (75 mg) plus prasugrel 
(10 mg) or aspirin (75 mg) plus ticagrelor (90 mg) for 7 days. Compliance was assessed 
by interview. Blood samples were collected prior to and following drug treatment in 
both studies on day 0 and day 7. 
 
7.2.3 Blood collection 
Blood was obtained by venepuncture performed in the ante-cubital fossa using a 19 
gauge butterfly needle.  
 
7.2.4 Laboratory markers 
Blood was taken for full blood count (FBC) analysis, including platelet count and 
haemoglobin into 4ml BD EDTA vacutainers and into 4.5ml BD citrate vacutainers for 
routine coagulation studies, including prothrombin time (PT), activated partial 
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thromboplastin time (APTT), activated partial thromboplastin time ratio (APTTr), INR 
and fibrinogen. Measurements were made by use of automated analysers, Sysmex XN-
2000 and Sysmex CS-2100i. 
 
7.2.5   Platelet function 
Blood for platelet studies was collected into tri-sodium citrate. PRP/PPP was prepared, 
as described in section 2.2.4.  
 
7.2.5.1    LTA 
Baseline aggregation to AA (1 mM), ADP (5 and 20 µM), Horm collagen (0.4, 4 and 10 
µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were determined, as described in section 
2.2.7.1. 
 
7.2.5.2   ADP + ATP secretion 
ADP + ATP secretion of PRP was evaluated by luminescence in the presence of Chrono-
Lume reagent after stimulation with collagen (4 µg/mL), as described in section 2.2.8. 
 
7.2.5.3   Flow cytometry 
PRP was activated with TRAP-6 (25 µM) and P-selectin and PAC-1 expression was 
assessed by flow cytometry, as described in section 2.2.9. 
 
7.2.6 Rheometry 
9ml aliquots of whole blood collected into Vacuette vacutainers without anti-coagulant 
were transferred directly and immediately (< 60 seconds) after sampling to a double-
gap concentric cylinder geometry of a TA instruments Discovery HR-2 controlled stress 
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rheometer (New Castle, DE, USA). All work was conducted at 37(±0.1) °C and all 
measurements were made on aliquots of the same sample by use of similar measuring 
geometries with identical measuring surfaces and surface preparation procedures. The 
viscoelastic properties of incipient clots were determined by detecting the GP of samples 
of whole unadulterated blood using small amplitude oscillatory shear rheometry [366]. 
From GP the values of TGP and df were measured and from df relative mass (RM) was 
calculated.  
 
7.2.7   Scanning electron microscopy 
For scanning electron microscopy (SEM) samples at each time point were allowed to clot 
at 37°C for a minimum of 15 mins.  Samples were then washed three times with 2 
cocadylate buffer pH 7.2 for the removal of excess salt and fixed for a minimum of 4 hrs 
in 2% glutaraldehyde solution.  The clots were then rinsed with cocadylate buffer and 
dehydrated in a series of ethanol concentrations from 30 to 100%.  The clots were then 
critical point dried with hexamethyldisilazane for 45 mins and placed in a fume hood for 
24 hrs.  Finally the clots were mounted to 0.5” SEM stubs (Agar Scientific, UK) and 
sputter coated with gold palladium. All samples were investigated with a Hitachi S4800 
scanning electron microscope (Hitachi, High-Technologies Corporation, Tokyo, Japan) 
[372] 
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7.3  Results 
 
7.3.1 Baseline fractal dimension (df) values and correlation with haemostatic and 
haematological coefficients 
Analysis of pre-treatment blood indicated a clearly defined df value within a narrow 
range, representing a normal index of haemostasis where df = 1.72 (± 0.05) (Table 7.1). 
Minimum and maximum df were 1.63 and 1.91, respectively. Further analysis of pre- and 
post-treatment df values demonstrated a clear correlation with fibrinogen (0.037, 
p=0.04). There was no correlation between df and PT, APTT, haematocrit, platelet count 
or haemoglobin (Table 7.2).   
 
Baseline df Value 
Minimum 1.63 
25th percentile 1.69 
Median 1.71 
75th percentile 1.73 
Maximum 1.91 
Mean 1.72 
Std. error of mean 0.05 
 
Table 7.1: Column statistics for baseline df values. df fractal dimension 
 
 
 
Table 7.2: Pearson correlation coefficients for df versus haemostatic and haematological 
parameters. PT indicates prothrombin time; APPT activated partial thromboplastin time; df 
fractal dimension. * = Significant result (p<0.05) 
Parameter Correlation coefficient 
Fibrinogen   0.376 * 
PT -0.301 
APTT 0.154 
Platelets 0.171 
Haemoglobin 0.238 
Haematocrit 0.252 
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7.3.2 Effects of aspirin (75 mg) therapy on platelet reactivity and fractal analysis of 
incipient clots 
In individuals taking aspirin, standard LTA responses to AA (1 mM) and collagen (0.4 
µg/ml) were strongly inhibited; 74%±6% to 2%±1% and 71%±6% to 16%±5%, p<0.05, 
respectively.  Responses to ADP (5 µM) were also significantly reduced; 74%±6 to 46%±8, 
p<0.05. Those to ADP (20 µM), collagen (4 µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) 
were unaffected (Figure 7.1.A).  Aspirin therapy did not affect dense granule secretion 
induced by collagen (4 µg/ml) as measured by ATP release (6.3±0.63 to 4.73±0.5 nM, 
p=0.11) (Figure 7.1.B), or TRAP-6 (25 µM) induced PAC-1 binding (19±3 to 15±4 MFI, 
p=0.40) (Figure 7.1.C) or P-selectin expression (32±6 to 28±8 MFI, p=0.73) (Figure 7.1.D). 
Haematological parameters and selected haemostatic parameters were not altered 
(Table 7.1.E). Aspirin treatment also produced no significant changes in the value of df 
(1.71±0.01 to 1.69±0.01, p=0.41) or the RM (-8±19% change, p=0.47) of incipient clots 
(Figures 7.2.A and 7.2.B).  
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Figure 7.1: Effects of aspirin (75 mg) therapy on platelet reactivity. Bar graphs representing 
platelet responses before and after treatment measured by: A) standard LTA to AA (1 mM), ADP 
(5 and 20 µM), collagen (0.4, and 4 µg/mL), TRAP-6 amide (25 µM) and U46619 (10 µM); B) ATP 
release after collagen (4 µg/ml) stimulation; C) TRAP-6 (25 µM) induced PAC-1 binding; D) TRAP-
6 (25 µM) induced P-selectin expression and E) tabulated corresponding haematological and 
haemostatic parameters. Data are presented as final aggregation (%, mean±SEM), ATP release 
(nmol, mean±SEM) or geometric mean fluorescence index (MFI) (units, mean±SEM). 
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Figure 7.2: Effects of aspirin (75mg) on fibrin clot microstructure as calculated by viscoelastic 
properties of incipient clots. Changes in A) df and B) RM of incipient clots before and after 
treatment. 
 
 
7.3.3 Effects of prasugrel (10 mg) monotherapy on platelet reactivity and fractal 
analysis of incipient clots 
Following prasugrel therapy, aggregatory responses to AA (1 mM), collagen (0.4 and 4 
µg/ml), ADP (5 and 20 µM), as well as U46619 (10 µM) were all significantly reduced. 
TRAP-6 (25 µM)-induced aggregation however, was unaffected (Figure 7.3.A). ATP 
release induced by collagen (4 µg/ml) was significantly decreased; 8.6±0.5 to 5.2±0.0.4 
nM, p<0.05 (Figure 7.3.B). TRAP-6 (25 µM) induced PAC-1 and P-selectin expression 
were also both reduced; 19.2±3.7 to 1.6±0.3 MFI and 25±6.1 to 8.8±3.4 MFI, p<0.05, 
respectively (Figures 7.3.C and 7.3.D). Haematological and coagulation profiles 
remained unchanged (Table 7.3.E). There were notable reductions in df (1.72±0.02 to 
1.67±0.01, p =0.03) and mean RM (-40±11% change, p=0.03) for incipient clots formed 
following prasugrel therapy (Figures 7.4.A and 7.4.B). 
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Figure 7.3: Effects of prasugrel (10 mg) therapy on platelet reactivity. Bar graphs of platelet 
responses measured by: A) standard LTA; B) ATP release after collagen (4 µg/ml) stimulation; C) 
TRAP-6 (25 µM) induced PAC-1 binding; D) TRAP-6 (25 µM) induced P-selectin expression and E) 
tabulated corresponding haematological and haemostatic parameters. Data are presented as 
final aggregation (%, mean±SEM), ATP release (nmol, mean±SEM) or geometric mean 
fluorescence index (MFI) (units, mean±SEM). Significance is shown as * p<0.05 vs non-treated 
throughout. 
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Figure 7.4: Effects of prasugrel (10mg) on fibrin clot microstructure as calculated by 
viscoelastic properties of incipient clots. Changes in A) df and B) RM of incipient clots before 
and after treatment. 
 
 
7.3.4 Characterisation of DAPT with aspirin (75mg) plus prasugrel (10 mg) on platelet 
reactivity and fractal analysis of incipient clots  
Platelet aggregation induced by AA (1mM), collagen (0.4 µg/ml) and ADP (5 µM and 20 
µM) in LTA were abolished in individuals taking prasugrel plus aspirin. Responses to 
collagen (4 µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were also all significantly 
inhibited (Figure 7.5.A). TRAP-6 (25 µM) induced P-selectin expression was also 
decreased; 29±8% to 2±1%, p< 0.05 (Figure 7.5.B). No change was observed in 
haemostatic or haematological parameters (Table 7.5.C). There was a significant 
reduction in df value (1.73±0.02 to 1.68±0.02, p=0.03) for incipient clots and a resulting 
decrease in mean RM (-35±16% change, p=0.04) (Figure 7.6.A and 7.6.B).  
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Figure 7.5: Influence of DAPT with aspirin (75mg) plus prasugrel (10 mg) on platelet reactivity. 
Bar graphs demonstrating platelet responses before and after treatment measured by: A) 
standard LTA; B) TRAP-6 (25 µM) induced P-selectin expression and C) corresponding 
haematological and haemostatic parameters. 
 
 
 
 
 
 
 
 
 
 
Figure 7.6: Effects of aspirin (75mg) plus prasugrel (10mg) on fibrin clot microstructure as 
calculated by viscoelastic properties of incipient clots. Changes in A) df and B) RM of incipient 
clots before and after treatment. 
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7.3.5 Characterisation of DAPT with aspirin (75mg) plus ticagrelor (90 mg) on 
platelet reactivity and fractal analysis of incipient clots 
Following DAPT with aspirin plus ticagrelor platelet responses followed a similar pattern 
to those in individuals taking aspirin plus prasugrel; LTA aggregation induced by AA 
(1mM), collagen (0.4 µg/ml) and ADP (5 µM and 20 µM) were powerfully inhibited. 
Those to collagen (4 µg/ml), U46619 (10 µM) and Trap-6 (25 µM) were significantly 
reduced (Figure 7.7.A). These reductions were associated with a reduction in P-selectin 
expression (p<0.05) induced by TRAP-6 (25 µM); 99±7 to 55±12 (Figure 7.7.B). 
Haematological and coagulation profiles remained unchanged (Tables 7.7.C). There 
were significant decreases in df for incipient clots formed (1.72±0.03 to 1.63±0.02, 
p=0.04) and marked reductions in RM (-45±14% change, p=0.04) (Figure 7.8a and 7.8b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Influence of DAPT with aspirin (75mg) plus ticagrelor (90 mg) on platelet reactivity. 
Bar graphs depicting platelet responses prior to and following treatment as measured by: A) 
standard LTA; B) TRAP-6 (25 µM) induced P-selectin expression and corresponding 
haematological and haemostatic parameters. 
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Figure 7.8: Effects of aspirin (75mg) plus ticagrelor (90mg) on fibrin clot microstructure as 
calculated by viscoelastic properties of incipient clots. Changes in A) df and B) RM of incipient 
clots before and after treatment. 
 
7.3.6 Clot structure analysis by SEM and fractal analysis 
SEM demonstrated that DAPT resulted in formation of clots with reduced fibrin density 
and increased fibrin strand diameter (Figure 7.9).  This reduction in clot density was 
consistent with the df measurements and projections of RFAs for the aspirin plus 
prasugrel and aspirin plus ticagrelor groups showing a reduction in the density of 
connectedness compared to that projected from blood collected under control 
conditions (Figure 7.10).     
 
 
 
 
 
 
 
 
Figure 7.9: Influence of DAPT with aspirin (75 mg) plus ticagrelor (90 mg) on clot structure. 
Corresponding SEM micrographs of clots formed in blood taken from one participant, before 
(panels A and C) and after (panels B and D) treatment with aspirin (75mg) plus ticagrelor (90 
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mg). Micrographs were captured at two different magnifications, 5K (panels A and B) and 10K 
(panels C and D), to visualize the organisation of clot structure. Sizing bars are along the bottom 
edges of the images.    
Figure 7.10: Visualisation of the relationship between df and mass. Figure (A) indicates the 
variation of the mass of a random fractal aggregate (RFA) as a function of df. The magnitude of 
the RFA is normalized to the mean healthy value, df = 1.72 (green circle). Mass values of RFA 
where df = 1.68 (red square) and df = 1.63 (black triangle) represent, respectively, the effects of 
aspirin + prasugrel and aspirin + ticagrelor. Figures (b), (c) and (d) are numerical realisations of 
RFAs with fractal dimensions of 1.63, 1.68 and 1.72 (normal), respectively. Each numerical 
realisation of RFA is comprised of a number of constituent particles of unit diameter all of which 
are connected to at least one other particle. The colour index in the RFA realisations represents 
the local densities of constituent connected particles (green and red shades represent low and 
high density regions, respectively). A RFA realisation containing many red areas denotes a more 
compact, densely connected structure than a RFA with predominately green areas. 
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7.4 Discussion 
 
Here, advanced rheology has demonstrated the key importance of platelets as 
regulators of clot microstructure under clinically relevant conditions. The measurement 
of df was used to quantify differences in microstructural organisation and mechanical 
properties of blood clots secondary to individual and combined anti-platelet therapy 
regimes. 
 
Analysis of pre-treatment blood indicated a clearly defined df value within a narrow 
range, representing a normal index of haemostasis where df = 1.72 (± 0.05). Further 
analysis of pre and post treatment df values demonstrated a clear correlation with 
fibrinogen (0.037, p=0.04), supporting the association of the microstructural 
characteristics of the fibrin clot with df. For platelet studies high pre-treatment levels of 
platelet reactivity were observed, as is normal in healthy volunteers [244, 323, 324]. 
 
Following treatment with aspirin or prasugrel there was powerful inhibition of platelet 
responses to AA or ADP, respectively, in keeping with consensus statement indicators of 
effective therapy [244, 324]. Aspirin monotherapy also inhibited platelet aggregations 
induced by low concentrations of ADP and collagen. ATP release, activation of GP IIb/IIIa 
receptors and P-selectin expression however, were not significantly affected. In 
accordance with these limited effects on platelet function, aspirin produced no 
significant change in clot microstructure as detected by df (1.71±0.01 to 1.69±0.01, 
p=0.41). The change in mean RM was also non-significant (-8±19% change, p=0.47). 
Prasugrel monotherapy substantially blunted platelet aggregation responses to all 
agonists tested apart from TRAP-6 and caused significant reductions in ATP release, P-
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selectin expression and GP IIb/IIIa receptor activation. Platelet inhibition was associated 
with both a significant reduction in df (1.72±0.02 to 1.67±0.01, p =0.03) and a 
considerable change in the mean RM of incipient clots (-40±11% change, p=0.03) 
indicative of a substantial change in microstructure.  
 
Following the monotherapy studies, which indicated a strong association between 
platelet activity and clot architecture, the next step was to characterise the influences 
of DAPT. Administration of aspirin plus prasugrel or aspirin plus ticagrelor resulted in 
significant levels of platelet inhibition to all agonists, abolishing responses to weaker 
agonists tested. P-selectin expression was also significantly reduced in both groups. 
Again, significant platelet inhibition was coupled with a reduction in df: aspirin plus 
prasugrel (1.73±0.02 to 1.68±0.02, p=0.03) and aspirin plus ticagrelor (1.72±0.03 to 
1.63±0.02, p=0.04). There were also significant reductions in mean RM both for aspirin 
plus prasugrel (-35±16% change, p=0.04) and for aspirin plus ticagrelor (-45±14% 
change, p=0.04).  
 
Overall, these results clearly demonstrate that stronger inhibition of platelet function is 
associated with the formation of less dense clots comprised of a more open/porous 
network of fibrin strands. It is important to recognise that df has a very narrow range 
and to appreciate the non-linear relationship between df and fibrin mass. Figure 7.10 
helps in this regard by providing a visual projection of how relatively small changes in df 
would underlie large changes in RFA; notably the lowest df has a lower frequency of 
high-density regions (i.e. the number of nearest neighbours is relatively low) 
consequently the projected form is relatively sparse and open which would equate to a 
mechanically weaker and more highly friable clot. On the contrary, the RFA with the 
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highest df is relatively more compact, due to the larger number of high density regions 
within the structure.  
 
This predicted link between df and thrombus structure is confirmed by SEM, which 
demonstrates a more open clot structure following treatment with anti-platelet 
therapies. These SEM images highlight that incipient clot structure quantified by df acts 
as a template to predict the structure of the mature clot. Notably, the number of small 
round particles, which represent platelets, is much reduced between the pre- and post-
treatment images. This is in keeping with reduced platelet-fibrin interactions which, I 
would expect following DAPT with aspirin plus ticagrelor in the healthy volunteer 
subject.  
 
These observations support the idea that indices of fractal analysis are intricately linked 
and reflect clot microstructure and strength and whilst these are determined by multiple 
components, are representative of the dynamic and interwoven properties of the fibrin 
clot and platelet reactivity. Importantly, the experiments reported here show that this 
technique is able to quantify the effects of individual therapeutic interventions. 
Comparison of responses in the absence and presence of different levels of platelet 
inhibition identifies a significant relationship between platelet function and the 
complex, highly disordered microstructure of incipient clots in whole unadulterated 
blood from healthy volunteers. These results are readily understandable as as 
highlighted in chapter 1, platelets are central to several key coagulation processes.  
 
The results in this chapter, in keeping with previous studies suggest that this novel point 
of care visco-elastic technique is able to accurately and reproducibly assess clot 
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architecture with the potential of determining the effects of disease and therapeutic 
intervention on clot quality. This technique could be applied to investigate the functional 
relationship between coagulation pathways and platelets as a potentially more globally 
representative marker of haemostasis and thrombosis.  
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Chapter 8: General discussion  
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8.1 Discussion 
 
This thesis explores the hypothesis that the level of platelet reactivity during DAPT will 
be a function of the level of P2Y12 receptor blockade and the levels of endothelial 
produced NO and PGI2 in individual patients because of the strong synergistic 
interactions between these three mediators. I show firstly in vitro the powerful 
potentiation by P2Y12 receptor blockade of the recognised synergy between NO and 
PGI2. I then show in healthy individuals and patients with cardiovascular disease 
receiving a P2Y12 receptor blocker as monotherapy or as DAPT, that ex vivo responses to 
the strong primary platelet activators collagen and TRAP-6 are powerfully influenced by 
the presence of NO and PGI2. The strong synergies between P2Y12 inhibitors and the 
cAMP and cGMP signaling systems mean that in vivo platelet reactivity in patients 
receiving P2Y12 receptor blockers as part of DAPT will vary in accordance with 
endogenous levels of endothelial-derived NO and PGI2. This provides an explanation for 
different thrombotic outcomes in the presence of similar levels of platelet blockade; i.e. 
individual patients with different levels of endothelial function, or indeed disease-driven 
endothelial dysfunction, would have different levels of in vivo platelet inhibition for the 
same level of DAPT activity, as determined by ex vivo testing.  
 
DAPT, aspirin plus a P2Y12 receptor blocker, is the preventative therapy provided to 
patients at particular risk of coronary thrombosis, notably for the first 12 months 
following coronary stent implantation or an ACS [127, 260]. Despite this therapeutic 
approach coronary thrombosis still occurs, and there have been great efforts made to 
find ex vivo tests that could predict for clinical outcomes [266, 267]. Deductive reasoning 
leads to the conclusion that less effective platelet blockade would leave individuals at 
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increased risk of thrombosis and so multiple efforts have been made to link levels of 
platelet reactivity in ex vivo tests to clinical outcomes. Despite the attractive logic of this 
approach, tailoring anti-platelet therapy to ex vivo platelet responses has failed to 
provide any improvement in clinical outcomes, as noted in large scale studies such as 
ADRIE [274] and several large-scale, prospective RCT, such as GRAVITAS [275], ARCTIC 
[276], TRIGGER-PCI [277] and TRILOGY [278] .  
 
In patients receiving clopidogrel, there are well-characterised metabolic differences that 
can produce suboptimal levels of its active metabolite and consequently result in 
suboptimal levels of P2Y12 receptor blockade [262]. There are also some reports of 
variability in the effects of prasgurel and ticagrelor, although to a much lesser extent 
than for clopidogrel [144]. Biochemical resistance to the effects of aspirin are also 
particularly rare [223]. Allowing for differences dependent upon adherence to therapy, 
individuals on DAPT may in fact present rather a more homogenous level of platelet 
inhibition than can be associated to different clinical outcomes. Appreciating that 
blockade of P2Y12 receptors greatly increases the inhibitory effects of NO [238], and 
knowing that not only is there a similar interaction with the inhibitory effects of PGI2 
[237] but that NO and PGI2 powerfully synergise to inhibit platelets [74], one can reason 
that differences in the levels of NO and PGI2 in the presence of the same levels of P2Y12 
receptor blockade would produce different levels of platelet inhibition. By testing this 
hypothesis firstly in vitro and then in individuals receiving P2Y12 blockers, results 
reported here show that strong and synergistic interactions between P2Y12 receptor 
blockade and endothelial derived mediators produce profound inhibitory effects upon 
platelets.  
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The in vitro studies presented firstly highlight the strong amplification by P2Y12 blockade 
on the inhibitory effects of both PGI2 and NO individually and then secondly 
demonstrate the even more dramatic inhibitory effects of all three interacting to 
produce profound platelet inhibition. Blockade of platelet P2Y12 receptors dramatically 
enhances the anti-platelet potency of NO and PGI2 over a range of concentrations, 
causing over a 1,000-fold increase in their inhibitory activity against platelet 
aggregation. Notably, these powerful interactions between NO, PGI2 and P2Y12 receptor 
blockade in inhibiting platelets are markedly synergistic, as noted by isobolographic 
analysis. Utilizing very low concentrations of NO and PGI2 in the nanomolar range I 
further demonstrated this powerful potentiation through platelet aggregation and ATP 
release experiments in response to activation of receptors for ADP, thrombin and 
collagen. To then make data readily accessible results have been presented in the form 
of heat maps that move from red to green, indicating movement from full platelet 
activation to no platelet activation. These results demonstrate that even in the context 
of 100% P2Y12 blockade when neither NO or PGI2 are present both collagen and TRAP-6 
stimulation still result in high levels of platelet aggregation. Aggregation is reduced in 
the presence of both inhibitors individually but virtually abolished with NO and PGI2 
acting in combination with P2Y12 blockade. In accordance with this, marked reductions 
in platelet activation were recorded in ATP release experiments with the potentiation of 
the actions of both NO and PGI2 by P2Y12 blockade. Interestingly, the addition of aspirin 
to PAM in the absence of endothelial mediators reduced aggregation induced by 
collagen but not by TRAP-6. Aspirin however, added little additional inhibitory effect to 
platelet inhibition resulting from the synergistic interactions of P2Y12 blockade, NO and 
PGI2.  
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An in vitro approach was also used to model events in the presence of suboptimal levels 
of P2Y12 receptor blockade by using concentrations of PAM that were 50% and 25% of 
the effective concentration.  Under these conditions it was noted that relative to 
consensus levels of DAPT there were no significant reductions in platelet aggregation. 
Notably, however, in the presence of NO and PGI2, effective levels of inhibition were 
achieved, even when platelets were exposed to only 25% of the effective concentration 
of PAM. As expressed in heat maps, there is a clear interaction between PAM, DAPT and 
the endothelial mediators that move platelets from reactive (‘red’) to unreactive 
(‘green’). Interestingly, these comparisons indicate that 25% of the effective 
concentration of PAM plus NO and PGI2 produces a stronger inhibition in LTA, the ‘gold 
standard test’, than 100% of the effective concentration of PAM in the absence of NO 
and PGI2 (i.e. the normal conditions for testing ex vivo platelet responsiveness). This 
suggests that in individuals in whom suboptimal P2Y12 inhibition is achieved, such as 
poor clopidogrel metabolisers, anti-platelet efficacy may be particularly sensitive to any 
changes in endothelial function. The in vitro data also demonstrates that the triple 
synergy between P2Y12 blockade, NO and PGI2 can be explained by changes in cAMP 
signaling which, is consistent with the known interactions between NO and PGI2 [322] 
and PGI2 and P2Y12 [237]. cGMP was not increased even in the optimal condition of P2Y12 
receptor blockade, NO and PGI2. For both primary platelet agonists tested, cAMP was 
not affected by the combination of NO and PGI2 or P2Y12 individually but significant 
elevations were noted when all three were allowed to interact. These interactions were 
further supported by measurements of phospho (Ser239)-VASP, a downstream marker of 
PKG and PKA activation and therefore, representative of cyclic nucleotide activity within 
platelets. PAM treatment resulted in elevations of VASP-phosphorylation in all 
treatment conditions tested following TRAP-6 stimulation but notably the highest 
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increase was observed, again, in the presence of P2Y12 blockade, NO and PGI2. Of note, 
aspirin treatment alone did not produce any increase in VASP phosphorylation in any of 
the conditions tested. 
 
To further test the overarching hypothesis, I then sought to ascertain whether these in 
vitro interactions held true in man. I did this by analysing platelet behaviour ex vivo using 
several tests of platelet activity in healthy volunteers prescribed monotherapy aspirin or 
prasugrel or the two in combination, prescribed as DAPT. Firstly, it was established that 
the drug regimes used in the studies elicited satisfactory reductions in baseline reactivity 
in the LTA therefore, establishing effectiveness of P2Y12 and/or COX inhibition in 
accordance with suggested analytical cutoffs [324]. These reductions were against high 
pre-treatment levels of platelet reactivity (>70% response to 5 µM ADP) [123]. In these 
studies and others presented here, care was taken to include the standard measures of 
platelet function as determined in consensus statements [324, 325]. In volunteers taking 
prasugrel or aspirin there were inhibitions of responses to ADP or AA, respectively that 
were in keeping with consensus statements of effective therapy. For DAPT volunteers 
both AA and ADP were also appropriately inhibited; i.e. the drugs were working to an 
effective level of clinical efficacy. Despite this level of effective inhibition, high 
concentrations of the strong primary platelet activators, TRAP-6 or collagen, still caused 
notable platelet activation in all three treatment groups. Addition of low concentrations 
of NO and PGI2 had moderate effects on their own following TRAP-6 stimulation in both 
prasugrel and DAPT treated volunteers but no effect in those taking aspirin. In 
combination to model the environment within the blood vessel, PGI2 and NO led to 
almost complete inhibition in platelets from individuals treated with DAPT or prasugrel. 
In the aspirin group levels of platelet inhibition were much more modest. TRAP-6 is a 
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strong platelet agonist and even at high concentrations the powerful synergy between 
P2Y12 blockade, NO and PGI2 remarkably, completely eliminated platelet activation. An 
effect which was notably not associated with aspirin therapy. Whilst PGI2 plus NO was 
associated with reductions in all three treatment groups following collagen stimulation, 
this effect was most marked in the DAPT group and least so in aspirin treated volunteers. 
The modest inhibitory effect associated with aspirin therapy can be explained by the 
synergy between PGI2 and NO acting alone in the context of relatively weak platelet 
stimulation with low dose collagen. Similarly, in ATP release experiments, in the context 
of DAPT, NO or PGI2 alone had modest effects upon platelet granule release however, 
when combined they caused more than 50% inhibition.  
 
These results indicate that even in the presence of effective DAPT, i.e. within consensus 
guidelines, the presence of NO and PGI2 lead to very much higher levels of platelet 
inhibition. The powerful interaction between P2Y12 blockade, NO and PGI2 was further 
supported by quantification of P-selectin and PAC-1 expression, two markers of platelet 
activation. Whilst expressions of both of these markers were reduced by P2Y12 blockade 
alone in both prasugel and DAPT groups, the addition of NO or PGI2 caused further 
significant platelet inhibition and the combination of PGI2 and NO abolished P-selectin 
and PAC-1 activation. Notably, neither P-selectin nor PAC-1 expression were reduced by 
aspirin therapy with or without the addition of NO or PGI2 individually or in combination.  
Having shown through several tests of platelet activation that the powerful 
antithrombotic effects of P2Y12 receptor blockers are mediated by profound 
potentiation of the endogenous synergy between NO and PGI2 ex vivo, in a similar 
manner to that demonstrated in in vitro experiments, I sought to establish whether this 
powerful synergism was also explained ex vivo by blockade of P2Y12 receptor-dependent 
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cyclic nucleotide pathways of platelet activation. Again, I was able to demonstrate that 
cAMP is an important signaling molecule and downstream effector of the synergistic 
actions of P2Y12 blockade, NO and PGI2. This interplay however, was not related to 
altered synthesis or degradation of cGMP. I observed this with two separate P2Y12 
receptor blockers, prasugrel and ticagrelor after activation with thrombin or collagen. 
Thus far, these experiments suggest that the true inhibitory potential of the synergy of 
NO and PGI2 is only revealed by blockade of P2Y12 receptors and that activation of this 
receptor has the ability to limit the powerful anti-platelet effects of NO and PGI2. 
 
Having demonstrated in vitro and ex vivo in healthy volunteers that after strong 
activation P2Y12 receptor blocked platelets, as determined by aggregation and ATP 
release experiments, as well as by VASP phosphorylation, P-selectin, PAC-1 and cyclic 
nucleotide activity, are able to sense nanomolar concentrations of PGI2 and NO acting 
in combination, I sought to establish whether these interactions take place to the same 
degree in disease states. In order to do this I studied platelets from patients with PAD, a 
disease associated with high morbidity and mortality [328] and interestingly, a patient 
group with an unexplained poorer prognosis following ACS [331]. For these reasons, I 
studied platelets from both treatment naïve patients and from patients prescribed a 
range of anti-platelet therapies, namely aspirin, clopidogel or aspirin plus clopidogrel as 
DAPT.  
 
I did not find any evidence that platelets from treatment naïve patients with PAD were 
more reactive in vitro compared to those from healthy volunteers, as assessed by two 
methods of platelet aggregation using several platelet agonists. This is suggestive that it 
is the in vivo environment that is key in determining platelet reactivity and therefore, 
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reduction in production of inhibitory endothelial mediators, associated with the diffuse 
endothelial dysfunction that occurs in this disease, could lead to increased platelet 
reactivity in vivo in these patients. This reduced bioavailability of NO and PGI2 could also 
reduce the efficacy of P2Y12 receptor antagonists by limiting the potency of their 
synergistic relationship with P2Y12 blockade. This could partly explain the poorer 
outcomes in this population following ACS despite appropriate DAPT therapy.  
 
There were higher levels of AA induced aggregation in platelets from patients taking 
aspirin compared to healthy volunteers prescribed aspirin for a week (15±6% versus 
2±1%, p=0.156). Although this difference was not found to be significant it could be 
indicative of non-adherence to therapy, elevated platelet turnover or reduced aspirin 
efficacy, which could increase thrombotic potential in this patient group. Aggregation 
was not significantly changed in response to any of the other agonists tested. I also 
tested platelet responses to NO plus PGI2 to both primary platelet agonists, TRAP-6 and 
collagen. I found that the combination of PGI2 and NO was associated with the lowest 
levels of platelet aggregation following collagen stimulation in all therapy groups tested. 
Of note, the effects of endothelial mediators were significantly more profound in 
clopidogrel and DAPT treated patients, indicative that the underlying three-way synergy 
between NO, PGI2 and P2Y12 blockade is present and effective in patients with PAD 
prescribed P2Y12 antagonist therapies at standard doses. Following stimulation with the 
stronger platelet agonist TRAP-6, PGI2+NO only significantly reduced aggregation in 
clopidogrel monotherapy and DAPT treated patients. Again with this second agonist 
tested, further evidence was found of the aforementioned synergy with significantly 
more profound platelet inhibition produced in the presence of P2Y12 blockade with 
clopidogrel or DAPT, in contrast to aspirin which did not reduce aggregation as 
246 
compared to treatment naïve patients (naïve, 59±8; aspirin, 59±4%; clopidogrel, 36±9% 
(p<0.05); DAPT, 31±12% (p<0.05)). These experiments confirm that in PAD, a disease 
associated with atherosclerosis and atherothrombosis, high levels of platelet 
aggregation are still observed ex vivo following stimulation with the primary agonists 
TRAP-6 and collagen despite anti-platelet therapies and that in vivo if present, PGI2 and 
NO could greatly influence platelet activity leading to far greater levels of platelet 
inhibition.  
 
These in vitro and ex vivo studies in both healthy volunteers and patients with 
cardiovascular disease demonstrate the well-known synergy of NO and PGI2 in inhibiting 
platelets [74] and the ability of P2Y12 antagonism to potentiate the inhibitory actions of 
both PGI2, dependent upon cAMP [237], and NO, dependent upon cGMP generation 
[238]. Furthermore, the three way synergy between these three inhibitors is many more 
times more powerful than the synergy existing between any combination of two 
inhibitors acting in pairs and provides evidence to support the hypothesis that in vivo 
the efficacy of P2Y12 blockade will be highly influenced by levels of NO and PGI2 and that 
in vivo platelet function will be a product of both internal platelet reactivity and the 
environmental influence of the endothelium. Though not widely commented upon, the 
body contains many more endothelial cells than platelets, in the order of 50 times more, 
and the two populations constantly interact meaning that within the circulation DAPT 
will exert its effects upon platelets in the presence of endothelial-derived mediators. 
Before going on to describe the therapeutic and diagnostic implications of these key 
interactions I will highlight the potential importance in the process of atherothrombosis. 
As shown here and in previous studies the inhibitory effects of NO and PGI2 are severely 
blunted by activation of platelet P2Y12 receptors by ADP. The observation that P2Y12 
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activation can attenuate this powerful synergy suggests that following strong platelet 
stimulation, activation of P2Y12 receptors is a principal mechanism that enables platelets 
to overcome the effects of endothelial inhibitory mediators [74] allowing for platelet 
activation and thrombus formation. Considering the strong inhibitory tone conferred 
upon platelets by endothelial cells, the endogenous intraplatelet pathways and key 
importance of P2Y12 receptors described above, it is interesting to give some 
consideration into how it is that fast flowing platelets are able to aggregate at sites of 
arterial injury. It may well be that platelets carry their cyclic nucleotide tone with them 
from their passage through capillary beds and are also exposed to circulating levels of 
both PGI2 and adenosine that will continue to elevate levels of cAMP. Platelets appear 
to be able to overcome this strong inhibitory tone through release of secondary 
mediators by the first arriving platelets most notably, ADP that activates P2Y12 receptors 
on platelets. Crucially then, P2Y12 receptor activation rapidly leads to a blockade of AC 
which turns off cAMP production and counteracts the inhibitory actions of cGMP. These 
concepts put the relationship between the endothelium and platelets at the centre of 
atherothrombosis. Endothelial cells produce NO and PGI2 that together with adenosine 
and others elevate cAMP and cGMP in platelets and these two systems synergise to 
produce the greatest inhibition of platelet reactivity. This effect likely largely takes place 
within capillary beds that make up the majority of the cardiovascular system, not the 
large vessels, but rapidly moving platelets carry the effects of endothelial cell exposure 
with them.  Exposure of platelets to a damaged blood vessel wall releases ADP that 
through P2Y12 receptor activation pivotally turns off the cAMP and cGMP generating and 
signalling systems and in concert with very active phosphodiesterases rapidly switches 
the platelet to being strongly reactive. 
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The concept that the efficacy of P2Y12 receptor antagonists will vary markedly as a 
function of endothelial activity in individual patients begs the question as to how anti-
thrombotic therapies can best be optimised in particular individuals or patient groups 
with cardiovascular disease. Therapeutically, should we consider optimising the 
availability and activity of endothelial-derived mediators (such as by the co-
administration of PDE inhibitors), or providing mimetic drugs, rather than adding in 
further anti-platelet therapies? The data reported here suggest that cAMP rather than 
cGMP is the major driver of this synergy so phosphodiesterase 3 (PDE3) inhibitors, such 
as cilostazol, may have an enhanced effect compared to PDE5 inhibitors, such as 
sildenafil or dipyridamole. Interestingly, several clinical studies have suggested that the 
addition of cilostazol to DAPT may be beneficial. In a small study of patients with 
complex lesions undergoing PCI cilostazol reduced MI (1.6% vs 13.6%, p=0.018) and 
MACE (1.6% vs 16.7%, p=0.004) respectively, without increasing bleeding [373]. 
Treatment with cilostazol was also found to be superior to DAPT in STEMI patients, 
notably procuring additional benefits in diabetic and older patients [374]. Both the 
DECARE-DIABETES and LONG trials also favourably associated add on cilostazol therapy 
to DAPT which was shown to improve patient outcome [167, 375]. These findings were 
reinforced by the results of a meta-analysis of RCT indicating that the addition of 
cilostazol significantly reduced the incidence of MACE and both target vessel and lesion 
revascularization in patients with IHD [376]. Authors of these studies state that the 
mechanisms behind the benefit of additional cilostazol are not fully understood. 
Proposed reasons are the pleiotrophic effects of cilostazol preventing the progression 
of atherosclerosis and a possible beneficial impact of cilostazol on plasma lipid profiles. 
It may be however, that the interaction between P2Y12 receptor blockade and cilostazol 
elevates cyclic nucleotide levels in platelets leading to much enhanced levels of platelet 
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inhibition to reduce thrombotic risk and improve outcome. Interestingly, a similar role 
for PDE5 inhibitors which increase cGMP in platelets was not suggested in the ACCEL-
DIP study with the addition of dypridamole to DAPT not reducing the prevalence of HPR 
[377]. This is in keeping with our recent finding that the synergy between P2Y12 
blockade, NO and PGI2 is mostly cAMP dependent [239]. These findings could, 
eventually, be applied clinically in a personalised medicine framework where 
endothelial mediator production of individuals is assessed and appropriate add-on 
therapy applied. In a more generalised approach these additional therapies could also 
be supplied to patient groups with known endothelial dysfunction, such as diabetics. 
This approach could provide increased anti-platelet efficacy while avoiding the 
increased risk of bleeding events associated with the approach of triple anti-platelet 
therapy (TAPT).  
 
The emergence of this complex and very powerful synergy also has additional 
therapeutic implications for DAPT.  Therapeutically, it provides us with even further 
cause to question the benefit of addition of aspirin to strong P2Y12 receptor blockade 
[148, 378]. As was outlined in the introduction of this thesis, in addition to its effects 
upon platelets, aspirin will also inhibit COX at other sites in the body and even at low, 
anti-thrombotic doses, aspirin produces substantial inhibition of COX within the 
vasculature, both in platelets and in the blood vessel wall.  Crucially, reduction in 
vascular PGI2 production through COX inhibition in endothelial cells can reduce platelet 
cAMP, increase platelet reactivity and so increase the potential for thrombosis.  The 
incremental increase in platelet inhibition provided by aspirin inhibiting TXA2 production 
on top of strong P2Y12 receptor blockade may well be insufficient to balance this 
thrombogenic effect, so the addition of aspirin could effectively have a net negative 
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influence on the cardiovascular system. Furthermore, inhibition of the production of 
PGI2 will lessen its participation and attenuate the powerful three-way synergy that we 
describe to increase platelet reactivity beyond that predicted for loss of PGI2 alone. So 
while consideration of platelet activation pathways in isolation could lead to the 
conclusion that the addition of aspirin to strong P2Y12 receptor blockade increases 
platelet inhibition, consideration of platelet activation pathways acting together in vivo, 
within the milieu of the circulation with the powerful influence of the endothelium may 
lead to the conclusion that the addition of aspirin to strong P2Y12 blockade could actually 
decrease platelet inhibition.   
 
Interestingly, as mentioned previously the role of aspirin in DAPT is being re-evaluated 
in clinical trials and has already been questioned in the context of TAPT with warfarin 
following publication of the WOEST study [379]. If aspirin were proven to provide little 
additional benefit to strong P2Y12 receptor blockade, then drugs such as prasugrel or 
ticagrelor alone could become standard of care.  DAPT could then become a strong P2Y12 
receptor blocker plus another drug; as suggested above, enhancing inhibitory cyclic 
nucleotide pathways in platelets could represent an efficacious line of therapy. In 
addition to the use of PDE inhibitors this could potentially be achieved through use of 
other drugs that increase platelet cyclic nucleotide levels such as synthetic PGI2 
analogues or direct GC activators. The use of some of these agents has previously been 
restricted due to negative effects upon the blood vessel wall for example, causing 
hypotension. However, due to the enhancing effects of P2Y12 receptor blockade upon 
the inhibitory potencies of these drugs it is possible that these agents could be provided 
at doses that have more pronounced effects upon platelets with lesser of the previously 
reported limiting effects on the vasculature. By focusing on promoting these 
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endogenous inhibitory mechanisms rather than attempting to further inhibit pro-
aggregatory pathways in platelets through the addition of a third anti-platelet agent, 
this newer DAPT approach could diminish platelet excitability and so reduce thrombosis 
without increasing the risk of bleeding.   
 
As a diagnostic implication of these synergistic interactions, an estimation of endothelial 
function alongside ex vivo platelet testing could enhance thrombotic risk prediction in 
individual patients. As discussed, NO and PGI2 markedly affect the potency of platelet 
inhibition by P2Y12 receptor antagonists while these are absent in ex vivo testing, 
providing an explanation for the disconnect which exists between platelet testing and 
thrombotic outcomes in patients. Adjuvant endothelial assessment could improve the 
usefulness of PFT in influencing therapeutic management, helping to identify those 
individuals who truly are at risk of thrombosis and may benefit from additional drug 
intervention in a personalized therapeutic manner.  
 
As a step towards the goal of measuring endothelial function in those patients with 
cardiovascular disease undergoing PFT and determining platelet activity as a product of 
these two factors, I pilot tested two methods of assessing endothelial function in healthy 
volunteers. Laser Doppler associated with iontophoresis and RH were selected as these 
methods are thought to assess the microcirculation and responses recorded in the skin 
microvasculature have been shown to be reflective of the responses taking place in 
other vascular beds [316]. Furthermore, these responses are thought to be under the 
influence of both PGI2 and NO production. RH following a period of occlusion will reflect 
NO and prostanoid bioavailability and administration of ACh and SNP are representative 
of endothelial-dependent vasodilatation dependent on NO and prostaglandin 
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participation and smooth muscle dependent on non-endothelial pathways of 
vasodilation, respectively. Both techniques were well tolerated and despite intial 
difficulties in optimising the protocols due to lack of standardisation of both techniques, 
both gave accurate and reasonably reproducbile results, in keeping with published 
studies in healthy volunteers. Notably, I observed equal responses to ACh and SNP as 
would be expected in healthy volunteers lacking endothelial dysfunction and 
appropriate maximim response to PORH.  
 
Of the two, I found PORH to be a more reliable technique as it gave the more 
reproducible results, was more time efficient and an easier technique to carry out. 
Iontophoresis with laser Doppler has in published studies been associated with poor 
reproducibility due to differences in skin resistance, spatial heterogeneity of skin blood 
flow and movement artefacts. However, as a technique it is possibly more sensitive and 
has the added benefit of being able to detect mild deficiencies in vascular response 
through administration of agonists at low and consequently graded current increments. 
This was certainly the more difficult technique to optimise however, substantial 
advances were made during the pilot period through minimisation of nonspecific, 
galvanic responses by current optimisation, choice of vehicle and reduction of spatial 
heterogeneity through careful and precise chamber placement. Therefore, this 
technique does hold promise. Certainly both techniques are attractive for the further 
exploration of the hypothesis that the efficacy of P2Y12 receptor antagonists will vary in 
individual patients in accordance with their endothelial function and that therefore, an 
incorporation of endothelial function testing could refine platelet function testing. 
Importantly, these techniques focus on endothelial function in the microcirculation 
which is especially attractive as as alluded to previously, it appears most likely that the 
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capillary beds and not the large conduit vessels are the principal site where the many 
more endothelial cells than platelets exert their influence on platelets. The reasons for 
this are explained through consideration of the anatomy and physiology of the 
cardiovascular system. The diameter of a blood platelet is 2-3 μm, the diameter of a 
capillary is 5-10 μm whereas the diameter of the proximal LAD is around 2.8-4.2 mm. 
Therefore, the volume to internal surface area ratio of a capillary of 8 μm diameter and 
1 cm in length is 0.5 whereas for the proximal LAD of 4 mm diameter and 1 cm length it 
is 1000. So in capillaries, as compared to large arterial vessels, there is actually a 2000 
fold greater ratio of endothelial cells to platelets. In addition, blood flows around 500 
times faster in arteries than in capillaries; blood flows in a healthy coronary artery 
around 10 to over 100 cm/sec but in a capillary at 0.1 cm/sec.  Similarly, as outlined in 
the introduction of this thesis while the cross-sectional area of the aorta is 3-5 cm2 that 
of the body’s total capillary bed is approximately 4500-6000 cm2, comprising the vast 
majority of the total surface area of the circulation [380-382]. Therefore, within 
capillaries, rather than the large vessels there is the space, time and area for platelets 
to have intimate interaction with local endothelial cells that cannot be matched in larger 
vessels and therefore, for the important synergistic interactions described in this thesis 
to take place. Furthermore, it is suggested that the microvasculature is the initial site of 
endothelial damage and dysfunction in subjects at risk of cardiovascular disease so the 
capillaries are of particular importance to my studies. Leading on from the pilot trials of 
these two techniques it will be interesting next to measure endothelial function in 
healthy volunteers and patients as an adjuvant to my platelet function studies.  
As an additional line of investigation in this thesis I explore the complex interplay of 
platelets and coagulation in atherothrombosis. This is because both play a critical role 
in thrombus formation and platelets are also fundamental in regulating the coagulation 
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system. This is important as configuration of the fibrin network has been shown to be 
associated with outcome with dense clots predisposed to thrombosis, raising the 
possibility of clot characterisation and modulation as a therapeutic intervention in 
atherothrombosis [364]. In order to do this, the effects of standard anti-platelet 
therapies on platelet activity were determined using traditional tests of platelet 
function, namely LTA, ATP release, P-selectin and PAC-1 expression. Advanced 
rheological analyses were then used to establish the influence of these therapies on clot 
microstructure. Importantly, viscoelastic properties of incipient clots have been shown 
to be representative of clot architecture and fibrin polymerisation [365]. The novel 
biomarker, GP was used which defines the point at which fluid blood turns into a 
viscoelastic solid, incipient clot. From this the fractal dimension (df) and relative mass 
(RM) were calculated as measures of clot complexity and density. Using this new 
biomarker which has been used to study clot formation in previous studies in different 
patient populations [383] but never related and validated against platelet reactivity, the 
effects of platelets and anti-platelet therapies on the microstructure of the fibrin 
network of incipient clots was determined. This method clearly defined a pre-treatment 
value of df = 1.72 (± 0.05) representative of a normal index of haemostasis, in keeping 
with previous published studies. Importantly, this correlated with high pre-treatment 
levels of platelet reactivity, in keeping with previous published cut-off values. Aspirin 
therapy alone had minimal effects on platelet reactivity reducing only AA and ADP 
induced platelet aggregation in the LTA but did not affect platelet reactivity through any 
other testing method, as found in my earlier studies. In keeping with, this aspirin also 
did not reduce either df or RM. In contrast, prasugrel therapy substantially blunted 
platelet reactivity as assessed by ATP release, P-selectin and PAC-1 expression and all 
agonists tested in the LTA apart from TRAP-6. Prasugrel therapy also led to significant 
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reductions in df and had a considerable impact on the RM of clots, which was reduced 
by 40%. These results are in keeping with low dose aspirin being a weak inhibitor of 
platelet reactivity and prasugrel, which is well known to be a more potent anti-platelet 
agent. Notably, these studies highlight the intricate link between platelet reactivity and 
the fibrin architecture of clots with changes in microstructure taking place when 
platelets were strongly inhibited by prasugrel but not when platelets remained relatively 
active following aspirin therapy.   
 
DAPT with aspirin plus prasugel or aspirin plus tigacrelor were both associated with 
strong reductions in aggregation to all agonists tested and also reduced P-selectin 
expression. Importantly, supporting the link between platelet activity and clot 
architecture both therapies decreased df and led to substantial reductions in the RM of 
clots of 35% and 45%, respectively. These results are illustrative that stronger inhibition 
of platelet function is associated with a more porous network of fibrin strands resulting 
in the formation of less dense clots which, importantly can be detected as changes in df. 
It was also found through projections of RFA’s and SEM’s that whilst changes in df are 
small they will have a large impact on the overall structure of the fibrin network of clots 
because of the non-linear relationship between df and fibrin mass.  
 
As well as providing further mechanistic insight into the links between platelet reactivity 
and clot formation, this set of experiments indicate that the therapeutic benefits of anti-
platelet therapies may also be linked to their abilities to reduce thrombus density. 
Results also demonstrate that it is activation of P2Y12 receptors that is the key driver of 
platelet interactions in clot formation, in keeping with the contribution of ADP but not 
TXA2 receptors in the initiation of intravascular coagulation [384]. In line with this 
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conclusion, no significant microstructural change was noted in volunteers taking aspirin 
75mg. This is in contrast to a recent study, where 300mg aspirin in patients with 
ischaemic stroke produced a significant reduction in Df [385]. Aspirin primarily acts to 
inhibit platelet COX-1 however, at higher doses it exerts other effects such as acetylation 
of fibrinogen, prothrombin and other coagulation factors [386, 387]. These direct roles 
in clot modulation might be seen with higher doses of aspirin (300mg) but perhaps not 
at lower doses (75mg). It is also notable that addition of aspirin to prasugrel produced 
no further reduction in markers of clot density despite additional inhibition of platelet 
TXA2 pathways. As previously reported, this may be further indicative that in the 
presence of strong P2Y12 receptor blockade aspirin produces little or no additional 
therapeutic benefit [149, 388]. 
 
These results are also in keeping with previous studies suggesting that this novel point 
of care visco-elastic technique is able to accurately and reproducibly assess clot 
architecture with the potential of determining the effects of disease and therapeutic 
intervention on clot quality. Importantly, this technique uses unadulterated whole blood 
and is measured immediately at the bedside during real-time clot formation, providing 
a rapid assessment of coagulation that can be more readily performed than current 
methods [389]. A more thorough understanding of how the fibrin network is structurally 
organised could be more informative in determining the effects and outcomes of anti-
platelet therapies and used in the clinical setting with the potential of individualising 
therapies. 
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8.2 Conclusion 
 
To conclude, despite substantial therapeutic developments over the last decade, 
recurrent thrombotic events and bleeding complications continue to occur, highlighting 
the need for further optimisation of standard treatment strategies, especially in those 
patients who remain at increased risk of MACE. The new therapeutic approaches put 
forward in this thesis share the common goal of optimizing thrombotic risk by reducing 
not only thrombotic risk but also by reducing bleeding risk. Therapeutic approaches to 
atherothrombosis are certain to evolve over the next decade and could potentially, take 
into account some of the fundamental concepts highlighted in this thesis. On the 
contrary, a wealth of cardiovascular research worldwide continues to attempt to link ex 
vivo platelet function studies in large randomised cardiovascular clinical trials to 
thrombotic risk and outcomes. Whilst a therapeutic window of platelet reactivity and 
the tailoring of anti-thrombotic therapy in a personalised therapeutic manner, both 
based on platelet reactivity are attractive concepts full of apparently obvious potential 
to improve cardiovascular medicine for patients, are these realistic goals? Randomised 
trials repeatedly fail to reduce ischaemic complications and improve patient survival 
through platelet testing and despite intense efforts, no causal relationship between the 
results of platelet testing and thrombotic events has actually been firmly established. 
This thesis highlights the exquisitely complicated nature of atherothrombosis exploring 
not only the key roles of platelets but also the coagulation system and the endothelium. 
Whilst it is proposed that genotyping as an adjuvant to platelet testing could be helpful, 
I would further suggest that due consideration needs to be given to both the in vivo 
environment in which platelets reside and a more global representation of thrombosis 
involving both the cellular and protein parts of the coagulation system is called for. Given 
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the multifactorial and complex nature of atherothrombosis, whilst therapies will evolve 
I believe that identification of a single marker predicting thrombotic outcomes beyond 
traditional and newer risk factors for cardiovascular disease will remain a more 
challenging goal. A current principal aim of cardiovascular research and medicine today 
has to focus on the modification and optimisation of risk factors as prevention will 
always be better than cure.  
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